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Abstract 
Raised plasma homocysteine (Hcy) levels have been cited as a major risk factor for 
several vascular disorders. Yet hyperhomocysteinaemia is easily treated through dietary 
intervention and vitamin supplementation. 
Commercial assays have facilitated routine plasma Hcy analysis. However, the 
problem faced by clinicians is stabilisation of Hcy in whole blood samples prior to 
delivery to the laboratory. Following blood collection, erythrocytes continue to produce 
and excrete Hcy increasing plasma concentrations by up to 10% per hour. 
This thesis describes the investigation of stabilising plasma Hcy in whole blood, 
allowing wide scale screening for hyperhomocysteinaemia. The most effective method 
appears to be inhibition of the enzyme responsible for Hcy production, S-
adenosylhomocysteine hydrolase (SAHH), using a competitive inhibitor 3-
deazaadenosine (3DA). 
Clinical trials were conducted on a pilot batch of evacuated blood tubes. Samples 
were stored in EDTA whole blood in the presence and absence of 3DA, at ambient 
temperatures (20 to 25ºC), and under refrigerated conditions (2 to 8ºC). Only samples 
that were collected into EDTA plus 3DA tubes and stored refrigerated showed stability 
over 72 hours (p = 0.2761). 
For wide scale screening, samples must be stable under ambient conditions. As the 
structure of SAHH is known a molecular modelling approach was adopted in an attempt 
to identify other potential inhibitors from screened databases. Interference of SAHH, in 
an immunochemical method for Hcy, was to be utilised for in vitro screening before any 
further clinical trials were conducted. 
The thesis also focuses on Hcy as a marker of vitamin deficiency and explores links 
between thiol metabolism and the development of cognitive decline eventually leading 
to dementia. Disruption of single carbon metabolism can lead to an increase in Hcy and 
a decrease in available methyl groups important in regulation of several metabolic 
pathways. Increased oxidative stress may also be a causative factor. 
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1.1 Homocysteine Metabolism 
Homocysteine (Hcy) is a naturally occurring amino acid. Although not found in 
protein, it can be found in vivo within the circulating plasma where it is usually present 
in trace amounts, such that the clinical reference ranges for a human adult are in the 
order of 5 to 15µmol/L1. 
In mammals Hcy is formed solely from the intracellular metabolism of methionine 
(Met)2, via the pathway shown in Figure 1. The primary source of Met is dietary 
protein, in particular protein derived from animal products, however, Met may also be 
supplied from proteins within the body, due mainly to turnover of muscle mass. 
In the first step of the cycle Met adenosyltransferase catalyses transfer of the 
adenosine moiety, from ATP to Met, yielding a high-energy compound, S-
adenosylmethionine (S-AdMet). The methyl group can then be transferred to a wide 
range of acceptor compounds including, DNA, RNA, proteins and lipids. This reaction 
is key to several metabolic processes, in particular, the methylation of DNA, which is 
important in the regulation of gene expression. 
Although over 100 methyltransferases exist most are subject to potent feedback 
inhibition by the product of methyl transfer, S-adenosylhomocysteine (S-AdHcy). It is 
important, therefore, that S-AdHcy is quickly removed, which is brought about by 
hydrolysis forming adenosine and Hcy. Under physiological conditions the enzyme 
responsible, S-AdHcy hydrolase (SAHH), actually favours the reverse, condensation 
reaction3, however in vivo the reaction is driven forward to produce Hcy by effective 
removal of the other product of the reaction, adenosine, by adenosine kinase, and 
adenosine deaminase. 
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Figure 1 Metabolism of methionine and homocysteine. 
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Hcy then acts as a branch point in Met metabolism; it can either be used to synthesise 
cysteine (Cys) or to regenerate Met. Its route is determined by a number of nutritional 
factors including, vitamin status, and the oxidative environment within the cell. 
Vitamins are important cofactors for several of the subsequent reactions in Hcy 
metabolism. Therefore deficiencies, due to poor diet or inadequate absorption from the 
gut, may cause disturbances within the pathway, which will be discussed in more detail 
later (see section 1.4.7). Provided that vitamin status is adequate, the fate of Hcy is 
governed by the availability of Met from the diet. Due to the importance of S-AdMet, if 
Met is scarce, the transfer of a methyl group from a donor compound brings about 
remethylation of Hcy, feeding the cycle in order to maintain the production of S-AdMet. 
In the majority of tissues this reaction involves 5-methyltetrahydrolfolate (5-MeTHF) as 
the donor molecule and vitamin B12 as cofactor for the enzyme Met synthase (MS). 
This enzyme is unique in its ability to metabolise the methyl group of 5-MeTHF, 
channelling one-carbon units derived from formate and amino acids such as serine, 
histidine and glycine into the methylation cycle, thus providing a methyl group for the 
synthesis of S-AdMet via Met and subsequently a methyl group that is used by many 
essential methyl transferases4. Serine-glycine hydroxymethyltransferase, 
methylenetetrahydrofolate dehydrogenase and methylenetetrahydrofolate reductase 
(MTHFR) then serve to regenerate 5-MeTHF, from tetrahydrofolate (THF). 
Most of the body’s cells possess MS, however a small number tissues, including the 
liver and kidney, exhibit an alternative remethylation pathway which utilizes betaine 
(trimethylglycine) as a methyl donor in place of 5-MeTHF2. 
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At times when Met is present in plentiful supply, Hcy enters the transsulphuration 
pathway where it undergoes a condensation reaction with serine to form cystathionine. 
In this case vitamin B6 acts as cofactor for the enzyme cystathionine β-synthase (CBS). 
Cys is formed through the hydrolysis of cystathionine by γ-cystathionase, the by-
product of which is α-ketobutyrate. Cys may then be used for protein synthesis or the 
formation of glutathione, an important antioxidant. Alternatively, oxidation of the 
sulphur atom of Cys is responsible for the urinary excretion of about 70% of the sulphur 
of dietary Met as inorganic sulphate4. 
It is not the Met levels per se that regulate which pathway Hcy enters, but the levels 
of S-AdMet that acts upon key enzymes within the process. An abundance of S-AdMet 
promotes transsulphuration by its negative allosteric affect on MTHFR blocking 
remethylation, and a positive allosteric affect on CBS, thereby allowing the removal of 
excess Met and Hcy. If S-AdMet levels are low, allosteric regulation is removed, 
feeding the remethylation pathway and the regeneration of Met. 
Flux through the remethylation or transsulphuration pathways, may also be 
influenced by redox status4. Both MS and CBS have redox-active cofactors. MS is 
dependent on vitamin B12 (cobalamin) as cofactor. The cobalt atom central to the 
structure of the vitamin can exist in three oxidation states (+1, +2 or +3). Cob(I)alamin, 
an intermediate in the transfer of a methyl group from 5-MeTHF to Hcy, is labile to 
oxidation leading to MS inactivity5 (Figure 2), such that MS activity is favoured by a 
lower redox potential. As a result, MS requires periodic reactivation by MS reductase, 
which utilises S-AdMet to donate a methyl group to the inactive cob(II)alamin, to 
reform methylcobalamin. Within CBS, the oxidised ferric state of haem is more 
favourable to Hcy binding, possibly through conformational changes in the surrounding 
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protein. Therefore under conditions of oxidative stress, Hcy is channelled into the 
regeneration of depleted glutathione via the transsulphuration pathway. 
Thus Hcy metabolism is complex, involving several enzymes, and B vitamins and 
folate as cofactors and substrates. Deficiencies in the supply or functioning of any of 
these compounds can have serious effects on homeostasis. 
 
Figure 2 Vitamin B12 involvement in the action of methionine synthase. 
 
1.2 Clinical Importance of Hcy 
Although compared to the amino acids involved in protein synthesis Hcy is only 
present in small amounts in the plasma, it has recently provoked a huge amount of 
interest as can be seen in the explosion in Hcy related publications which took place 
from 1991 onwards6. 
Met5MeTHF
S-AdMet
THF
Cob(I)alamin
Hcy
Cob(II)alamin
CH3-Cob(III)alamin
Activation
Oxidation
e
-
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1.2.1 Vascular disease 
Diseases of the vascular system, including ischaemic heart disease, acute myocardial 
infarction, and stroke are responsible for more deaths per year, in the western world, 
than any other disorder. In England and Wales in the year 2003, there were a total 
number of 538254 deaths7. Of these deaths, ischaemic heart disease and cerebrovascular 
disease accounted for 99790 and 57808 respectively. In total, 29% of mortality from all 
causes was due to diseases of the circulatory system. In the US, where the numbers are 
treated slightly differently, statistics available for the same year listed diseases of the 
heart as the number one cause of death, cancer was the second highest, but 
cerebrovascular diseases were ranked third8. Yet, in the Framingham Heart Study, 
conducted on over 5000 participants in the US, established risk factors including 
cholesterol, smoking, and family history only accounted for about 50% of the risk of 
cardiovascular event9;10. 
The majority of cardiovascular disease cases present in an acute, traumatic way, such 
as myocardial infarction or sudden death10, clearly this highlights the need to establish 
the risk factors involved in order to instigate risk factor reduction programmes, before 
the development of symptoms. 
Hcy was first postulated as a causal factor in vascular disease some four decades ago. 
In 1959, in Northern Ireland, a family presented in which two young sisters were 
showing signs of mental retardation, and congenital anomalies11. Initial tests proved 
negative for any of the inborn errors of metabolism that were known about at that time. 
Amino acid analysis was still quite crude, but raised levels of a sulphur-containing 
compound believed to be homocystine were detected in urine samples taken from the 
siblings. 
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Three years later in Wisconsin an infant was discovered with a similar presentation, 
however improvements in the methodology meant that the presence of increased 
amounts of homocystine excreted into the urine could now be chemically proven12. Also 
of note was the detection of increased excretion of Met. 
From these cases came the first clinical description of the syndrome referred to as 
homocystinuria, in which the clinical features of mental deficiency, fine, fair hair, 
ectopia lentis (dislocated ocular lenses), malar flush (red cheeks), peculiar gait, and 
genu valgum (knock knees) are relatively constant. Variable features may include pes 
cavus (high-arched) foot, long extremities and digits, convulsions, thrombotic incidents, 
cardiovascular disorders and fatty liver. Almost without exception, patients have 
elevated levels of Met and Hcy in plasma in addition to increased amounts of 
homocystine in the urine13. 
Laster, Finkelstein and Mudd13;14 later mapped the underlying most frequently 
observed genetic cause of homocystinuria to a defect in the enzyme CBS, responsible 
for the removal of Hcy from the circulation via the transsulphuration pathway (Figure 
1). A blockage in Met metabolism at this point leads to a build up of Hcy and its 
precursors, to a level where the renal threshold is exceeded causing homocystine to 
become detectable in the urine. 
Through family studies they found that the disorder showed an autosomal recessive 
mode of inheritance15, with heterozygotes possessing half the enzyme activity in 
cultured liver cells, but showing no clinical symptoms of the disease. 
If left untreated, half the number of patients with homocystinuria due to CBS 
deficiency will experience a thromboembolic event before the age of 30 years16. It was 
plausible that either raised Met levels or raised Hcy levels observed in these cases may 
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be the causal factor of premature atherosclerosis. In order to shed further light on this 
issue, in 1969, McCully17, took post mortem tissue samples from two different cases of 
disturbed Met metabolism and studied the similarities and differences between them. 
Arterial and venous specimens taken from a 7½ week old boy, who had died from the 
effects of an abnormality in vitamin B12 metabolism, were compared with samples 
from an 8 year old boy who had suffered a fatal thrombus in the carotid artery due to 
CBS deficiency. Both cases showed similar widespread arterial lesions, with fibrous 
plaques caused by damage to the intimal elastic lamina of the vessel walls. Since each 
child possessed a blockage in Met metabolism that occurred in a different location, the 
pattern of excess metabolites present in the plasma differed between the two. 
In the younger child, a deficiency in vitamin B12 metabolism caused Hcy and 
cystathionine to be raised, whilst Met concentrations were lower than normal (Figure 1). 
In CBS deficiency transsulphuration is blocked, Hcy accumulates in the plasma and 
feeds the remethylation pathway. In this way, cystathionine concentrations are low and 
Hcy and Met are raised. 
These two cases, therefore, showed similar vascular pathology, which could only be 
linked to an accumulation of Hcy in the circulation. 
McCully postulated that moderately elevated concentrations of Hcy, or one of its 
derivatives, might also be involved in the aetiology of atherosclerosis in individuals free 
from known enzyme defects. Together with his colleagues, he produced experimental 
evidence of this theory, by causing hyperhomocystinaemia in rabbits which led to the 
development of vascular lesions18;19. Furthermore, the addition of cholesterol to the diet 
resulted in lipid deposition in the aortic lesions, suggesting that the involvement of 
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cholesterol in arterial plaques is a secondary complication of pre-existing vascular 
injury. 
1.2.1.1 Cardiovascular disease 
If short term exposure to high levels of Hcy could lead to vascular disease in 
childhood, it followed that chronic exposure to milder elevations in plasma Hcy may be 
a risk factor for premature coronary disease in the general population. In 1976, Wilcken 
and Wilcken20 showed that differences existed in Met metabolism between individuals 
of similar ages with and without coronary artery disease, suggesting a reduced ability to 
metabolise Hcy in the diseased group. 
Between the late 1970’s and early 1990’s little was published on Hcy and vascular 
disease. A few scattered reports seemed to confirm that a link existed, but at the time 
attention was focused on the links between cholesterol and the development of 
atherosclerosis, with efforts being concentrated towards developing pharmacological 
treatments to lower plasma lipid levels. 
Over the last two decades, there has been a shift in interest back towards Hcy, due in 
part to a publication by Clarke et al. in 199121, who recognised elevated Hcy as an 
independent risk factor for vascular disease. Within their study they found that 
hyperhomocysteinaemia was present in 30% of patients with premature vascular 
disease. Recent developments have also been facilitated by the emergence of various 
assays for Hcy measurement suitable to a clinical environment22-30, which have been 
comprehensively reviewed by Rassmussen and Møller31. 
Twenty-seven of the early studies relating Hcy to arteriosclerotic vascular disease 
were reviewed by meta-analysis32, a summary of those investigations which looked 
specifically at cardiovascular disease reported a graded risk for atherosclerosis of 
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cardiovascular vessels, such that a 5µmol/L increase in Hcy conferred an 80% increase 
in risk in women, odds ratio 1.8 (95%CI 1.3 to 1.9) and 60% increase in risk in men, 
odds ratio 1.6 (95% CI 1.4 to 1.7). However, the analysis included mainly cross 
sectional and case-controlled studies, which may be subject to bias compared to cohort 
studies, in particular selection of cases and controls. Therefore, a more recent meta-
analysis, involving more than 38 studies of coronary heart disease and Hcy33, attempted 
to update the data and divide the studies according to whether they were cohort, nested 
case-controlled, or case-controlled studies. They showed that whilst a stronger 
relationship was shown in case-controlled studies, with an odds ratio of 2.11 in women 
(95% CI 1.30 to 3.42), and 1.63 in men (95% CI 1.44 to 1.85), the link between Hcy 
levels and cardiovascular disease remained supported within the cohort studies. 
However, the association was weak with a 5µmol/L increase in Hcy conferring an 
increased risk of 6%: odds ratio 1.06 (95% CI 0.99 to 1.13). 
While case-controlled studies may be subject to positive bias, cohort studies may 
show negative bias when assessing the links between Hcy and vascular disease. Many 
of these studies were initially designed to assess the degree by which well-established 
risk factors may be associated with the development of vascular disease. When the 
studies were initiated, and baseline samples were collected, Hcy may not have been 
considered for inclusion in the panel of blood tests to be conducted. Retrospectively, 
samples have been re-analysed as new risk factors are introduced. However, blood 
samples collected for Hcy analysis may be subject to false elevations if not handled 
under strict sampling conditions as will be discussed in Chapter 2. Therefore the 
boundaries between Hcy levels in those that subsequently become cases, and control 
individuals may not be clear-cut. 
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In both of the meta-analyses women showed a higher risk than men for 
cardiovascular disease, when exposed to a 5µmol/L increase in Hcy concentration. 
Although pre-menopausal women tend to have lower circulating levels of Hcy, they 
appear to be more sensitive to any increase in Hcy concentration, which may be due to 
increased sensitivity of the vascular walls to the damaging effects of Hcy. 
As the evidence mounts, Hcy is now regarded by many as a significant risk factor in 
the development of cardiovascular disease. Yet, the story does not end here; Hcy is now 
being implicated as being central to the pathology of a multitude of other systemic 
disorders. 
1.2.1.2 Cerebrovascular disease 
Vascular disease is not only associated with heart disease, but also accounts for a 
large proportion of cerebral haemorrhage or stroke. Although fewer studies have looked 
independently at the risk of cerebrovascular disease, the link with Hcy appears to be 
stronger than that which exists between Hcy and cardiovascular disease. Meta-analysis33 
showed an odds ratio of 1.10 (95% CI 0.94 to 1.28) in 2 cohort studies associated with a 
5µmol/L increase in Hcy, whereas a summary of 22 case controlled studies showed an 
odds ratio of 1.97 (95%CI 1.61 to 2.40). In contrast to the figures for cardiovascular 
disease, men, rather than women showed a higher risk of developing cerebrovascular 
disease, associated with elevated Hcy. 
Elevation in Hcy again shows a linear and graded risk in association with 
cerebrovascular disease. In a prospective cohort study, involving almost two thousand 
participants the associated risk of subsequent stroke incidence increased with increasing 
quartile of baseline Hcy concentration34. 
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1.2.1.3 Peripheral vascular disease 
In addition to the vascular disease of major organs, increased Hcy shows a strong 
association with peripheral vascular disease32. Where peripheral disease is present, 
circulating Hcy concentrations may predict adverse outcome of surgical intervention, 
for example those with higher Hcy levels have a higher incidence of vein graft 
restenosis following lower extremity bypass. 
1.2.2 Cognitive decline and Alzheimer’s Disease 
In recent years there has been increased interest in the possibility that Hcy 
metabolism is involved in cognitive decline, eventually leading the development of 
Alzheimer’s Disease. Investigations into the metabolism and mechanisms involved 
form a major part of this thesis; as such this clinically important link will be discussed 
in depth later (see Chapter 4). 
1.2.3 Adverse pregnancy outcomes 
The Hordaland Homocysteine study was designed to investigate the relationships 
between established cardiovascular risk factors and plasma Hcy, however, within this 
fraction of the Norwegian population, high Hcy levels also correlated with a higher 
incidence of adverse outcomes in pregnancy, including neural tube defects (NTD)35. 
Pre-eclampsia, prematurity, low birth weight and increased frequency of miscarriage 
were also observed in women with Hcy concentrations in excess of 15µmol/L. 
After cardiac defects, isolated, i.e. nonsyndromic, NTD are the most common 
congenital structural defects worldwide. The average prevalence is 1 in 500, although 
incidence is dependent on country, ethnicity, and socio-economic class. In Finland the 
incidence is relatively low at 1 in 2500, but in South Wales as many as 1 in 80 births 
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occur with some form of NTD. These rates, however, exclude spontaneous abortions, 
and it is estimated that less than 2% of NTD affected pregnancies will result in a live 
birth, with most (93%) not developing beyond the embryonic stage. The figures suggest 
that the actual incidence of NTD affected embryos may be as high as 1 in 10. 
NTD and its association with folate and Hcy is thoroughly reviewed in a recent paper 
by van der Put et al.4. The link between folate, or at least nutritional adequacy and 
NTD, has been known about for many years, yet the mechanisms concerned have yet to 
be elucidated in full. However, as more is known about the involvement of folate in Hcy 
metabolism, theories may be established to explain the observed associations between 
folate intake and the development of NTD in pregnancy. 
In studies of serum folate levels there appeared to be no difference between those 
women whose pregnancies were normal compared to those that went on to have a child 
with NTD4. However, in the first trimester, the levels of red cell folate, an indicator of 
folate stores, were lower, in the cases of NTD affected births. Therefore, although folate 
intake may be adequate during pregnancy it is more important to have an adequate store 
of folate prior to conception. Closure of the neural tube occurs towards the end of the 
first month of pregnancy, before most women are aware that conception has taken 
place, therefore it is recommended that folate is supplemented peri-conceptually. 
Studies have shown that such measures decrease the incidence of NTD, and it may be 
possible to prevent up to 70% of affected pregnancies. 
The elevated Hcy levels observed in women with NTD pregnancies may be a 
consequence of a deficiency in folate, or in the enzymes involved in the remethylation 
cycle, which may be overcome by folate supplementation. Two common mutations in 
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the MTHFR gene are associated with an increased risk of NTD. In each case, the 
deficiency may be overcome by additional folate intake. 
Although it is clear that folate supplementation reduces the risk of NTD, the reason is 
not fully understood. Folate is involved in DNA synthesis within the developing embryo 
both directly, acting as a substrate for the enzymes involved in the process, and 
indirectly through the regeneration of S-AdMet, via Met, which is used to methylate the 
developmental genes. Such methylation is partly responsible for the regulation of these 
transcription factors. Regulation which needs to be tightly controlled, particularly in the 
rapid changes involved in gene expression associated with neural tube closure. 
Therefore, a maternal disturbance in folate metabolism may result in low folate levels in 
the developing embryo, leading to defective DNA synthesis, or impaired transcription 
of genes involved in the closure of the neural tube. 
Hcy may be acting purely as a marker of impaired folate metabolism. However, 
theory and evidence suggests that Hcy may also be directly involved in the mechanisms 
of defective tube closure. When Hcy was applied to chick embryos during the closure 
process, defects were induced suggesting a directly toxic effect. Increased Hcy leads to 
an increase in its precursor, S-AdHcy, which inhibits the action of methyltransferases, 
thereby mimicking the effects of S-AdMet depletion occurring in a deficiency of the 
folate cycle. In addition to DNA methylation, methylation involving S-AdMet is 
necessary for the proteins, actin and myosin filaments, required for contraction and 
folding in the process of neural tube closure. 
One final theory is that in some cases, increased Hcy may be an indicator of reduced 
MS activity, which would also lead to a depletion of Met and S-AdMet. Removal of the 
negative allosteric effect of S-AdMet on MTHFR activity, leads to an increased 
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production of 5-MeTHF (Figure 1). This form of THF cannot be converted to the forms 
required for nucleic acid synthesis, a process commonly referred to as the “methyl trap 
hypothesis”, which could lead to an insufficient supply of materials required to close the 
neural groove. 
1.2.4 Cancer 
Certain forms of cancer are frequently associated with high circulating levels of Hcy. 
In some cases this may be expected as several drugs used to treat cancer act through 
their anti-folate properties, thus inhibiting cell growth and division, however, in a case 
controlled study, women with Hcy levels in the highest three quartiles had statistically 
significant elevations in their risk of developing invasive cervical cancer, compared to 
women in the lowest quartile for Hcy36. None of the women involved in this study were 
on chemotherapy and their Hcy levels were not related to folate intake. What was more 
concerning was that women, whose Hcy level was ≥6.3µmol/L, showed risk factors of 2 
to 3 times, those with values <6.3µmol/L, i.e. increased cancer risk was observed at the 
low end of what would be considered to be “normal” Hcy concentrations. 
However, it is again unclear whether Hcy is the cause of the tumour or results from 
its presence. Disruption of one carbon metabolism may interfere with DNA synthesis, 
repair and methylation in a similar fashion to the mechanisms proposed in the 
development of NTD. In cancer, regulation over these processes is lost, leading to 
uncontrolled cell division and growth and subsequent tumour development. 
In samples taken from cancer patients, plasma Hcy fluctuations coincided with 
fluctuations in tumour markers for breast, ovarian, colonic and pancreatic carcinoma37. 
Cultured cell lines taken from tumour cells released much more Hcy into the culture 
media than normal cells37. However, when expressed as Hcy concentration per cell 
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number the difference between tumour cell lines and normal cells was much less 
pronounced, therefore, Hcy production may simply be a marker of rapidly proliferating 
cells. More significantly perhaps, as the cells started to die, Hcy production declined 
whereas the concentration of tumour markers continued to rise. Hcy may therefore 
reflect the number of live viable cells, whilst tumour markers reflect the total cell 
burden (live and dead cells combined)37. Proliferating cells create a drain on folate 
stores as a result of DNA synthesis. This folate depletion causes increased Hcy, due to 
impaired remethylation and Hcy is therefore exported into the circulation. 
Thus Hcy may be a much more sensitive marker of tumour activity, than those 
currently used, reflecting the number of surviving tumour cells, enabling monitoring of 
treatment with cytotoxic drugs providing that these do not interfere with folate 
metabolism. 
1.2.5 Renal disease 
Patients with chronic renal disease have plasma Hcy concentrations which are much 
higher than the moderate elevations commonly found in patients with atherothrombotic 
vascular disease38-41, with some 75% of nephrology patients showing plasma Hcy 
concentrations of >13µmol/L38. Hcy is unlikely to be the cause of renal failure, but may 
be the consequence of reduced elimination of amino acids in the urine, in particular 
some sulphur containing amino acids. However, it is more likely that compromised Hcy 
metabolism within the kidney contributes to the elevation in plasma concentrations, as 
the kidney is one of only four tissues in mammals found to possess all the enzymes 
responsible for Hcy degradation through the transsulphuration pathway42. However, in a 
study conducted by Gale et al, although the severity of carotid atherosclerosis was 
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greatest in those with the poorest renal function, and those with the poorest renal 
function had the highest Hcy levels, the two relationships appeared to be independent40. 
1.3 Proposed mechanism of vascular damage 
Associations between raised Hcy levels and several clinical disorders are well 
founded; however the finding of an unusual level of a compound in a disease state does 
not provide information or evidence as to whether the compound is the cause of the 
disease or an effect of disturbed metabolism caused by the disease itself. Some of the 
possible mechanisms by which raised Hcy may be involved in the development of 
disease have been discussed above; however, the absolute mechanisms whereby Hcy 
may cause vascular damage remain unclear. 
Inborn errors of Met metabolism, due to CBS deficiency, or cobalamin C disease, 
share two significant features16;17. Firstly, if untreated, they all develop progressive and 
premature vascular disease in the form of atherosclerosis and thrombus formation in the 
arteries and veins of major organs. Secondly, in each case the disturbance in Met 
metabolism results in high levels of circulating Hcy. It is therefore plausible that Hcy, 
or an Hcy derivative is directly toxic to the vessel walls. 
Several reviews summarise the experimental evidence to date9;43-46. The consensus 
opinion is that Hcy may be implicated as a participant in several processes, which may 
lead to vascular damage and dysfunction, resulting in atherosclerosis. 
One barrier to developments in this field is the difficulty in mimicking slow 
atherosclerotic effects in short term in vitro studies. Therefore there is a tendency to use 
very high levels of Hcy compared to those present in the plasma of individuals with 
hyperhomocysteinaemia. Very few studies exist on in vivo models, however one study 
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used a primate model in which moderately raised Hcy levels were induced by dietary 
intervention, and found that upon relative stimuli, increased Hcy levels caused increased 
vasoconstriction or decreased vasodilation resulting in reduced blood flow to the 
limbs47. Hcy may produce these effects either through decreased responsiveness of the 
vascular smooth muscle to the endothelial derived relaxing factor, nitric oxide (NO), or 
through inactivation of NO. 
Hcy may also be directly toxic to the endothelial cells. There is a growing body of 
evidence to suggest that Hcy promotes oxidative damage through the formation of free 
radical species. If Hcy metabolism is impaired, excess intracellular Hcy is exported into 
the circulation, where it rapidly undergoes auto-oxidation, resulting in the production of 
hydrogen peroxide, superoxide and hydroxyl radicals, which may be damaging to the 
vasculature. A chain reaction of events then occurs in an attempt to repair the damage. 
However, Hcy has also been shown to interfere, in several repair processes, in such a 
way as to cause fibrous plaques to develop, which may be followed by thrombosis and 
infarction. 
Lesions in the elastic membrane of the vessel are followed by increased proliferation 
in the smooth muscle cells, which leads to intimal thickening and the development of 
fibrotic plaques. In the inborn errors of metabolism associated with high Hcy levels, 
these plaques differ from those seen in the vessels of elderly atherosclerotic vessels in 
their lack of deposited lipids, implying that the underlying vascular pathology is 
independent of circulating lipid levels. 
By the age of 15 years almost 30% of untreated CBS deficiency cases will have 
suffered a thromboembolic event16. Hcy may predispose to thromboembolism through 
disruption of the components of the clotting cascade. Raised Hcy has been shown to 
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enhance the activities of factor XII and factor V, and depress the activation of protein C. 
Hcy also leads to decreased expression of the natural anticoagulant, heparin sulphate, 
and blocks tissue plasminogen activator binding to human endothelial cells. Combined 
these events may lead to inappropriate thrombus development and vascular occlusion. 
Macroscopic changes, including the development of atherosclerotic plaques occur 
later in the progression of vascular disease. Cholesterol has now become widely 
recognised as a risk factor for heart disease yet on its own it possesses few atherogenic 
properties and requires oxidative modification before it becomes damaging to tissues. 
The development of free radicals caused by autooxidation of Hcy may lead to oxidative 
modification of low-density lipoprotein (LDL) enhancing LDL binding at the site of 
fibrous plaques through the binding of lipoprotein (a) to fibrin. Inflammation resulting 
from vascular damage attracts macrophages to the site which may take up the modified 
LDL, leading to the development of foam cells, and the accumulation of lipids within 
the pre-existing fibrous plaques, eventually leading to occlusion of the vessel. 
Raised Hcy may therefore result in vascular disease through a combination of 
vascular injury, vascular dysfunction, and disturbance of antithrombotic activities 
predisposing to platelet adhesion and thrombus formation. 
1.4 Determinants of Hcy 
The complex metabolism of Met and Hcy is described in detail earlier (Section 1.1 
and Figure 1). The pathway involves several enzymes, which require cofactors and 
substrates such as B vitamins and folic acid. Genetic or acquired abnormalities in many 
of the steps involved in the pathway may result in raised circulating Hcy levels. The 
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extent by which Hcy is elevated depends on the severity of the underlying defect, and in 
many cases can be overcome, or at least controlled by dietary intervention. 
As a follow on to the initial cohort studies34 which had their basis in determining risk 
factors for vascular disease, several second generation studies have been established, 
such as the Framingham offspring study, and the Hordaland Homocysteine Study, 
focussing initially on obtaining cross-sectional data, on the relationship between Hcy 
and life-style and risk factors related to chronic diseases, in particular cardiovascular 
disease 35;48-50. In the longer term, these studies aim to relate Hcy to future all cause and 
coronary heart disease mortality and morbidity. In the mean time 
hyperhomocysteinaemia has been found to be associated with several physiologic and 
lifestyle factors, including age, gender, blood pressure, serum cholesterol, smoking, 
alcohol and coffee consumption, physical activity, diet and vitamin status. 
Although genetic causes of disturbed Met metabolism may result in marked 
elevations in Hcy, in the general public a combination of acquired and environmental 
factors results in a wide range of observed Hcy concentrations. 
1.4.1 Genetic variability 
Classical homocystinuria is a deficiency in the CBS gene14, so severe that Hcy levels 
exceed the renal threshold and homocystine becomes detectable in the urine12. Since the 
discovery of the initial cases, it has come to light that individuals with CBS deficiency 
are a heterogeneous population, with varying degrees of responsiveness to vitamin B6 
therapy (vitamin B6 being the cofactor for the CBS enzyme). In some cases, individuals 
show no improvement in their Hcy levels when treated with vitamin B6, whereas in 
others a combination of Met reduction and vitamin B6 treatment can reduce Hcy levels 
to near normal. Therefore, in CBS deficiency, the age of onset of symptoms, and the 
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clinical severity of the disease, differs considerably between cases16, being influenced 
by the nature of the defect within the coding gene. 
Hcy usually exists in the circulation in very small amounts, and therefore most of the 
factors influencing Hcy levels are concerned with elevations above normal 
concentrations, however, an unusual situation occurs in Down’s syndrome, or trimosy 
21. As the CBS gene is located on chromosome 21, this group of individuals has a gene 
dosage of 150% of normal, consequently they clear Hcy, through the transsulphuration 
pathway, much more efficiently, leading to very low Hcy and Met concentrations, with 
increased levels of cystathionine and Cys51. However, as Hcy is not available for Met 
regeneration, a decrease in MS activity creates a “methyl trap” similar to that described 
in the case of NTD, whereby 5-MeTHF fails to be converted to THF. THF being the 
metabolically active form of folate required for de novo synthesis of nucleotides for 
RNA and DNA synthesis. Although the transsulphuration pathway is stimulated, 
glutathione levels are significantly lower in Down’s syndrome than in control subjects. 
Glutathione may be depleted due to increased oxidative stress caused by over 
expression of the Cu-Zn superoxide dismutase gene that also resides on chromosome 
21. 
Patients with genetic defects affecting MS activity have also been reported. These 
may be related to defects in the enzyme itself, as appears to be the case in cblG, or they 
can be defects in the redox proteins involved in the activation of MS as seen in cblE 
patients5 (see Figure 2). In both cases reduced MS activity leads to the same clinical and 
biochemical outcome, of megaloblastic anaemia, homocystinuria and 
hypomethioninaemia. 
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There have been conflicting reports about the association of several genetic 
polymorphisms in the enzymes involved in Met metabolism and their possible 
association with vascular disease. This inconsistency may lie in a failure to address the 
effects of combinations in genetic variability, and environmental factors. Mild genetic 
defects may, under normal circumstances, have no effect on the metabolism, however 
under stressed conditions, such as inadequate nutrition, or stress in the case of infection 
or ischemia, these mild defects may come to light through a temporary accumulation of 
metabolic intermediates. Should the stressed conditions be prolonged, or repetitive, 
elevated intermediate levels may result in the development of disease. 
One such case is found in a commonly occurring polymorphism, which exists in the 
enzyme MTHFR, involved in Met regeneration from Hcy (Figure 1). A mutation of      
C → T at position 677 in the gene causes a deficiency in the protein, such that the 
enzyme becomes thermolabile. When folate status is adequate, the enzyme is capable of 
maintaining homeostasis. However, the enzyme possesses a low catalytic activity and 
reduced affinity for 5,10-MTHF and the flavin adenine dinucleotide (FAD) cofactor, 
such that when folate levels are only moderately reduced the enzyme becomes stressed 
leading to an increase in Hcy concentration. Therefore individuals possessing the TT 
genotype have an increased predisposition towards hyperhomocysteinaemia which is 
governed by lifestyle35, which may explain the inconsistency of reports looking at 
MTHFR themoliability and Hcy concentration. 
Several enzymes are involved in Hcy metabolism and it possible that mild defects in 
any of these may lead to alterations in Hcy levels, under stressed conditions. 
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1.4.2 Age and gender 
Prior to puberty Hcy levels are very similar in boys and girls52. Although Hcy 
increases are observed within both sexes with increasing age, between the ages of 
puberty and the menopause, plasma Hcy concentrations are on average lower in females 
than in males48. This phenomenon may be related to higher circulating oestrogen levels 
in women, which is supported by the evidence that in the post menopausal age group, 
the differences between men and women become less pronounced35. 
In order to investigate this theory further, Giltay et al.53, observed the effect on Hcy 
levels, caused by sex steroids used in the treatment of transsexuals. Prior to treatment, 
male to female (M→F) transsexuals had slightly higher Hcy levels at baseline than 
F→M, although this difference was not significant. However, following treatment with 
ethyl estradiol and antiandrogens, Hcy levels dropped from a mean of 8.2µmol/L to 
5.7µmol/L, conversely, F→M transsexuals, treated with testosterone esters, showed an 
increase in Hcy from 7.7µmol/L to 9.0µmol/L. 
These findings support the theory that sex steroids in some way may be responsible 
for the gender differences in circulating Hcy. Furthermore, when the results on all 
subjects were controlled for proportional change in plasma creatinine level, the effects 
of steroid treatment on Hcy levels disappeared, thus implying that the differences may 
be due to the anabolic or catabolic effects of steroids on muscle mass, and muscle 
turnover. Young weight lifters using additional androgenic steroids, in an attempt to 
improve their muscle mass and hence their performance, have been shown to develop 
premature myocardial infarction and stroke54, which may be related to increased 
circulating Hcy. 
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Although some of the effect of steroids on Hcy levels may be due to muscle turnover 
a primary hormonal effect should not be excluded. In the study of Giltay et al.53, M→F 
transsexuals who had no change in creatinine level, still showed a 20% decrease in Hcy, 
suggesting a direct effect of oestrogens on Hcy. 
Increasing Hcy levels over the early years of development may therefore be due to 
increasing muscle mass, when boys reach the age of puberty they show a marked 
increase in Hcy, in conjunction with increased androgens53. However, the general 
tendency for Hcy levels to increase with increasing age in both genders may be due to 
declining nutritional status with increasing age. It has been shown that the mean Hcy 
levels can be decreased in an elderly population by an improved diet, however a decline 
in renal function, and impaired absorption of nutrients, from the intestine associated 
with age may also contribute to higher Hcy levels being observed in this age group55. 
1.4.3 Pregnancy 
Substantial reductions in Hcy levels are observed during pregnancy56, which appear 
to be independent of folate status and rapidly return to normal within two to four days 
post delivery. It is not clear what causes these changes but it may be an adaptation 
during pregnancy in order to maintain adequate placental circulation. It is also possible 
that for some reason the foetus is involved in the uptake of maternal Hcy. 
1.4.4 Disease states 
In some disorders raised Hcy is considered to be an effect rather than the cause of the 
underlying disease state. However, it may explain some of the vascular pathology, 
associated with these conditions. The association of hyperhomocysteinaemia, with 
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cancer and renal disease, and how in each case the disease may be both an effect and 
exacerbating cause has been discussed earlier in section 1.2. 
Moderate elevations in plasma Hcy have also been shown in hypothyroidism, and 
hypothyroid patients have a high prevalence of coronary artery disease57;58, however the 
reasons behind these observations are unclear. The effect of hypothyroid disease 
causing impaired renal function may be an explanation57. In addition hypothyroidism is 
associated with a decreased ability to convert riboflavin to FAD, the cofactor required 
for the action of MTHFR involved in Hcy remethylation. This may be due to decreased 
circulating thyroxine levels, since treatment with thyroxine, resulting in euthyroidism 
has been shown to reduce Hcy concentrations to within reference ranges58. 
1.4.5 Medications 
Several therapeutic drugs interfere with Met metabolism in some way, leading to 
mild hyperhomocystinaemia. In most cases Hcy levels revert to normal upon cessation 
of treatment. 
Methotrexate, a cytotoxic drug used in cancer chemotherapy, prevents cell 
proliferation through its interference in folate metabolism. However, depletion of folate 
leads to a decrease in the remethylation of Hcy. 
Anticonvulsants, such as phenytion and carbamazepine, inhibit the polyglutamation 
of folate which is important for cellular retention and storage of folate in addition to 
playing an important role in the normal functioning and regulation of one-carbon 
metabolism4. 
Bile sequesterants, such as cholestyramine, prevent the reabsorption of bile from the 
gut and thereby lower cholesterol levels, through an increased demand for cholesterol in 
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the regeneration of bile. However, they may also interfere with folate and vitamin B12 
absorption from the intestine. 
Nitrous oxide, or laughing gas, may cause transient rises in Hcy levels, due to the 
irreversible oxidation of cob(I)alamin (Figure 2), and the inactivation of MS. 
Theophylline, a bronchodilator used in the treatment of asthma, emphysema and 
bronchitis, may also cause disturbed Hcy metabolism, leading to transient, post-prandial 
increases in Hcy, as the drug impairs pyridoxal phosphate (vitamin B6) synthesis, by 
inhibiting pyridoxal kinase. 
Cyclosporin A is used as an immunosuppressant following organ transplant, however 
treatment needs to be closely monitored as some of the metabolites are nephrotoxic. 
Impaired renal function may therefore explain the association between cyclosporin 
treatment and elevated Hcy levels. 
Decreased Met and S-AdMet, and increased Hcy levels were seen in a group of 
patients treated with levodopa for the relief of Parkinson’s disease59. Levodopa is 
administered with dopa decarboxylase inhibitors, in order to prevent its peripheral 
degradation. However, as a consequence, conversion of levodopa to 3-O-methyldopa, is 
increased which requires the transfer of a methyl group from S-AdMet, leading to 
mildly increased levels of Hcy (Figure 1). 
Some sulphhydryl containing drugs such as D-penicillamine, and N-acetylcysteine, 
may actually decrease Hcy, which is possibly due to thiol disulphide exchange, which 
may enhance excretion, or lower plasma protein binding, altering the distribution of 
Hcy. 
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1.4.6 Blood pressure and cholesterol 
In the Hordaland Homocysteine study a positive relationship between both diastolic 
and systolic blood pressure and plasma Hcy values was observed35. However, the 
correlation was weak and other studies have reported conflicting results and suggest that 
antihypertensive medication might be responsible for the observed associations48. A 
weak relationship was also observed between cholesterol levels and Hcy. 
1.4.7 Diet 
Diet has a large part to play in the control of Hcy levels. The primary source of Met 
is dietary protein, in particular protein derived from animal products. Affluent societies, 
which tend to have a high intake of meat, also show a higher incidence of 
cardiovascular disease compared to less affluent groups. Yet, strict vegetarians, who 
refrain from all foods of animal origin, have been shown to have higher Hcy levels, than 
those with an omnivorous diet60. Vitamin B12, important in the remethylation of Hcy to 
Met, is also typically found in foods of animal origin. Thus it appears that raised Hcy 
levels in individuals on a strict vegan diet can be explained by insufficient vitamin B12 
consumption. Vegetarians who maintained an intake of egg and dairy products, showed 
only a slight rise in median Hcy level, compared to high meat eaters, which did not 
reach statistical significance. 
It has been suggested that in the US, prior to the introduction of the folate 
supplementation program61, two-thirds of hyperhomocysteinaemia was attributable to 
inadequate blood levels of one or more of the vitamins involved in Met metabolism, in 
particular, vitamin B12 and folate55. These two compounds are responsible for 
maintaining homeostasis, whereas vitamin B6 is involved in post-prandial control of 
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Hcy levels. Transient rises in plasma Hcy may be detected following a meal, or post 
Met load testing, but in the absence of a severe enzyme defect, fasting 
hyperhomocysteinaemia, usually indicates a deficiency in the cofactors involved in 
remethylation. Hcy is a sensitive indicator of vitamin deficiency and plasma levels start 
to rise as vitamin levels drop below mean values, well before signs of any clinical 
vitamin deficiency. 
In the Hordaland Homocysteine study35 folate derived from food showed a weaker 
negative correlation to Hcy levels, than folic acid taken in the form of vitamin 
supplements. These observations may be due to poor estimates of dietary intake, or due 
to a greater availability of metabolically active forms of folate being derived from 
supplements. 
1.4.8 Smoking 
In both the Caerphilly50 and the Framingham Offspring48 cohorts, smokers had 
significantly higher Hcy levels than ex-smokers or those who had never smoked. The 
Hordaland Homocysteine study35 also showed a strong graded relationship between Hcy 
concentration and the number of cigarettes smoked per day. This was particularly true in 
women, where the estimated increase in Hcy corresponded to approximately 2% per 
cigarette per day. Following cessation of smoking habit, Hcy values usually return to 
normal within a short space of time. 
Smokers tend to consume a less healthy diet than non-smokers, and smoking itself 
may effect the metabolism of B vitamins leading to altered Hcy metabolism48;62. 
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1.4.9 Alcohol 
Chronic alcoholism leads to increased plasma Hcy levels, relating to low levels of B 
vitamins63. The relative increase in Hcy and decrease in folate however appear not to be 
related to the intensity of alcoholism, the presence of liver disease or renal failure, but 
are in fact influenced by irregularity in feeding patterns. Moreover, 
hyperhomocysteinaemia is more intense in those patients who are homozygote for the 
TT polymorphism of MTHFR. Upon withdrawal, improved feeding habits in 
hospitalised patients can reduce Hcy levels by up to 40% over the course of couple of 
weeks. 
Animal models and in vitro experiments however showed a direct relationship to 
increases in Hcy64-66. It is believed that acetaldehyde a metabolite of ethanol, forms 
covalent adducts with proteins that are inhibitory to MS activity. Folate deficiency due 
to irregular feeding habits may simply exacerbate the problem. 
Mild alcohol consumption on the other hand, may help to reduce Hcy levels. A weak 
U-shaped relationship was observed in the Hordaland cohort35, with a negative 
correlation between Hcy concentrations and the level of alcohol consumed up to 14 
units per week. Beyond this point a positive relationship developed. 
In the Caerphilly study50, moderate alcohol intake was again negatively correlated 
with Hcy levels. However, it was noted that the cohort consisted of a large group of 
men in whom the preferred beverage was beer, which contains a large amount of folate. 
A recent intervention trial showed that red wine and liquor consumption correlated 
with an increase in Hcy, but beer consumption did not67. These findings were confirmed 
in the Framingham Offspring Cohort48. Consumption of spirits also led to a decrease in 
folate levels, although this was not the case with red wine. 
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1.4.10 Caffeine 
Heavy coffee consumption has been reported to increase Hcy levels35. However, this 
was not the case with decaffeinated coffee, implying that caffeine is in some way 
interfering with Met metabolism. This theory was strengthened in the Framingham 
Offspring study48 where Hcy levels were also positively associated with consumption of 
soft beverages containing significant levels of caffeine. 
1.4.11 Physical activity 
Levels of physical activity have been shown to be inversely related to Hcy levels35, 
however this may reflect a healthier attitude to lifestyle, which may be associated with a 
better diet. 
1.4.12 Combined influences 
Several factors affect Hcy levels, and these factors may combine, such that an 
individual who is a heavy drinker and smoker, who consumes a poor diet, may have 
much higher levels of Hcy, and therefore be more at risk of vascular disease, than a tea 
total, non smoker, who is well nourished. 
In the Hordaland cohort35, individuals with contrasting lifestyles of folate intake, 
caffeine consumption, and smoking showed 3-5µmol/L differences in their Hcy 
concentration. The total differences were greater than could be ascribed to each 
individual factor, therefore suggesting that each factor has its own individual 
mechanism for influencing Hcy concentrations. 
Furthermore, such effects may be responsible for the skewed distribution towards 
higher Hcy concentrations that are observed upon definition of population based 
reference ranges49. Reference ranges calculated in populations with high folate intake, 
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low caffeine consumption, who are generally non-smokers form an essentially normal 
distribution. 
1.5 Treatment of Hyperhomocysteinaemia 
The association of Hcy with a number of diseases is well founded, and several 
factors may cause elevations in circulating concentrations of Hcy. So how can the 
clinician help his patient to reduce their Hcy level? 
In homocystinuria, the first line of treatment is Met restriction in the diet. However, 
as Cys is produced from Met via Hcy, Cys then becomes an essential amino acid, 
requiring supplementation. 
CBS deficiency is a heterogeneous disease, some individuals may respond to vitamin 
B6 supplementation to improve the function of CBS and thereby reduce Hcy levels 
through the transsulphuration pathway. However, in some cases vitamin B6 therapy is 
unable to induce the activity of CBS, and treatment with folic acid and vitamin B12 
may be required to stimulate MS activity, and reduce Hcy levels through the 
regeneration of Met. Betaine therapy may also be useful to promote alternative 
remethylation pathways (Figure 1). 
Since vitamin B6 responsive individuals have some residual CBS activity, if they are 
left untreated they tend to have a better prognosis than those who would not response to 
vitamin B6 therapy. Untreated, vitamin B6 non-responsive, cases have a much higher 
incidence of mortality in their early years. In an international study of homocystinuria, 
death was shown to occur before the age of 30, in 23% of non-responsive cases, versus 
4% of vitamin B6 responsive cases16. Moreover, 50% of untreated cases were expected 
to have suffered a thromboemobolic event prior to the age of 30 years. Untreated 
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vitamin B6 non-responsive cases also show a much higher degree of mental retardation, 
than vitamin B6 responsives, with an average IQ of 57 versus 79. If detected early 
enough in new born screening programmes, vitamin B6 responsive individuals, who 
comply with treatment, may develop normal, or near normal intelligence levels. Upon 
treatment, it is possible to reduce Hcy levels dramatically, and vitamin B6 responsive 
cases may see their Hcy concentrations return to within population based reference 
ranges68, thereby greatly reducing the prevalence of complications69. In the vitamin B6 
non-responsive cases, where treatment is not as effective in reducing Hcy levels, 
complications may still occur, but compliance with the diet slows down the progression 
of the disease considerably, with patients showing improved IQ levels. 
Even if homocystinuria remains undetected until the teenage years, commencement 
of dietary treatment at this late stage can increase the life expectancy70. 
Although homocystinuric patients clearly have a better prognosis if their Hcy levels 
can be reduced by dietary intervention, their pre-treatment levels are much higher than 
the mild elevations associated with an increased incidence of cardiovascular disease in 
the general population. Nevertheless, it may still be possible to reduce Hcy levels in the 
population as a whole, possibly leading to a reduction in the incidence of associated 
disease. 
Eukaryotic cells are unable to synthesize folate de novo, therefore folate is an 
essential nutrient4. Natural sources include a wide variety of fruits and vegetables, 
particularly green leafy vegetables such as spinach or Brussel sprouts. Yeast, beans and 
organ foods such as liver are also rich in folate. Folic acid, the synthetic form of folate, 
is also present in several multivitamin preparations. Therefore improved diet and 
vitamin supplementation may help to lower Hcy levels, through stimulation of the 
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remethylation pathway (Figure 1). Even if plasma levels of vitamins B12 and B6, and 
folate are within the normal range, vitamin supplementation can effectively reduce Hcy 
levels32. 
Prior to government intervention in the US, two-thirds of the incidence of 
hyperhomocysteinaemia was attributable to inadequate B vitamin concentrations55 and 
it was estimated that over 80% of adults consumed less than the recommended intake of 
400µg / day of folate32. 
In 1993, the US government recommended that cereal products should be fortified 
with folic acid. The aim of this project was to increase folate intake by women of 
childbearing age in order to reduce the incidence of NTD, and fortification came into 
force by 1st January 199861. However although the level of supplementation suggested 
in this program (140µg / 100g cereal grain products) may increase plasma folate levels 
there are conflicting results as to the effect that such supplementation may have on 
effectively reducing Hcy concentrations to levels which might reduce the incidence of 
cardiovascular disease71-73. 
In 1995, Boushey et al.32, predicted that compulsory folic acid supplementation of 
flours and cereal products, could reduce the annual incidence of death due to heart 
disease by 30,000 men and 19,000 women per year, but this would require the 
introduction of a 350µg / 100g cereal grain products fortification scheme. 
In 2002, a recommendation to follow the example of the US and introduce a folic 
acid supplementation program in the UK, was rejected by the Food Standards Agency74, 
on the basis that folic acid supplementation may mask the anaemia whereby vitamin 
B12 deficiency usually presents. Progressive neurological damage may continue 
undetected, and may only present when severe damage has occurred to the spinal cord. 
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Therefore it may be wise to exclude vitamin B12 deficiency prior to folate fortification, 
or to introduce a combination of folate and vitamin B12 supplementation. 
Additional supplementation with approximately 1mg of oral vitamin B12 per day is 
expected to avoid the theoretical risk of neuropathy due to unopposed folic acid therapy 
in patients deficient in vitamin B12, even in those with intrinsic factor deficiency or 
malabsorption states. 
The minimum effective dose of any vitamin supplementation, of course, depends on 
the severity of the underlying deficiency. Whilst recommendations have been made for 
the reduction of Hcy levels in the population as a whole, hyperhomocystinaemia due to 
renal insufficiency, for example, may require much higher doses of folate. 
Following initiation of treatment, Hcy levels rapidly drop. On average values return 
to normal within four to six weeks, but some may respond to therapy much faster, and 
Hcy may fall into the normal range within as little as two weeks. 
The treatment of hyperhomocystinaemia is therefore, effective, inexpensive and 
relatively safe, although vitamin B12 supplementation may be recommended in addition 
to folic acid treatment. 
1.6 Treatment Targets 
Normal ranges, or more specifically “reference” ranges, will by the very nature of the 
way in which they are established, include a number of individuals with Hcy levels 
higher than might be desired. In Appendix A, a number of published poster abstracts 
and papers are included which make up a large part of the practical aspects of this 
thesis, Poster VI describes the establishment of a reference range for Hcy in accordance 
with IFCC guidelines75 on 143 volunteers. The method used was the Drew DS30 Hcy 
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system (Drew Scientific Ltd., Barrow-in-Furness, UK), a HPLC system that will be 
described in more detail in Chapter 2. Exclusion criteria stated that no participant 
should have a prior history of cardiovascular disease, and that the volunteers should 
have been abstinent, for at least 6 months, from any medications known to affect Hcy 
levels. In this population a skewed distribution towards higher Hcy levels was observed 
in accordance with the findings of others49. Using a 95% interval the reference range 
was determined as 5.2 to 15.1µmol/L, which is also in line with other publications76. 
Hyperhomocysteinaemia therefore refers to a Hcy concentration above the defined 
reference range; moderate elevations are between 15 to 30µmol/L, intermediate 
increases as may be observed in heterozygotes for CBS deficiency are in the region of 
31 to 100µmol/L, and anything over 100µmol/L must be described as severe 
hyperhomocysteinaemia, which is usually only present in those homozygote for an 
inborn error of metabolism77. 
Differences in reference ranges do occur however, and these may be due to 
differences in the performance of the methods used to analyse Hcy, or they may be due 
to true population differences. Therefore it is recommended that each laboratory should 
establish an appropriate reference range based on healthy individuals from the 
population under investigation. 
Nevertheless, reference ranges are far from ideal in setting treatment targets. As Hcy 
concentration shows a graded association with disease risk, it may not be wise to think 
in terms of threshold values but the lower the level that can be achieved through 
intervention the better. A 5µmol/L reduction could potentially lessen the risk of vascular 
disease by as much as 80%32. 
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Many studies have looked at different treatment regimes to assess the degree of Hcy 
reduction possible through intervention. These include studies on folate, vitamins B12 
and B6 and combinations thereof. In an attempt to determine the optimal treatment 
regime, the Homocysteine Lowering Trialists' Collaboration, performed a meta-analysis 
on data from 1114 patients who participated in 12 trials covering periods of 3 to 12 
weeks duration78. The aim was to evaluate the extent by which Hcy could effectively be 
lowered to assist in the development of protocols for future intervention trials. They 
found that a greater proportional and absolute reduction occurred in those with higher 
pre-treatment Hcy levels and lower pre-treatment folate levels, but no association was 
found with vitamin B12. Those within the highest quintile of pre-treatment Hcy values 
showed that a 39% reduction (95% CI 36% to 43%) in Hcy concentration was possible, 
whereas those in the bottom fifth, showed only a 16% reduction (95% CI 11% to 20%). 
Standardising to a starting Hcy concentration of 12µmol/L and folate of 12nmol/L 
(approximately average concentrations for Western population), the meta-analysis 
estimated that supplementation of dietary folic acid may be capable of reducing Hcy 
levels by approximately 25% (95% CI 23 to 28%), with similar effects observed across 
a range of daily dosages (0.5mg to 5mg). Complementary vitamin B12, given as 0.02mg 
to 1mg daily (mean of 0.5mg), could lead to an additional reduction of 7% (95% CI 3 to 
10%). Vitamin B6 (mean 16.5mg / day) was not particularly effective in reducing Hcy 
values as it is involved in post-prandial metabolism rather than in maintaining Met: Hcy 
homeostasis. 
It is therefore predicted that dietary supplementation may reduce Hcy levels in a 
Western population by a quarter to one third of current values. Such an estimate 
corresponds to a reduction from 12µmol/L to approximately 8 or 9µmol/L. 
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Boushey et al.32, indicated that a prolonged lowering of Hcy concentration by 
1µmol/L was associated with a 10% reduction in risk, throughout the range of Hcy 
concentrations from 10 to 15µmol/L. If a 3 to 4µmol/L reduction in Hcy could be 
achieved by intervention, this could lead to a 30 to 40% reduction in the incidence of 
vascular disease. 
1.7 The current position 
Although it has been shown that dietary intervention is capable of reducing Hcy 
concentrations, the true effect that this could have on reducing the incidence of disease 
remains to be determined. Therefore, there is still some debate on the benefits of 
treatment79. 
It is hoped that treatment will at least retard, if not stop the progression of vascular 
disease. It may also be possible to reverse the damage that has already been done, 
through the regeneration of tissues and the shrinkage of vascular plaques. 
To date a number of randomised control trials have shown that lowering Hcy 
improves surrogate markers of cardiovascular disease, for example vascular function 
may be improved80-83 or the rate of restenosis following coronary angioplasty may be 
decreased84-86. However, many of the studies that have shown vascular improvements 
have used quite high doses of folic acid (~5mg / day) and the effects may be dose 
dependent, although folate supplementation of 400µg / day may be capable of reducing 
Hcy concentrations, at this dosage no improvement to endothelial function was noted87 
and the US supplementation program is using an even lower dose61. 
The addition of B vitamins to the treatments used in these studies complicates the 
interpretation. Where B12 and B6 were provided in the form of supplements, Hcy 
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reduction was greater than with folate alone, and in general more positive outcomes are 
observed, however Hcy reduction maybe a side effect and the surrogate markers of 
vascular function may be related to other mechanisms involving B vitamins. A true 
benefit of Hcy reduction could only be proved if a number of treatments leading to 
reduced Hcy levels produced the same degree of reduced risk of vascular events. 
Although appropriate dosage regimes may improve vascular function, this tentative 
evidence of a potential benefit in Hcy reduction needs to be strengthened by 
demonstration in randomised control trials that lowering Hcy is followed by a 
significant reduction in the incidence of mortality and morbidity due to vascular disease. 
Within the last decade a number of large-scale prospective randomised clinical 
intervention trials have been initiated, and the results are starting to emerge. The details 
of nine of these studies are summarised in Table 1. Although each study is slightly 
different, they are all essentially designed to assess the effects of Hcy lowering on the 
prevention of vascular endpoints. Each trial will look at the potential benefits of folic 
acid supplementation versus placebo, and some will also include vitamin B12 and / or 
vitamin B6 in their assessments. In six of the trials detailed, the primary endpoint is 
coronary artery disease, whereas three trials will look at the possibility of reducing the 
incidence of stroke. We should expect to see preliminary results published from some of 
the studies over the course of the next couple of years. From these results it may be 
possible to determine an optimal treatment regime, for a reduction in the incidence of 
vascular disease as a whole. Of course it may be shown that Hcy is not directly causal 
but is a purely a marker of disease and that folate levels are directly associated with 
vascular disease. 
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Table 1 Ongoing intervention trials using folic acid to lower Hcy concentrations. 
Primary 
End Point 
Study Name Base 
Country 
Sample 
Size 
Folic Acid 
dose (mg) 
Coronary artery disease 
 Western Norway B Vitamin Trial 
(WENBIT) 
Norway 2000 0.8 
 Cambridge Heart Antioxidant Study 
(CHAOS-2) 
UK 4000 5 
 Norwegian Study of Homocysteine 
Lowering with B-vitamins in 
Myocardial Infarction (NORVIT) 
Norway 3000 0.8 
 Prevention with a Combined Inhibitor 
and Folate in Coronary Heart Disease 
(PACIFIC) 
Australia 10 000 2 
 Study of the Effectiveness of 
Additional Reductions in Cholesterol 
and Homocysteine (SEARCH) 
UK 12 000 2 
 Women’s Antioxidant and 
Cardiovascular Disease Study 
(WACS) 
US 6000-8000 2.5 
Stroke 
 Heart Outcomes Prevention 
Evaluation-2 (HOPE-2) 
Canada 5000 2.5 
 Vitamin Intervention for Stroke 
Prevention (VISP) 
US 3600 2.5 vs. 0.2 
 Vitamins to Prevent Strokes 
(VITATOPS) 
Australia 8000 2 
 
One difficulty faced by several of these trials is that they were designed based on 
estimates of achievable Hcy reduction compared to control groups prior to the 
mandatory folic acid fortification of cereal products78, introduced in Northern America 
in 199861. Although this ruling was introduced to prevent folic acid deficiency during 
pregnancy in order to reduce the number of NTD affected births, it is likely that it will 
also have the effect of reducing Hcy concentrations in the general public and may assist 
in reducing the incidence of vascular disease. 
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In a study of coronary angiograph patients pre- and post- fortification the ruling 
appeared to achieve a 1.5µmol/L reduction in median Hcy levels88. There was also a 
shift in the distribution of results with a significant reduction in the number of patients 
with Hcy >15µmol/L. Mortality risk was slightly reduced but the results were not 
significant. Although over 2000 patients were followed over 2 years a much larger and 
longer study would be required to detect if such a modest reduction would be beneficial 
in the population as a whole. 
The consequence of mandatory folic acid fortification coinciding with the early 
phases of these large intervention trials, therefore, is that a reduction of ~1.5µmol/L 
Hcy may also be expected in control groups, and the predicted difference of 4 to 
6µmol/L between treatment and control groups may not be feasible in individuals 
residing in Northern America. 
Results are starting to emerge from some of the studies and it appears that the fears 
are being proved correct. Authors are suggesting that a failure to show a significant 
reduction in vascular events is due to underpowered studies, rather than a lack of 
association89-92. 
VISP, a US based study, was only able to achieve a Hcy reduction of 2µmol/L in a 
group of patients on high dose B vitamins compared to low dose90;92-94. Although a 
slight reduction in all cause mortality was observed this failed to reach significance92. In 
fact the selection criteria had to be adjusted to compensate for a shift in the expected 
Hcy distribution89. A further limitation was that the control group received the 
recommended daily intake of vitamin B1292. 
Both HOPE-2 and WACS, based in Canada and the US respectively, have also only 
managed to achieve meagre reductions in Hcy levels (approximately 1µmol/L)89. 
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In the UK, where mandatory folic aid fortification has so far been rejected74, 
CHAOS-2 achieved a 13% reduction in Hcy, but also failed to show a significant 
reduction in vascular events89. However in this study folic acid alone was used as 
treatment and B vitamins, in particular B12 may be required to achieve an adequate 
reduction in Hcy. A negative result may also be caused by a recent tendency for 
increased vitamin supplementation, and improved diet in the general population. 
Voluntary folic acid fortification is also becoming a popular practice with cereal 
manufacturers. 
If treatment is inexpensive and harmless, the potential benefits should not be 
dismissed on the basis of one or two negative results from studies that may well be 
underpowered. More worrying was the recently announced results of the NORVIT 
study95, which appeared to show that a combination of folate and B vitamins may 
actually increase the risk of cardiovascular disease. However an isolated result, in again 
what may be deemed an underpowered study, should not be enough to eliminate the 
theory that Hcy reduction is beneficial. 
VITATOPS, based in Australia, is recruiting patients in 19 countries, most of which 
do not have mandatory folic acid fortification. In light of the findings from VISP, an 
early assessment of Hcy reduction was conducted at one centre in Perth, Australia. After 
6 months of treatment, Hcy levels were 3.7µmol/L lower than levels in the placebo 
group94, indicating that this study may prove to be one of the first that is adequately 
powered to measure the effect of Hcy reduction on the incidence of serious vascular 
events. However the authors warn that in Australia voluntary fortification of foods with 
folic acid is increasing. Luckily perhaps the study includes several centres based in the 
Far East, where nutritional status is expected to be lower and free from the effects of 
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supplementation. This is also a much larger study than some of the published ones as 
calculations of the number of participants required were based on the detection of more 
modest predictions of relative risk reductions90. 
While awaiting publication of the remaining intervention trials, clinicians will have 
to judge whether they believe the potential benefits of vitamin supplementation 
outweigh the potential risks and costs. Although most studies have so far failed to prove 
any benefit, slight reductions in Hcy levels and cardiovascular events have been seen in 
addition to those brought about by population-based increases in folate intake. 
1.8 Summary 
Hyperhomocysteinaemia is implicated as a risk factor for several diseases. Hcy is 
influenced by several factors and plasma levels are determined by a combination of 
acquired and lifestyle factors. Treatment to reduce Hcy levels is inexpensive and safe, 
however, there is still some debate as to whether raised Hcy is a cause or effect of 
disease. Therefore it is important that research in this field continues so that we may 
establish the mechanisms by which hyperhomocysteinaemia causes disease and the 
potential benefits of treatment. 
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Aims 
The aim of this project was: 
• To study the metabolism of Hcy in detail in order to develop a method of 
stabilising whole blood samples for plasma Hcy measurement.  
• To study Hcy and its interaction with other aminothiol in patients with 
Alzheimer’s Disease. 
Objectives 
The main objective in the first part of this project was to produce a commercially 
viable method of stabilising Hcy in whole blood samples. 
In order to fulfil this objective the following targets should be met: 
• Develop an understanding of Hcy metabolism, and the factors influencing 
Hcy concentrations both in vitro and in vivo. 
• Determine the most suitable currently available method for Hcy stabilisation 
in whole blood samples and investigate its usage in a commercial product. 
• Produce a non-invasive in vitro method for investigation of potential 
stabilising agents. 
• Identify key enzyme(s) involved in Hcy production by erythrocytes as 
potential target(s) for inhibition. Develop an understanding of the reaction 
mechanisms, enzyme structure and key amino acids involved in substrate 
binding at the active site of the enzyme(s). 
• Use molecular modelling techniques to identify a subset of enzyme inhibitors 
for further investigation using the in vitro assay. 
• From the results of in vitro screening select one or two compounds for use in 
non-evacuated blood collection tubes in pilot studies. 
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• Select a single compound and produce a pilot batch of evacuated blood tubes. 
• Conduct clinical trials and shelf life studies to assess the performance of a 
commercially viable product, and compare it with the most effective currently 
available method. 
The objective within the second part of this thesis was to investigate plausible 
mechanisms linking increased plasma Hcy concentrations and the development of 
cognitive decline and Alzheimer’s Disease. This objective may be met, through studies 
using patients with Alzheimer’s Disease in the following way: 
• Study the relationship between Hcy, vitamin B12, and transcobalamin. 
• Investigate the theory that transcobalamin phenotype may determine Hcy 
concentrations. 
• Conduct studies to support the theory that vitamin B12 is involved in the 
development of Alzheimer’s Disease through a functional rather than a 
dietary deficiency. 
• Determine how Hcy relates to concentrations of the other aminothiols 
involved in remethylation and transsulphuration. 
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Hyperhomocysteinaemia has been associated with a number of disorders, particularly 
vascular disease. Expansion in this field of research has driven the requirement for fast 
and reliable Hcy analysis. Should prospective studies eventually provide confirmation 
of the beneficial effects of Hcy reduction on the incidence of vascular disease, then the 
establishment of widescale Hcy screening programs will increase the demand for 
accurate Hcy measurement within the clinical setting. 
2.1 Total Hcy 
The term “homocysteine” is often misused, it should relate to the free reduced form 
of the amino acid, but the term commonly refers to the sum of a number of compounds, 
including the free monomeric form, the oxidised dimer, and mixed disulphides. 
Disulphide links are formed with other thiols in the circulation, which are present either 
in the free thiol state or contained within protein structures. The methyl transfer 
reactions (Figure 1), which convert Met to Hcy, occur intracellularly throughout the 
body42. Although the thiol group of the Hcy is easily oxidised, the reducing potential of 
the intracellular environment maintains Hcy in its monomeric form. Upon export into 
the circulation, Hcy undergoes rapid oxidation to form disulphide bonds, the majority of 
which (~80%) are formed with cysteine residues within plasma proteins, in particular 
albumin, the principal protein present in the circulation. Another 5-10% of Hcy forms 
mixed disulphides with other plasma aminothiols, and 5-10% exists as the dimer, 
“homocystine”, only a trace amount (<2%) remains in the free form. During storage of a 
processed plasma sample, redistribution occurs such that virtually all the Hcy becomes 
bound to plasma protein. Therefore when assessing risk of vascular disease it is 
important to measure all forms of Hcy. This is achieved through the use of reducing 
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agents that break the disulphide bonds and allow measurement of “total Hcy”. 
Therefore, unless specifically stated analysis of plasma “homocysteine”, refers to the 
measurement of the sum of all these forms. 
2.2 Hcy Analysis 
Although there are methods available for measuring the different forms of Hcy, 
many of these are only suitable for a research environment and to date there is little 
information about whether measuring free Hcy has any advantage over measuring the 
total amount present, therefore the routine clinical laboratory remains focussed on 
analysis of total Hcy. 
There are currently a number of techniques available for Hcy measurement, many of 
which have been reviewed by Ueland et al.76 and more recently by Rassmussen and 
Møller31. The majority of methods can be loosely divided into two groups, those that 
use chromatography22-28, and those that are based on immunological techniques29;30. 
Other less popular methods include enzymatic colorimetric assays96, molecular 
imprinting techniques97 and substrate trapping using mutant enzymes98. 
2.2.1 Chromatographic techniques 
Hcy analysis was originally performed by thin layer chromatography. This 
qualitative technique was not sensitive enough to detect plasma levels of Hcy, and as 
part of a general screen was used purely as a way of detecting abnormally high levels of 
the dimeric form of the amino acid present in the urine of patients with severe inborn 
errors of metabolism. Much more sensitive analysis, capable of detecting a few µmol/L 
is provided by high performance liquid chromatography (HPLC). 
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In order to determine total Hcy, a reduction step is necessary in order to free Hcy 
from its covalent attachment to other thiol compounds. Reduction agents vary from 
method to method, earlier methods used compounds such as tri-butyl phosphine 22;27;28, 
and dithiothreitol23-25. These reducing agents tend to have poor solubility and certainly 
have an unpleasant aroma. A much more desirable alternative was offered in the form of 
tris(2-carboxyethyl)phosphine (TCEP)26 which is “nonvolatile, stable, and soluble in 
aqueous solution and thus is more suitable for routine use”99. 
Chromatography is used to separate out the different thiols present within plasma. In 
the plasma of a normal individual the most abundant total thiol is cysteine. Cysteinyl-
glycine, a breakdown product of glutathione is the second most abundant, and Hcy and 
glutathionine are usually present in much smaller quantities. In very fresh plasma, it is 
sometimes possible to detect γ-glutamyl-cysteine, which is an alternative breakdown 
product of the tripeptide glutathione following a single peptide cleavage; however this 
thiol rapidly degrades to undetectable levels. 
These compounds do not naturally absorb light or fluoresce, which are the easiest 
ways of detecting compounds emerging from a HPLC column, therefore some other 
method of detection is required. 
Various detection techniques are used, which may involve pre- or post- column 
derivitisation. However most methods rely on derivatives using either ammonium 7-
fluoro-2,1,3-benzoxadiazole-4-sulphonate (SBD-F), or 4-(aminosulphonyl)-7-fluoro-
2,1,3-benzodiazole (ABD-F) to attach to the sulphur of the thiol rendering the 
compound fluorescent. 
Some methods use electrochemical detection, since the thiol group is capable of 
undergoing redox reactions. However, since plasma contains a number of compounds 
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that undergo redox reactions, these methods produce noisy traces, which can be difficult 
to interpret. 
The advantage of chromatographic analysis is that it allows the simultaneous 
measurement of other thiol compounds within the plasma. Commercial kits based on 
HPLC methodology are currently available from several manufacturers. 
One such kit is used for Hcy measurements throughout this thesis. The DS30 Hcy 
Assay System, manufactured by Drew Scientific Ltd. (Barrow-in-Furness, UK), is a 
dedicated reverse-phase HPLC system with assay kits capable of measuring total 
plasma Hcy in 30 samples per batch. For full details of the assay kit, see the product 
insert (Appendix B). In summary the method uses cysteamine as internal standard, 
TCEP to reduce all disulphide bonds, tricarboxylic acid to precipitate protein and SBD-
F as a fluorescent tag. Correlation of the DS30 Hcy system against an in-house HPLC 
method using electrochemical detection is described in Poster VII. 
Where other thiols were estimated these were run using a software adaptation to the 
commercial method to allow quantification of Cys, cysteinyl-glycine and glutathione. 
2.2.2 Immunochemical techniques 
The development of a monoclonal antibody against a small molecule such as Hcy, 
which is specific enough to allow it to be distinguished from other plasma thiols with 
minor structural differences, has so far not been possible. However, one group has 
produced an antibody against its precursor S-AdHcy100. This antibody forms the basis of 
several commercially available immunochemical techniques available for Hcy 
measurement29;30. All immunochemical methods require two initial steps. Firstly Hcy 
needs to be reduced, so that total Hcy may be measured in the monomeric form. 
Secondly, the enzyme, SAHH must be used in the reverse direction to form S-AdHcy. 
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The antibody is then employed in several different fashions, depending on the method, 
in order to determine the amount of S-AdHcy produced in the reaction, the 
concentration measured is used as an estimate of the total amount of Hcy originally 
present. 
Although immunoassay only allows the measurement of a single analyte, it lends 
itself to the development of rapid and easy to use, automated analysis, requiring small 
sample volumes. 
2.2.3 Other Hcy methods 
In recent years new methodology has emerged with assays for Hcy based on 
enzymatic assay with fluorescent detection96, molecular imprinting techniques97, and 
substrate trapping enzyme technology98. However, to date, such methods have not 
found their way in to routine use. 
2.3 Sampling Techniques 
2.3.1 Sample type 
Hcy is produced from the intracellular metabolism of Met. This process occurs 
throughout the body42. If Hcy exceeds the capacity for remethylation, it is exported into 
the circulation and transported to the liver, kidney, pancreas and small intestine for 
utilisation in the transsulphuration pathway, leading to the formation of Cys and 
glutathione42. Intracellular concentrations of Hcy are therefore very low, and 
hyperhomocysteinaemia represents an increase in plasma Hcy, i.e. extracellular 
concentrations. 
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The absence of tissues capable of the transsulphuration pathway in vitro, means that 
any Hcy produced in the erythrocytes101, accumulates within the plasma. Plasma Hcy 
levels in whole blood samples have been observed to rise at a rate of some 10% per 
hour following venipuncture22;101. Since intracellular Hcy concentrations are some ten 
fold less than in the plasma, any rise in Hcy must be due to continued metabolism rather 
than cellular leakage. 
The current recommendation is to store collected blood samples on ice until such 
time as centrifugation can be performed. Once the red blood cells have been removed 
plasma Hcy is stable for at least 24 hours at room temperature and for several months, if 
not years, when stored frozen22. 
Hcy may be measured in plasma or serum. Only in the rare genetic disorder of CBS 
deficiency, does the level of Hcy become so high that it is detectable in the urine, which 
gives this disorder its name “Homocystinuria”. Hcy can be measured in serum, 
however, such samples are not ideal for Hcy measurement since significant rises in Hcy 
may be observed in the time required for adequate blood clotting to take place, therefore 
plasma is the sample of choice when screening for hyperhomocysteinaemia. EDTA is 
commonly used as anticoagulant, in addition to preventing blood clotting the chelation 
of divalent ions helps to prevent metal catalysed oxidation occurring within the sample 
during analysis. If the sample is not chilled and processed quickly, Hcy export from 
erythrocytes will cause rapid elevations in plasma Hcy concentrations101. 
If a 5µmol/L increase is associated with an 80% increased risk of vascular disease32, 
artifactual elevations in plasma Hcy, caused by delays in sample processing could easily 
lead to false positive results being reported. Although the treatment for 
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hyperhomocysteinaemia is simple and non-invasive, proper risk assessment demands 
accurate data. 
Several attempts have been made to modify collection procedures in order to prolong 
the stability of samples and avoid artifactual increases in plasma Hcy prior to sample 
processing in the laboratory. 
2.3.2 Storage temperature 
At present, the standard practise in the collection of samples for Hcy measurement is 
to put the whole blood sample on ice and centrifuge as soon as possible, preferably 
within 30 minutes to 1 hour post venipuncture. This protocol may allow plasma Hcy 
measurement to be undertaken within a small hospital with a fast and efficient portering 
system where one can guarantee that the samples will be received and processed within 
an hour of the sample being collected. However, as hospital resources are stretched 
increasingly, how confident can the clinician be that a sample has been correctly 
handled on its way to the laboratory, and that the Hcy values reported are an accurate 
assessment of the patient’s Hcy status? Hcy measurement is not undertaken as part of an 
emergency situation, and is likely to be carried out as part of a screening programme, in 
risk assessment or in clinical studies. If Hcy measurement is to move into the 
community, an alternative method of sample collection and handling must clearly be 
developed. 
Chilling samples may help to slow down the action of erythrocyte enzymes involved 
in the manufacture of Hcy. Alternatively, it may slow down the processes involved in 
Hcy export from the cells. To date, assessments into the stability provided by chilling 
samples23;102-104 has shown that the maximum period of stability reported is 6 hours on 
“ice”104. Although this may be more practical within a hospital environment than the 
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current recommendations, it still does not open up Hcy screening into the community 
setting. 
2.3.3 Acid citrate 
If ice is unavailable, acid citrate may provide an alternative means of sample stability 
in the short term under ambient conditions. Again, however, the maximum stability 
reported is only 6 hours at “room temperature”, and less if the temperature is higher, 
with significant changes being observed at 37ºC in under 4 hours105. Ducros et al.103, 
found that sample stability is also dependent on the method of analysis. All the 
chromatographic methods investigated showed sample stability when collected into acid 
citrate and stored at room temperature up to at least 4 hours after collection, whereas 
when using an immunochemical method (fluorescence polarization immunoassay), a 
significant change was observed over the same time course. Similar observations were 
reported by Salazar et al.106 and O’Broin et al.107 who showed a significant rise after 
two hours, or a 10% rise after 6 hours respectively when using an immunochemical 
method to measure Hcy. Whereas chromatographic methods measure Hcy itself, or an 
Hcy derivative, immunochemical methods are indirect. Hcy is estimated by the amount 
of its metabolic precursor, S-AdHcy, formed during the assay using the reverse reaction 
of the enzyme SAHH. In acid citrate the low pH may prevent Hcy production by 
inhibiting SAHH, however precursor build up is not prevented, thereby giving the 
impression of sample instability. Where stability is reported, there are conflicting 
reports about whether acid citrate increases105;107 or decreases106 baseline Hcy compared 
to EDTA stored on ice. This confusion may be related to corrections for dilution due to 
the addition of acid citrate as a liquid, requiring haematocrit estimates. Either way it 
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appears that the use of acid citrate in blood collection tubes for Hcy measurement would 
require separate reference intervals for interpretation. 
2.3.4 Cell lysis 
An attractive alternative for sample collection for Hcy measurement appeared to be 
offered in the way of capillary whole blood lysates108. Sample collection is easy, and 
less invasive than venipuncture. The blood collection tube contains a non-ionic 
detergent (such as Non-idet P40), which lyses the blood cells and hence dilutes the 
enzymes and substrates required for Hcy production. This method has been reported to 
stabilise Hcy concentrations for at least 2 days under ambient conditions. However, a 
flaw with this approach is that, even following correction for dilution caused by the 
lysing agents, the results produced are lower than those in plasma due to further dilution 
by intracellular fluid, which is low in Hcy. Much of the literature on Hcy focuses on 
measurements made in the plasma, and hence if this approach were to be used new 
reference ranges would need to be established, with a much lower threshold value 
associated with increased risk of vascular disease. Even if the reference ranges were 
corrected for lysate measurements, this takes no account of an individuals’ haematocrit 
and falsely high results may be observed in anaemic individuals with low haematocrit 
values. Further problems exist in relation to the assay used to measure Hcy, as greater 
method sensitivity would be required to differentiate between the lower concentrations 
obtained in blood lysates. 
2.3.5 Sodium fluoride 
Sodium fluoride samples, at 2 to 3 hours post collection have shown similar Hcy 
concentrations to baseline EDTA values109;110 and have therefore been recommended as 
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an alternative if there is to be a delay in sample collection. Yet on closer inspection, Hcy 
continued to rise over time. The fact that values at 2 to 3 hours post collection were 
similar to the baseline EDTA values was a result of an initial drop in concentration 
caused by the formation of hypertonic saline and consequential fluid shifts. This effect 
was confirmed by Hughes et al.111, who saw a sodium fluoride concentration-dependent 
drop in haematocrit. The theory behind the use of sodium fluoride as a stabilizer in Hcy 
samples is related to the fact that the fluoride inhibits anaerobic glycolysis and therefore 
ATP production. Conversion of methionine to S-AdMet, the first step in the production 
of Hcy, requires ATP. Therefore sodium fluoride may indirectly prevent erythrocyte 
Hcy production by removing one the substrates required in the early stages of the 
pathway from Met to Hcy. However, the fact that Hcy values continue to rise in samples 
collected into sodium fluoride, may be attributed to cellular reserves of S-AdMet, first 
postulated by Andersson et al.101. In contrast Scheidhauer et al.112 reported that 
following the initial drop in Hcy levels measured in plasma samples collected at 15 
minutes, between 24 and 144 hours post collection Hcy levels remained stable. 
2.3.6 Gel separator tubes 
Within recent years the drive towards minimising infection risk through primary tube 
sampling has meant that the use of serum or plasma separator tubes has become 
widespread. These tubes contain a gel that, following centrifugation, keeps the red cells 
apart from the serum or plasma. Provided that Hcy cannot cross this gel membrane the 
measured total Hcy concentration should be unaffected by the continued production 
from red cells. Serum separator tubes were shown to keep Hcy concentrations within 
4.5% of baseline levels over a 48hour period at room temperature113. Although this 
study showed only a small increase in Hcy levels, the tubes require time for the blood to 
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clot before centrifugation can take place and there is potential that at elevated ambient 
temperatures significant rises in Hcy may occur during this time. In a recent study 
heparinised gel tubes were used which could be centrifuged immediately after 
collection114. The samples were then stored at 2 to 8ºC prior to analysis. Heparinised 
plasma Hcy levels remained stable for up to 72 hours. 
The downside of either of these types of tube is that they require a centrifuge at the 
site of blood collection prior to transport. Additionally EDTA is the recommended 
sample type for several methods and as yet no gel tubes containing EDTA have been 
evaluated for Hcy measurement. In some HPLC assays EDTA improves the fluorescent 
yield56; and in other assays its presence helps to prevent metal catalysed re-oxidation 
prior to derivitisation of the reduced disulphide bonds76. 
2.3.7 Enzyme inhibition using 3-deazaadenosine 
Of the attempts made to stabilise Hcy concentrations in collected blood samples, 
none have produced a satisfactory approach to blood collection away from a centralised 
laboratory, without the requirement for considerable readjustment of literature reference 
ranges. 
A more rational approach to the problem was taken by al Khafaji et al.115. They 
studied the pathway and decided to investigate the use of inhibitors to the enzymes and 
transport processes involved in the various steps of Hcy production. At 100µmol/L in 
EDTA whole blood, they reported that 3-deazaadenosine (3DA) stabilized plasma Hcy 
for up to 72 hours at “room temperature” prior to centrifugation. On the seven healthy 
volunteers used in their study, the mean Hcy concentration increased by 10% over 72 
hours post collection, which was not shown to be statistically significant. 3DA prevents 
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the release of Hcy from red blood cells through competitive inhibition of the enzyme 
SAHH; the final enzyme in the pathway from Met to Hcy (Figure 1). 
2.4 Pilot Study 
Posters VIII and IX describe the results of a pilot study to evaluate the feasibility of 
developing the use of 3DA into a commercially available blood collection system. The 
ultimate goal was to produce an evacuated blood tube, containing 3DA at a final 
concentration identical to that used in the report of al Khafaji et al.115, that would 
stabilize blood samples for up to three days under ambient conditions. 
The tubes would be marketed for use in Hcy analysis, particularly in conjunction 
with the Drew DS30 Hcy system (Drew Scientific Ltd., Barrow-in-Furness, UK), which 
requires 200µL of plasma. Manufacture was to be contracted out to a company who 
were specialists in the production of blood collection tubes (L.I.P (Equipment and 
Services) Ltd., Shipley, UK). The smallest blood volume they could produce in an 
evacuated tube was 2.5mL, which would require 67µg per blood tube to give a final 
3DA concentration of approximately 100µmol/L in the whole blood sample. For large 
scale manufacturing procedures this would have to be delivered to the tubes in the form 
of a liquid, however, in order to avoid dilution of the plasma, the liquid used for 
delivery should then be removed leaving 3DA behind as a solid. This process could be 
achieved by spraying the interior of the tubes with the appropriate volume of solution 
containing 67µg of 3DA, followed by a drying, evacuation and γ irradiation (used to 
sterilise the tubes). The liquid used to spray the tubes also contained the equivalent of 
3.25 mg of dipotassium EDTA per tube. EDTA is used as an anticoagulant. 
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The intention of the pilot study was to establish whether the 100µmol/L 3DA, in 
whole blood collected into EDTA would ensure ambient temperature stability for at 
least three days to allow transit of samples through various delivery systems. However, 
as 3DA acts through competitive inhibition its effectiveness in the inhibition of Hcy 
production proved to be temperature dependent. Descriptions such as “ambient”, or 
“room”, temperature can cover quite a wide range of temperatures, controlling the 
storage of samples between 20 and 25ºC, the mean Hcy from four healthy volunteers 
rose significantly from 8.5µmol/L to 11.5µmol/L over 72 hours. This rise of 35%, 
conflicts with the 10% rise reported by al Khafaji et al.115. When samples containing 
3DA were stored at 2 to 8ºC, over 72 hours, the mean Hcy dropped by a statistically 
insignificant 0.5µmol/L. As a control, whole blood samples collected into EDTA alone 
were also stored at 2 to 8ºC and these showed a significant rise from 8.8µmol/L to 
16.7µmol/L over the course of three days. The increase in the mean Hcy at “time zero” 
was attributed to a rise in Hcy over the short time taken to centrifuge the samples and 
remove the plasma prior to refrigerating the whole blood. 
To ensure that the spray drying process had not caused degradation of the 3DA, 
samples were collected from a further 5 volunteers in tubes containing liquid 3DA. 
Significant rises were again observed over 72hours. The spray drying process had no 
effect on the stability of the inhibitor as the mean increase in Hcy was very similar 
between the two processes (7.8µmol/L for liquid vs. 7.9µmol/L). Even with 3DA 
present at 200µmol/L the release of Hcy into the plasma could not be prevented. In 
blood collected from a single volunteer, the Hcy concentration rose by 1.5µmol/L over 
72 hours at ambient temperature (Hill and Kenney unpublished results). 
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2.5 Clinical Validation - 3DA Blood Tubes 
Despite the small number of volunteers used in the pilot studies, some important 
conclusions could be drawn. Firstly the use of 100µmol/L of 3DA cannot provide 
prolonged stability (up to three days) under ambient conditions. Doubling the 
concentration may reduce the amount of Hcy produced over time, however significant 
rises were still observed over two to three days storage. As 3DA is an expensive 
chemical any further increase in 3DA would not be cost effective in the development of 
a commercial product. Although not ideal, a combination approach of chilled storage at 
2 to 8ºC, and the use of 100µmol/L 3DA showed some promise in allowing a delay 
between sample collection and processing. At worst the availability of such tubes would 
provide an interim solution for clinicians, enabling them to collect and store samples 
before having to send them to a centralised laboratory for processing. Therefore a trial 
batch of evacuated tubes was produced containing 3DA spray dried into the tubes in the 
presence of EDTA. Clinical validation of these blood tubes, conducted in such a way as 
to confirm whether a combined effect of low temperature and 3DA was sufficient to 
provide long-term stability of plasma Hcy in whole blood is described in Paper I. The 
study was conducted at two centres in order to collect samples from subjects spanning a 
large age range and from a range of initial plasma Hcy concentrations.  
Most studies on sample stability have been conducted on apparently healthy 
populations. For a thorough clinical validation of the collection tubes, it was important 
to compare the stability of samples collected from a more diverse population, including 
patients with vascular disease and elderly patients, in addition to healthy volunteers. 
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Poster X describes the results from one of these centres where the volunteers were 
healthy individuals. The other centre recruited mainly aged patients with a tendency 
towards higher plasma Hcy levels. 
DS30 Hcy Blood Collection Tubes (Drew Scientific Ltd., Barrow-in-Furness, UK), 
were manufactured for Drew Scientific Ltd. by LIP Ltd. (Shipley, U.K). The tubes 
contained 3.25mg of K2 / EDTA as anticoagulant, and 67µg of 3DA (100µmol/L final 
concentration) to inhibit Hcy production. Each tube was evacuated to collect 2.5mL 
(±0.25mL) of whole blood. 10mL K3 / EDTA Vacutainer tubes (Becton Dickinson, 
Cowley, UK) were used for comparison. 
Hcy analysis was conducted using the DS30 Hcy analysis system (Drew Scientific 
Ltd., Barrow-in-Furness, UK) (Appendix B). 
Only a combination of the DS30 Hcy blood tube and storage under refrigerated 
conditions offered stability of the plasma Hcy concentration in whole blood samples at 
all times up to 72 hours (p=0.2761). The changes in plasma Hcy over 72 hours under 
the three other storage conditions were all highly significant (p<0.0001). P values were 
calculated using one-way within-subject ANOVA (repeated measures). 
Further analysis of the data showed that in EDTA alone the rise in Hcy concentration 
was significant before 3 hours had elapsed, regardless of whether the tubes were 
refrigerated or left at ambient temperature. Although long-term storage of blood in 
DS30 Hcy blood tubes requires that the tubes are kept at 2 to 8ºC, samples proved to be 
stable for up to 6 hours at 20 to 25ºC. A small subset of patients provided enough blood 
to show that whole blood stored in the DS30 Hcy collection tubes at 2 to 8ºC would 
maintain stable plasma Hcy concentrations for up to 1 week post venipuncture. 
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The study also highlighted the need for careful interpretation of published results 
regarding the stability of Hcy in collected blood samples. Many studies report their 
findings as percentage change over time, yet the rate of Hcy export from erythrocytes 
proved to be independent of initial plasma Hcy concentrations. This is clearly illustrated 
in Figure 3, where the percentage changes in the 0 to <5µmol/L and 5 to <10µmol/L 
bands over 72 hours differ significantly from any of the other groups. Beyond 10µmol/L 
percentage changes were not significantly different between the groups. 
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Figure 3 Absolute, and percentage changes in plasma Hcy after 72 hours storage of EDTA whole blood 
at 20 to 25ºC.  Error bars show mean ±2SEM 
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Studies containing samples from individuals with moderately raised Hcy 
concentrations are therefore less likely to show a significant percentage rise over a 
given time frame. Greater credence should be given to reports of sample stability where 
the subjects have initial Hcy concentrations towards the lower end of the normal range, 
or studies that report absolute differences where Hcy is measured by a method with low 
imprecision. 
In light of these findings, the data was reanalysed in two groups based on whether 
the initial Hcy was ≤10µmol/L or >10µmol/L. In each case the final result was the same 
after 3 days of storage, however, at 20 to 25ºC changes in Hcy became significant much 
earlier in the group with low baseline concentrations. 
Within this study the sampling times were chosen to simulate different delivery 
scenarios. Current recommendations state that samples should be processed within 1 
hour of collection. The initial sampling time of 3 hours was used to assess stability 
against baseline levels if delays occurred in sample delivery within the hospital setting. 
Sampling at 6 hours gave an indication of Hcy changes that might occur with same day 
delivery such as might be expected from clinics and doctors surgeries. A 24 hour delay 
may occur if samples are taken and stored overnight before delivery to the laboratory. 
Finally 72 hours allows enough time for delivery through postal services, as the ultimate 
aim of this project was to provide a means of allowing blood sampling to occur within 
the community with easy sample delivery to the laboratory under ambient conditions. 
The results showed that if delays occurred within the hospital setting the samples 
must either be either chilled or contain a preservative in addition to EDTA. Chilling 
alone could only provide stability up to 3 hours, whereas 3DA at 20 to 25ºC stabilizes 
samples for 6 or even 24 hours, dependent on the initial Hcy concentration. This offers 
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advantages for samples collected near the site of processing, providing some relief in 
the requirement to have ice on hand and to get the sample delivered quickly to the 
laboratory. However, if there is a longer delay in transport, refrigerated storage in DS30 
Hcy Blood Collection Tubes can offer prolonged stability for 72 hours and possibly up 
to a week. 
From the results of this trial, product claims have been filed and approved, as part of 
FDA Section 510k notification for marketing in the US (510k No. 012152) (see 
Appendix C). The claims state that if whole blood is drawn into a Drew DS30 Hcy 
Blood Collection Tube and stored at 2 to 8ºC, plasma Hcy will remain stable for up to 
72 hours. Although the data showed that samples may be stored up to 1 week under the 
same conditions, the numbers were limited, and 3 days storage should be adequate in 
most cases. The data also showed that the blood tubes might allow samples to be stored 
for up to 6 hours at 20 to 25ºC. Again no product claim was made to this effect as 
stability has been shown to be temperature dependent and it is difficult to ensure that the 
tubes are maintained at temperatures of <25ºC. Stability over 6 hours at room 
temperature, in vacutainers containing 100µmol/L 3DA, was however supported by 
further work done by two of the authors of the Al Khafaji paper, who in this case 
injected 40µL of a 3DA solution into 4mL vacutainers without loss of vacuum116, they 
also showed very similar changes in plasma Hcy in tubes containing EDTA alone stored 
at room temperature (mean increase 3.2µmol/L over 6 hours). 
During the clinical evaluation of evacuated blood tubes containing 3DA described 
above (Paper I), despite the wide range of initial Hcy values observed (3.9 to 
28.7µmol/L), the absolute increase in Hcy in unpreserved samples showed very little 
difference after 72 hours storage. Consequentially, significant differences in the 
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percentage change over time were seen, with an inverse relationship to baseline Hcy. 
Similar phenomena have previously been noted over 24 hours by Fiskerstrand et al.23 
and more recently over 4 hours by Duarte et al.117. Poster XI describes further analysis 
of the data where the initial rates of Hcy production in blood samples were compared 
according to participants baseline plasma Hcy concentration. Median rates, measured 
over the first 3 hours post venipuncture, were 0.6µmol/L/h for those with Hcy values 
≤10µmol/L and 0.7µmol//h where initial Hcy was >10µmol/L. These results were not 
significantly different (p=0.3890, Mann-Whitney U test). It follows, therefore, that the 
rate of Hcy production from erythrocytes in vitro appears independent of the in vivo 
mechanisms that cause moderate hyperhomocysteinaemia. For cellular survival a supply 
of S-AdMet must be maintained in order to repair cell proteins118. As described in 
Chapter 1, this can only be achieved if Hcy is removed, as the metabolic pathways 
involved are absent in erythrocytes42 these cells must export Hcy into the plasma to 
maintain a source of methylated donor within the cell. Any excess in S-AdMet 
production would lead to a risk of uncontrolled methylation, therefore flux through the 
pathway is likely to be limited at the level of methyl adenosyltransferase119 (see Figure 
1). Plasma Hcy concentrations in vitro therefore are regulated by Hcy production and 
subsequent export from the cells. 
Plasma total Hcy concentrations are much higher than intracellular levels, 
consequently any export of Hcy must occur against a concentration gradient. Within 
erythrocytes a high concentration of glutathione is required to prevent oxidative damage 
when carrying oxygen, the resultant reducing environment means that thiols are 
maintained in a reduced monomeric state. Upon leaving the cell Hcy is rapidly oxidised 
to form disulphides with other plasma thiols. In this way a gradient is established for the 
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reduced form favouring export. Blom119 proposed a reduced Hcy carrier specifically 
involved in this mechanism; he also proposed that there must be a separate carrier for 
Hcy uptake which would recognise all forms of oxidised Hcy. This introduces the 
possibility of another level of control for intracellular Hcy concentrations, whereby the 
reduced Hcy carrier protein may be regulated to maintain a steady supply of S-AdMet. 
The results of the study presented in Poster XI support these theories in that plasma Hcy 
levels were found to increase at rates independent of baseline Hcy concentrations. 
2.6 Shelf life Testing - 3DA Blood Tubes 
The results of clinical validation of the DS30 Hcy Blood Collection Tubes were 
presented in Paper I. As a commercial product it is also necessary to establish a shelf 
life in order to quote expiry dates, in order to give the customer some guarantee that, 
providing the product has been stored under the recommended conditions, it will 
perform to the product specifications. This work is currently unpublished and therefore 
will be described in detail. 
For the Drew DS30 Hcy Blood Collection Tube, the product specifications state that 
the blood tube should draw 2.5mL (± 0.25mL) of blood upon venipuncture. On the basis 
of the results of the clinical validation the specifications also state that plasma Hcy 
concentration will be stable for up to 3 days prior to centrifugation provided that the 
blood is maintained at 2 to 8ºC. The stability of both of these claims needed to be 
established in shelf life tests. 
For ease of use by the customer, ambient storage conditions were chosen. The 
recommendation is to store unused tubes at 15 to 25ºC. Although real time ageing was 
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assessed up to 2 years under ambient conditions, accelerated aging tests were used in 
order to prevent delays in product launch. 
Accelerated ageing is achieved by storage at elevated temperature120. Assumptions 
are made, based on the Arrhenius equation, which state that a 10ºC rise in temperature, 
will lead to an approximate doubling in the rate of chemical reaction. The theory then, is 
that doubling the rate of reaction, doubles the rate of decay. This process is subject to 
several errors and should be accompanied by real time testing, however, it can give an 
indication of the possibility of premature failure. 
Shelf life testing of the DS30 Hcy Blood Collection Tubes, including assessment of 
fill volume and the functionality of the tubes, was conducted on the first batch of tubes 
manufactured following clinical trials. On subsequent batches it was decided that 
quality control testing would involve assessment of draw volume at the site of 
manufacture, and functionality testing (as outlined below) would be conducted as part 
of the goods inwards quality control upon receipt of each new batch before the product 
is released for sale to the customer. 
2.6.1 Assessment of fill volume 
2.6.1.1 Materials 
A sample batch of DS30 Hcy Blood Collection Tubes (Drew Scientific Ltd., Barrow-
in-Furness, UK), was used to assess fill volume. A Vacutainer  Brand, Needle Holder 
and Precision Glide (Becton Dickinson Ltd, Cowley, UK), were used to draw water into 
the tubes. Weights were measured on an AT261 Analytical Balance (Mettler-Toledo 
Ltd., Beaumont Leys, UK). 
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2.6.1.2 Methods 
Storage conditions 
Sufficient tubes were stored to allow duplicate analysis to be performed if necessary 
at each of the time points described. 
Accelerated shelf life tests were conducted on blood tubes stored at 40ºC for 6 
months. Testing was performed as described below at 3 monthly intervals. 
Real time data was collected at 6 monthly intervals on blood tubes stored under 
ambient conditions up to 24 months. 
Fill volume 
Due to changes in the density of water caused by atmospheric pressure and 
temperature, the density of water was estimated each time the assessment of fill volume 
was conducted. This was performed by recording the weight of 100mL of deionised 
water in a volumetric flask. The density, calculated in mg/mL, was then used to 
calculate the volume of water collected into each blood tube. 
Fill volumes were assessed by determining the mass of water collected into each tube 
using a Vacutainer Brand, Precision Glide and Needle Holder. At each time point 9 
tubes were measured. The fill volume of each tube, the mean fill volume, and the 
percentage deviation of the fill volume of each tube from the mean were then used to 
assess the degradation of blood tube vacuum over time. 
2.6.1.3 Results 
Accelerated shelf life testing up to 6 months storage at 40ºC is presented below. Data 
was collected at the time of receipt post manufacture (Table 2), and at 3 and 6 months 
(Table 3). The same baseline results (Table 2) were used for real time assessment. Real 
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time data for 6, 12, 18 and 24 months of storage under ambient conditions are shown in 
Table 4. 
 
Table 2 Baseline data on fill volumes for Drew DS30 Hcy Blood Collection Tubes. 
Baseline data Tube No. 
Fill volume (mL) Percentage deviation from the mean fill volume 
1 2.62 0.43 
2 2.62 0.20 
3 2.61 -0.22 
4 2.62 0.39 
5 2.61 -0.07 
6 2.62 0.16 
7 2.60 -0.34 
8 2.60 -0.68 
9 2.62 0.12 
Mean 2.61  
 
 
 
 
Table 3 Accelerated shelf life data on fill volumes for Drew DS30 Hcy Blood Collection Tubes. 
 
3 months 6 months 
Tube No. 
Fill volume 
(mL) 
Percentage 
deviation from the 
mean fill volume 
Fill volume 
(mL) 
Percentage 
deviation from the 
mean fill volume 
1 2.36 0.53 2.25 1.89 
2 2.28 -3.22 2.24 1.48 
3 2.36 0.53 2.23 0.94 
4 2.38 1.16 2.18 -1.60 
5 2.39 1.82 2.20 -0.65 
6 2.35 -0.07 2.20 -0.52 
7 2.31 -1.76 2.15 -2.60 
8 2.38 1.07 2.22 0.27 
9 2.35 -0.07 2.23 0.80 
Mean 2.35  2.21  
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Percentage 
deviation from 
the mean fill 
volume 
0.43 
1.02 
0.34 
-0.68 
-0.56 
0.08 
-0.22 
-0.20 
-0.21 
 
24 months 
Fill 
Volume 
(mL) 
2.04 
2.05 
2.03 
2.01 
2.02 
2.03 
2.02 
2.02 
2.02 
2.03 
Percentage 
deviation from 
the mean fill 
volume 
-2.19 
-4.22 
-5.46 
6.86 
-13.96 
7.53 
-0.78 
7.27 
4.96 
 
18 months 
Fill 
Volume 
(mL) 
1.91 
1.87 
1.84 
2.08 
1.68 
2.10 
1.93 
2.09 
2.05 
1.95 
Percentage 
deviation from 
the mean fill 
volume 
-0.35 
-0.89 
-0.63 
-2.58 
1.75 
-0.59 
0.54 
1.51 
1.25 
 
12 months 
Fill 
Volume 
(mL) 
2.17 
2.15 
2.16 
2.12 
2.21 
2.16 
2.19 
2.21 
2.20 
2.17 
Percentage 
deviation from 
the mean fill 
volume 
-0.48 
1.47 
-2.04 
1.29 
2.91 
0.72 
-3.66 
0.12 
-0.35 
 
6 months 
Fill 
Volume 
(mL) 
2.39 
2.44 
2.36 
2.44 
2.47 
2.42 
2.32 
2.41 
2.40 
2.40 
Tube No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Mean 
Table 4.Real time shelf life data on fill volumes for Drew DS30 Hcy Blood Collection Tubes. 
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Product specifications claim that the fill volume of each tube should lie within the 
range 2.5mL ±0.25mL. At baseline, all recorded fill volumes were within the specified 
range (Table 2). In accelerated tests, conducted at 40ºC (Table 3), the fill volumes of the 
sampled tubes were all within the range at 3 months, however, before 6 months had 
elapsed the volume of liquid drawn into each tube had fallen below the product 
specifications. In real time storage tests conducted under ambient conditions, the fill 
volumes were all within specifications at 6 months, however, after 12 months storage 
the volumes had dropped such that each tube fell below the specified lower limit (Table 
4). 
At each time point the fill volumes are measured on only a sample of the whole 
population. Assuming a normal distribution and using the product specifications as 3SD 
limits, to ensure that the fill volumes of the whole population fall within the specified 
range, the estimated mean from this sample of 9 blood tubes should lie within the range 
2.38mL to 2.63mL. Under accelerated shelf life tests the mean fill volume at 3 months 
was just below this limit, indicating that although all the tubes measured lay within the 
range, some tubes from the whole population may draw less than the specified volume 
of blood. By 6 months storage at 40ºC, the sample population all lay below the specified 
range. In real time shelf life tests the indications were that the whole population of 
blood tubes would be acceptable at 6 months, however, by 12 months all fill volumes 
were below the product limits. 
If failures were observed, percentage deviation from the mean was used to assess if 
the tubes were all degrading in a similar manner. Under each storage condition and at 
each time point, apart from 18 months, the measurements showed a tight grouping 
around the mean fill volume, with the maximum deviation from the mean being             
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–3.66%. At 18 months the results showed a wider spread around the mean, which was 
not the case at 24 months. It was felt that these results were due to experimental error. 
Perhaps the tray that these tubes were stored in had been mis-handled, or exposed to 
higher temperatures than the other tubes. In retrospect the 18 month testing should have 
been repeated on another tray of tubes but the error was only highlighted when a tight 
grouping, typical of the results at baseline, 3, 6, and 12 months was observed again at 
24 months. 
2.6.1.4 Discussion 
Product specifications for the Drew DS30 Hcy Blood Collection Tubes state that the 
each tube will draw 2.50mL ± 0.25mL. For testing purposes it has been assumed that 
the volume of liquid drawn into the tube, upon breaking of the vacuum seal, is 
independent of liquid viscosity. Therefore water was used in place of blood to assess the 
draw volume of each tube. At the time of manufacture the evacuation procedure was set 
to produce tubes with a fill volume at the high end of the product specifications to allow 
for degradation upon storage under ambient conditions. As such the mean fill volume of 
the tested tubes was 2.61mL. 
Accelerated aging tests were conducted in order to prevent delays in product launch. 
Accelerated ageing was conducted at 40ºC, assuming that a 10ºC rise in temperature, 
doubles the rate of decay120, then 3 months storage at 40ºC gives an indication of the 
degradation expected after 9 months at 25ºC. If this relationship holds then the data 
from accelerated tests indicates that after 9 months storage at 25ºC a small percentage of 
tubes may have fill volumes of <2.25mL, lying below the product specifications. The 
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results of accelerated testing at 6 months indicate that the vacuum remaining in the 
tubes after 18 months storage at 25ºC will fail to meet the product specifications. 
Although accelerated ageing tests help to prevent delays in product launch they are 
subject to error, since they make several assumptions about the nature of product failure 
and kinetics of any chemical reactions that may occur. Therefore accelerated testing 
should be backed up with real time ageing tests. After 6 months storage under ambient 
conditions the draw volumes of the tubes lie within product specifications, however the 
mean fill volume has dropped by 0.2mL from the time of manufacture, the maximum 
range allowed being 0.5mL over the shelf life of the product, based on a specification of 
2.5mL ± 0.25mL. After 12 months storage under ambient conditions the tubes have 
failed to meet the product specifications. In this case the results of accelerated ageing 
tests, as an indication of the life of the vacuum within the tubes, were confirmed by real 
time testing. Accelerated tests indicated early signs of failure by 9 months storage at 
25ºC, and complete failure before 18 months had elapsed; during real time testing 
product failure occurred between 6 and 12 months. Although the mean fill volume after 
6 months storage at 40ºC should give an indication of the effect of 18 months storage at 
25ºC, the mean fill volume after 12 months storage under ambient conditions showed 
greater degradation of the vacuum within the tubes. Ambient storage was not performed 
under any temperature control and it is possible that the tubes were exposed to 
temperatures in excess of 25ºC. In addition temperature cycling may produce a greater 
stress on the system. 
The vacuum in the tubes degrades over time, such that the volume of blood drawn 
upon venipuncture decreases depending on how long the tubes have been stored 
between manufacture and use. The reason for the decrease in fill volume is gas transfer 
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over time through the rubber bung used to seal the tubes following the evacuation 
procedure. Using the current materials, the maximum shelf life that can be guaranteed to 
ensure that the product meets its fill volume specifications of 2.5mL ± 0.25mL is 6 
months. A short shelf life such as this is impractical since this does not allow sufficient 
time for delays between manufacture, quality control testing, shipment to distributors, 
and supply to the end customer. Therefore for future production alterative materials will 
need to be investigated for the closure of the blood tubes. Shelf life testing on the fill 
volumes will need to be repeated should a suitable alterative be found. Unfortunately, 
changes to the product line of Drew Scientific have meant that this line of investigation 
was not pursued. 
Although the tubes were found to fail the fill volume specifications before 12 months 
storage has elapsed under ambient conditions, the functionality of tubes in terms of the 
ability to maintain plasma Hcy concentrations in whole blood also needed to be 
assessed. This was especially true if an alternative blood tube closure was to be sourced 
as the functionality of the tubes may have a longer shelf life. Testing of this feature was 
to continue until either 2 years had elapsed or product failure was recorded in order to 
prevent this part of the work from having to be repeated should a suitable alternative 
closure have been sourced. 
2.6.2 Functionality Testing 
2.6.2.1 Materials 
DS30 Hcy Blood Collection Tubes (Drew Scientific Ltd., Barrow-in-Furness, UK), 
were tested for their ability to stabilise plasma Hcy in whole blood. Hcy measurements 
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were performed using the Drew DS30 Hcy system (Drew Scientific Ltd, Barrow-in-
Furness, UK) (Appendix B). 
DS30 Hcy Quality Control material was obtained from Drew Scientific Ltd. 
(Barrow-in-Furness, UK). 
A healthy volunteer, expected to have a low plasma Hcy concentration (≤8µmol/L), 
provided blood. 
2.6.2.2 Methods 
Storage conditions 
Sufficient tubes were stored to allow duplicate analysis to be performed if necessary 
at each of the time points described. 
Accelerated shelf life tests were conducted on blood tubes stored at 40ºC for 6 
months. Testing was performed as described below at 3 monthly intervals. 
Real time data was carried out at 6 monthly intervals on blood tubes stored under 
ambient conditions until 24 months had elapsed. 
Functionality testing 
For each time point and storage condition functionality testing was performed using 
the following protocol. 
A trained phlebotomist was employed to collect blood into 6 blood collection tubes 
from 1 venipuncture on the healthy volunteer. Each tube was immediately mixed by 
inverting a few times to ensure that the contents of the tube had dissolved and were 
evenly distributed in the blood. Aliquots of 1mL of whole blood were removed from 
each tube and centrifuged for 10 minutes at 11,000 g. The plasma was collected and 
stored at –80ºC until analysis. 
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The original blood samples were stored within the temperature range 2 to 8ºC, for 
three days, at which time a second 1mL aliquot was removed from each sample and 
centrifuged for 10 minutes at 11,000 g. The plasma was again collected and stored at    
–80ºC until analysis. 
Hcy was analysed on each sample using the DS30 Hcy system (Drew Scientific Ltd., 
Barrow-in-Furness, UK) (Appendix B). At each time point in the shelf life testing 
protocol, the plasma taken from the 6 tubes immediately after venipuncture and the 
plasma collected after 3 days storage of the blood at 2 to 8ºC was analysed within a 
single run. Thus between batch imprecision was avoided. 
Two levels of DS30 Hcy Quality Control material (Drew Scientific Ltd., Barrow-in-
Furness, UK) were run in each batch of samples to ensure that the assay was performing 
consistently. 
Assuming that a shift in Hcy concentration of ±1µmol/L would be considered 
clinically relevant, the validity of the number of tubes used at each time of testing was 
assessed using the mean initial Hcy concentration, and information on the maximum 
coefficient of variation expected within a single batch. For a detailed explanation of 
these test criteria see section 2.6.2.4. Thus in terms of the ability of the blood tubes to 
stabilise plasma Hcy concentrations in whole blood the shelf life will be considered to 
have been exceeded should a shift in Hcy concentration of over 0.5µmol/L be observed. 
2.6.2.3 Results 
Results obtained on DS30 Hcy Quality Control material run in each batch of samples 
are shown, against the target values and acceptable ranges for the Drew DS30 Hcy 
assay, in Table 5. In each case the results were within the acceptable ranges. A single 
batch of QC material was used during shelf life testing up to12 months, however this 
 Chapter 2 
Page 78 
batch was no longer available at 18 and 24 months. Between batch imprecision 
therefore was assessed across the first 12 months. Both the low and high Quality 
Control material (mean Hcy concentrations of 13.3µmol/L, and 23.1µmol/L 
respectively) gave CV results of 3.9% across 4 time points. 
Baseline results were collected at the time of receipt post manufacture (Table 6). 
Storage of the blood tubes at 40ºC allowed for accelerated shelf life testing which was 
conducted at 3 and 6 months (Table 7). The results of assessment of real time storage 
after 6, 12, 18 and 24 months under ambient conditions are shown in Table 8. 
At each time point 6 blood tubes were used to collect blood from a single volunteer 
expected to have a Hcy concentration of <8µmol/L. The reasoning behind this protocol 
will be discussed in detail later (see section 2.6.2.4). In each case the baseline plasma 
Hcy was shown to be <8µmol/L. 
 
Table 5 Results obtained from Quality Control samples during functionality shelf life testing of the 
DS30 Hcy Blood Collection Tubes. Results, Target Values and Ranges are shown as Hcy 
concentration in µmol/L. 
Level 1 QC Level 2 QC Time Point 
(months) Lot number Result Target Range Lot number Result Target Range 
0 MO-00103201 13.2 12.8 10.9 to 14.7 MO-0010302 23.9 22.4 19.2 to 25.6 
3 MO-00103201 14.1 12.8 10.9 to 14.7 MO-0010302 23.3 22.4 19.2 to 25.6 
6 MO-00103201 13.0 12.8 10.9 to 14.7 MO-0010302 21.8 22.4 19.2 to 25.6 
12 MO-00103201 13.0 12.8 10.9 to 14.7 MO-0010302 23.4 22.4 19.2 to 25.6 
 Mean 13.3   Mean 23.1   
 SD 0.5   SD 0.9   
 CV 3.9%   CV 3.9%   
 
 
       
Level 1 QC Level 2 QC Time Point 
(months) Lot number Result Target Range Lot number Result Target Range 
18 99082302 9.5 9.4 8.1 to 10.9 99082303 21.5 21.3 17.7 to 25.1 
24 MO-00143142 11.2 12.2 10.6 to 13.8 MO-00143143 21.3 22.4 19.6 to 25.3 
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Table 6 Baseline data on functionality for Drew DS30 Hcy Blood Collection Tubes. 
Hcy Concentration (µmol/L) 
Baseline Results Tube No. 
Day of 
venipuncture 
3 days post 
venipuncture Change 
1 6.5 6.4 -0.1 
2 6.5 6.7 0.2 
3 6.3 6.2 -0.1 
4 6.6 6.4 -0.2 
5 6.7 6.5 -0.2 
6 6.5 6.1 -0.4 
Mean 6.5 6.4 -0.1 
 
 
Table 7 Accelerated shelf life data on functionality testing for Drew DS30 Hcy Blood Collection 
Tubes. 
Hcy Concentration (µmol/L) 
3 months 6 months Tube 
No. Day of 
venipuncture 
3 days post 
venipuncture Change 
Day of 
venipuncture 
3 days post 
venipuncture Change 
1 5.3 4.8 -0.5 4.8 4.3 -0.5 
2 5.3 4.9 -0.4 4.8 4.5 -0.3 
3 5.2 4.8 -0.4 4.8 4.8 0.0 
4 5.3 4.6 -0.7 4.9 4.5 -0.4 
5 5.3 4.7 -0.6 4.9 4.7 -0.2 
6 5.2 4.7 -0.5 5.1 4.9 -0.2 
Mean 5.3 4.8 -0.5 4.9 4.6 -0.3 
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Change 
-0.3 
-0.2 
-0.3 
0.0 
-0.1 
-0.8 
-0.3 
Day 3 
5.2 
5.3 
4.9 
5.2 
5.0 
5.3 
5.2 
24 months 
Day 0 
5.5 
5.5 
5.2 
5.2 
5.1 
6.1 
5.4 
Change 
-0.5 
-0.1 
-0.3 
-0.3 
-0.3 
-1.6 
-0.5 
Day 3 
4.9 
5.4 
5.5 
5.4 
5.8 
5.5 
5.4 
18 months 
Day 0 
5.4 
5.5 
5.8 
5.7 
6.1 
7.1 
5.9 
Change 
-0.3 
-0.3 
-0.5 
-0.5 
0.0 
-0.2 
-0.3 
Day 3 
4.7 
4.6 
4.4 
4.6 
4.8 
4.8 
4.7 
12 months 
Day 0 
5.0 
4.9 
4.9 
5.1 
4.8 
5.0 
5.0 
Change 
0.0 
0.1 
-0.3 
0.2 
-0.8 
0.8 
0.0 
Day 3 
4.0 
4.0 
4.0 
4.5 
4.0 
4.8 
4.2 
Hcy Concentration (µmol/L) 
6 months 
Day 0 
4.0 
3.9 
4.3 
4.3 
4.8 
4.0 
4.2 
Tube No. 
1 
2 
3 
4 
5 
6 
Mean 
Table 8 Real time shelf life data on functionality testing for Drew DS30 Hcy Blood Collection Tubes. Day 0, and Day 3 refer to the time elapsed post 
venipuncture. 
 Chapter 2 
Page 81 
The product specifications state that the Drew DS30 Hcy Blood Collection Tubes 
will stabilise plasma Hcy in whole blood for up to 3 days when stored at 2 to 8ºC. A 
shift in Hcy concentration of <0.5µmol/L was considered to ensure that a clinically 
relevant shift in plasma Hcy would not be observed when using the blood tubes 
correctly. Although in accelerated tests, after 3 months storage of the unused tubes, and 
at 18 months under ambient conditions, the mean shifts in plasma Hcy were borderline, 
the results after 6 months storage at 40ºC, and results of all real time ageing at 6, 12 and 
24 months were within the limits of acceptable shift in plasma Hcy after 3 days storage 
of the whole blood at 2 to 8ºC. 
2.6.2.4 Discussion 
It would not be practical to perform full clinical testing on each batch of tubes 
manufactured, therefore the testing protocol was designed in such a manner, that shifts 
in plasma Hcy on a small number of blood samples collected from a single individual 
would represent a failure of the whole batch. Upon storage, whole blood samples 
collected from individuals with plasma Hcy concentrations at the lower end of the 
reference range (5.2 to 15.1µmol/L (Poster VI)) show more significant percentage 
increases in plasma Hcy concentration over time (Figure 3, Paper I and Poster XI). 
Knowledge of certain individuals’ lifestyles meant that a volunteer could be selected 
whose Hcy was expected to be <8µmol/L. If a mean shift over 3 days of storage of 
<0.5µmol/L Hcy would ensure that a clinically significant shift in Hcy would not be 
observed when using the blood tubes correctly, it was important that a change of this 
magnitude would not be masked by the imprecision of the assay. Within batch 
imprecision tends to be lower than between batch, therefore at each time of testing the 
plasmas collected immediately after venipuncture and after 3 days storage at 2 to 8ºC 
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were measured within a single batch. Upon quality control testing of the DS30 
instrument the coefficient of variation within batch must be <3%, in fact Zhang et al.121 
found that within batch imprecision was <2%. Nevertheless, working on a maximum 
Hcy concentration of 8µmol/L, and a coefficient of variation of 3%, the maximum 
standard deviation that would be observed within batch should be 0.24µmol/L. The 
number of tubes required can then be calculated by adapting criteria outlined in the 
NCCLS document for “Interference Testing in Clinical Chemistry”122, although this 
document is designed for the assessment of significant interference in clinical assays the 
principles concerned also apply to this situation. A parameter d is calculated based on 
the effect that is regarded as a significant change in the result, and the standard 
deviation of the method, such that d = effect ÷ standard deviation. Within the limits of 
the testing criteria used the maximum value for d is therefore given by                            
d = 0.5 ÷ 0.24 = 2.08. For 95% confidence in the results, comparing d to tables gives the 
maximum number of tubes required to be 6, thus a mean shift of >0.5µmol/L in plasma 
Hcy over 3 days of storage would be considered significant. Calculating 95% 
confidence intervals on a maximum mean shift of 0.5µmol/L Hcy gives a range for the 
mean of ±0.8µmol/L, which is within the clinically significant range of a shift of 
±1µmol/L. During shelf life testing each set of data collected met the testing criteria 
described here. 
Functionality testing follows the same procedure that will be used for quality control 
testing of subsequent batches prior to customer release. Therefore the baseline data 
show that the DS30 Hcy Blood Collection Tubes meet the product specifications, which 
state that the tubes are capable of stabilising plasma Hcy concentrations in whole blood 
for up to 3 days if stored at 2 to 8ºC. The results of accelerated ageing tests conducted at 
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40ºC indicated that this specification would hold if the unused tubes are stored for up to 
18 months at <25ºC. This is based on the theory that increases of 10ºC will 
approximately double the rate of decay120. However, expiry dates should not be 
assessed on the results of accelerated testing alone and real time data should be 
collected to back up the results. In this case the results showed that under real time 
conditions the unused tubes were stable for at least 24 months if stored according to the 
recommendations (15 to 25ºC). Even up to 24 months there was no sign of deterioration 
of the ability of the ability of the tubes to maintain stable plasma Hcy concentrations in 
whole blood for up to 3 days under refrigerated conditions. 
2.6.3 Summary – shelf life 
Although the shelf life tests have shown that the fill volume of the blood tubes has a 
shelf life of only 6 months under ambient conditions, the tubes maintained their ability 
to stabilise plasma Hcy concentrations up to at least 24 months of storage of the unused 
tubes under ambient conditions. Nevertheless, if an alternative material had been found 
for the tube closure the shelf life of the draw volume would need to have been 
reassessed. 
At any given stage in the shelf life testing, where a shift in the mean plasma Hcy 
concentration was observed between day 0 and day 3, the shift was downwards, 
however at no time did this shift become clinically significant. 
Figure 4 shows the mean Hcy concentration, measured during functionality testing of 
the blood tubes, plotted against the fill volume at each time point during the shelf life 
assesment. At first glance there appears to be a trend within the data collected during the 
real time shelf life testing between 6 and 24 months, such that a decrease in fill volume 
is associated with an increase in Hcy concentration. However the time zero point, and 
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data collected during accelerated shelf life testing does not fit the same trend. If the 
trend were true it may imply that an increase in the concentration of 3DA in the 
collected plasma, due to a decreased fill volume, might interfere with the Drew DS30 
Hcy assay. No such interference was observed during the studies conducted for Paper 1, 
3DA interference in HPLC assays for Hcy has to date not been reported in the literature, 
and there is no chemical basis to believe that 3DA would interfere in the assay. 
Although the same individual was used to collect blood throughout the shelf life testing, 
it is impossible to control the Hcy concentration across 24 months. Within this study the 
measured Hcy varied within the range 4.2 to 6.5µmol/L. As described in detail in 
section 1.4, there are a number of factors that can influence an individual’s Hcy 
concentration in particular the influence of diet, with transient increases in Hcy being 
observed following a meal. It is possible that the apparent association between fill 
volume and measured Hcy is a coincidental effect of a shift in the subject’s Hcy 
concentration across the course of the study. Further shelf life testing on subsequent 
batches of tubes should shed light on this theory. In retrospect the vacuum could have 
been broken on a set of tubes allowing manual filling with a single collection of blood 
to varying fill volumes in order to assess if increasing the concentration of plasma 3DA 
would interfere in the Drew DS30 Hcy assay. 
In summary the current shelf life of the DS30 Hcy Blood Collection Tubes 
containing 3DA and EDTA can only be guaranteed up to 6 months when stored at 
temperatures in the recommended range of 15 to 25ºC, based on the current product 
specifications. 
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Figure 4 Hcy concentration against blood tube fill volume during shelf 
life testing of the Drew DS30 Hcy Blood Collection Tubes. ( o = 
accelerated data, ♦ = real time data. Numbers by the data points 
represent storage time in months). 
 
2.7 Conclusions 
The initial aim of this thesis was to develop a commercially available blood 
collection system based on the best available knowledge, which would allow accurate 
plasma Hcy measurement on whole blood samples stored for up to 3 days prior to 
processing, thus enabling plasma Hcy measurement to move out of the hospital 
environment and into a community setting. The results of clinical validation of the 
DS30 Hcy Blood Collection Tubes show that such a product has been designed. 
However, whole blood must currently be stored at 2 to 8ºC prior to processing, which is 
far from ideal. Nevertheless, several samples may be collected and stored in doctors’ 
surgeries, or in mobile clinical trial facilities, before they have to be transported to a 
centralized laboratory for processing, thereby facilitating wider population screening. If 
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refrigerated conditions are not readily available, the use of DS30 Hcy Blood Collection 
Tubes may offer sample stability over 6 hours, within a hospital environment, which 
maybe particularly useful in cardiovascular clinics. These tubes can be used with a 
range of methods, providing the technique does not rely on the action of SAHH123, 
consequently tubes containing 3DA should not be used in some of the immunochemical 
methods currently available124;125. 
2.8 Further Work 
Firstly the shelf life of the current design of DS30 Hcy Blood Collection Tubes has 
an inadequate shelf life. In any future developments alternative materials must be 
investigated for their ability to maintain a vacuum over the course of 2 years storage 
under ambient conditions. The results of shelf life tests, conducted on the fill volume of 
the tubes, indicate that accelerated aging may assist in this selection procedure. 
Although the DS30 Hcy Blood Collection Tubes offer an improvement over the 
current recommendation for samples to be stored on ice and processed within 1 hour of 
venipuncture these tubes require that the whole blood is stored at 2 to 8ºC. The ultimate 
aim of this project is to develop a method of stabilising whole blood samples for plasma 
Hcy measurement for up 3 days under ambient storage conditions. 
In mammals SAHH is the enzyme responsible for Hcy production (Figure 1). 
Inhibition of this enzyme has been shown to stabilise plasma Hcy, however the 
compound used is a competitive inhibitor and as such its efficiency is temperature 
sensitive. The structure of the enzyme and several of its inhibitors are currently known, 
therefore a molecular modelling approach based on the active site of SAHH was 
proposed to postulate suitable compounds for use in blood tubes for the stabilisation of 
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plasma Hcy concentrations. This approach would allow a short list of candidate 
compounds to be drawn up based upon the theoretical strength of binding within the 
enzyme. 
Further selection should be based upon additional information on cost, toxicity, 
solubility, ease of manufacture, and stability. In fact this should include all factors 
concerned with their involvement in manufacturing processes and use for semi-invasive 
procedures in a clinical environment. 
It was hoped that a group of compounds would be identified for use in pilot studies, 
and should a compound appear to offer ambient temperature stability of plasma Hcy in 
whole blood, full clinical trials would again be conducted before a commercial product 
was released. 
The theories behind this alternative approach and results of the investigations that it 
was possible to conduct are discussed in the next chapter. 
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This section of the thesis focuses on an alternative approach to discovering a system 
of inhibiting Hcy production in whole blood samples when stored at ambient 
temperatures. Due to financial and logistical problems encountered during the course of 
this project the practical work is limited, however the theory behind this proposed 
approach is described in detail. 
3.1 Outline 
To date, as described in Chapter 2, the most practical approach to blood collection 
for plasma Hcy measurement away from the hospital setting involves collection into 
tubes containing 3DA. Although the samples can be stored for up to 3 days, the 
requirement for refrigerated conditions prior to centrifugation is far from ideal and does 
not lend itself well to large-scale studies or population screening. This chapter discusses 
a radical approach that might enable the discovery of a compound, which could provide 
stabilisation of plasma Hcy in whole blood at ambient temperatures over the 3-day time 
period required. 
3DA slows down Hcy production through inhibition of the enzyme SAHH, which is 
the final enzyme in the pathway from Met to Hcy (Figure 1). SAHH converts S-AdHcy 
into Hcy and adenosine. Physiologically, the reverse condensation reaction is favoured3, 
however subsequent reaction of adenosine drives the reaction forward. The structural 
similarities between adenosine and 3DA (Figure 5), mean that 3DA binds to the enzyme 
trying to drive the condensation reaction, however its structural differences mean that 
the reaction can’t take place and the enzyme is inhibited. 
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As shown in Posters VIII and XI, this competitive inhibition is temperature sensitive 
and can be overcome. If an alternative inhibitor for this enzyme could be found which 
has stronger binding characteristics this may prove to be suitable for use in Hcy blood 
collection tubes, yet for feasibility in a manufacturing process one must also take into 
account other factors such as price, solubility, and toxicity of any compounds selected. 
The idea was to use what is known about the structure of SAHH and its active site to 
formulate a computer model, which might allow rapid screening of chemical databases 
to produce a short list of compounds worthy of further testing. Scores based on strength 
of binding should assist selection. 
This in silico approach would only provide a theoretical idea of whether or not a 
compound might inhibit SAHH and an in vitro method would also be required to allow 
screening of a short list of suitable compounds. 
Figure 5 Structural similarity of adenosine and 3DA. 
Diagram modified from http://www.sigmaaldrich.com 
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3.2 In vitro screening method 
Molecular models can only provide a short list of compounds, which theoretically 
bind to the active site of SAHH, with perhaps some indication of the binding strength. 
In order to assess the true ability of these compounds to inhibit the enzyme an in vitro 
screening method would need to be developed which did not rely on the invasive 
procedures utilised in the pilot study and clinical trial described in Chapter 2 (Posters 
VII and XI and Paper I). This screening method could then be used to narrow down the 
short list further to 2 or 3 key inhibitors, which might be worthy of investigation in 
whole blood samples. 
Both Wolterdorf et al.125 and Dawling124 have reported interference in the Abbott 
IMx method for Hcy analysis30 due to the presence of 3DA. At final concentrations of 
100µmol/L in plasma or whole blood they showed reductions in the measured Hcy 
concentrations by 13% and 8.8% respectively. Han et al.123 showed that the interference 
is due to the fact that the method relies on conversion of Hcy to S-AdHcy, via SAHH, 
before reaction with an antibody against S-AdHcy. It may be possible to make use of 
this method interference to screen for other inhibitors of SAHH; however the Abbott 
method requires dedicated equipment. Axis-Shield also produce a commercial method 
which makes use of the same antibody against S-AdHcy100 and also relies on SAHH to 
covert Hcy to S-AdHcy29. This method is produced in kit format and uses microtitre 
plates in a competitive immunoassay, which can be run in most laboratories, provided 
there is access to a suitable spectrophotometer. It was decided to try to make use of the 
Axis-Shield method as an in vitro screening procedure. For details of the assay kit see 
the product insert (Appendix D). Comparing the degree of interference in this method 
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compared to that seen with 3DA could provide an indication of how well a candidate 
compound may perform in stabilising whole blood for plasma Hcy measurement. 
3.2.1 Materials 
Axis® Homocysteine Enzyme Immunoassay Kits were purchased from Axis-Shield 
(Dundee, UK). 3DA came from Sigma-Aldrich Co. (Poole, UK). EDTA plasma from 
healthy donors was obtained from Biochemed Pharmacologicals, Inc. (Whinchester, 
USA). Where raised Hcy concentrations were used samples were spiked with 
homocystine (Sigma-Aldrich Co., Poole, UK). 
Microtitre plate spectrophotometers used were a MRX Absorbance Reader (Dynex 
Technologies, supplied by Jencons-PLS Ltd. (Forest Row, UK), and a Double Strip 
MicroReader-1 fitted with a 450nm filter (Hyperion Inc. supplied by Wolf Laboratories 
Ltd., York, UK). 
Microtitre plates were washed with either a multichannel pipette or a semi-automatic 
8-manifold microtitre plate washer (Nalgene Labware, supplied by Wolf Laboratories 
Ltd., York, UK). 
Acid yellow 65 (Sigma-Aldrich Co., Poole, UK) was used for evaluation of the 
MicroReader-1 spectrophotometer. 
3.2.2 Methods 
3.2.2.1 Initial assessment of the screening method 
Familiarisation with the kit, equipment and assay procedure included a quick 
assessment of the capability of 3DA to show adequate interference in the Axis-Shield 
Hcy method. 
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An EDTA plasma sample was chosen with a Hcy concentration at the lower end of 
the adult reference range (Poster VI), the plasma was then spiked with an aqueous 
solution of homocystine to produce a plasma sample with a slightly raised Hcy 
concentration. Stock solutions of 3DA were used to spike both plasma samples in the 
ratio of 1:9 (3DA solution: plasma). Samples contained final 3DA concentrations of 
100, 500 and 1000µmol/L. To account for dilution an additional sample was produced 
in which deionised water was added to the plasma in place of the 3DA solution. 
Quality control samples were also run to ensure the method was producing accurate 
results. 
Homocysteine measurement was conducted according to the assay kit instructions. In 
the microtitre plate immunoassay steps reaction with the anti-S-AdHcy antibody the 
microtitre plates were washed manually using a multipipette. As in the method 
described by Frantzen et al.29, all samples including the calibrators and quality control 
were run in duplicate. 
Absorbance readings were taken using the MRX Absorbance Reader. 
A four parameter logistic curve, of the type shown below, was fitted to the 
absorbance readings from the calibration wells using XLfit Excel Add-In Version 4.2.1 
(ID Business Solutions Ltd., Guilford, UK). 
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Hcy concentrations in the QC material and plasma samples were also calculated 
using XLfit Excel Add-In Version 4.2.1 based on the equation generated for the 
calibration curve. 
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Measured Hcy concentrations were plotted against the concentration of 3DA used to 
spike the plasma sample. An estimate of the IC50 for SAHH was determined as the 
concentration of 3DA that would result in a 50% reduction in measured Hcy result. 
3.2.2.2 Initial evaluation of the Double Strip MicroReader-1 
Initial assessment of the Axis-Shield Hcy method was performed on equipment 
available at Cranfield University. Continuation of this work off site resulted in the 
requirement to purchase a new microtitre plate spectrophotometer, a Double Strip 
MicroReader-1 fitted with a 450nm filter. This new spectrophotometer needed to be 
evaluated prior to use. 
The Axis-Shield Hcy method states that absorbance readings should be conducted at 
450nm. As acid yellow 65 will also absorb at this wavelength a solution was made and 
diluted to suitable concentrations to allow assessment of the imprecision and linearity of 
the absorbance readings taken using the Double Strip MicroReader-1. 
The microtitre plates used were ThermoLife Sciences Combiplates 8 (Basingstoke, 
UK). Imprecision was assessed across 20 wells for blank readings, and at two 
concentrations of acid yellow 65 solution. Linearity was assessed and the working range 
confirmed by taking a saturated solution of acid yellow 65, centrifuging to remove any 
undissolved material, and then taking triplicate readings of 1 in 2 dilutions, until the 9th 
dilution, at which point the readings were approaching zero. 
3.2.2.3 Choice of plasma Hcy concentration & 3DA inhibition from 0 to 200µmol/L 
This was the first run of the Axis-Shield Hcy method performed using the Double 
Strip MicroReader-1 to measure the final absorbance readings. Initial assessment of the 
reader has suggested that precision may be reduced compared to Dynex MRX 
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Absorbance Reader, however the data suggested that the equipment would be suitable 
for a comparative screening method. 
The calibration curve obtained on the Dynex MRX Absorbance Reader showed 
absorbance readings ranging from 0.654 to 2.293. This range exceeds the quoted 
dynamic range of the MicroReader-1, however there is mention in the kit instructions of 
the possibility of reducing the incubation time during reaction with the second antibody 
/ horse radish peroxidase conjugate, if there are “optical densities exceeding the 
measuring range of the microtitre plate reader”. In this run the assay was performed 
following the instructions as written with a view to reducing the incubation time in 
further runs if required.  
The results of the initial assessment of the in vitro screening method (see section 
3.2.3.1) showed that in a plasma with a low starting Hcy concentration, large 
concentrations of 3DA would be required in order to detect a significant degree of 
interference in the method, yet at higher Hcy concentrations the precision of the 
measured results may be reduced since the nature of the calibration curve means that 
small changes in absorbance readings can lead to quite large difference in the reported 
Hcy concentration. As the precision of the assay was expected to be reduced using the 
MicroReader-1, results were compared on a sample containing a mean Hcy 
concentration reported as 35.3µmol/L with results on a sample containing 20.9µmol/L, 
which is closer to the centre of the calibration curve. Samples were spiked with 3DA 
solution in a 1:9 ratio as above. In this run, however, the aim was to evaluate inhibition 
at lower concentrations of 3DA. In the initial assessment the 3DA concentrations used 
were 100, 500 and 1000µmol/L; here the concentrations were 20, 50, 100 and 
200µmol/L. 
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3.2.2.4 Further development of a potential in vitro screening method 
Although the Axis-Shield Hcy method is intended for use with serum or plasma, it 
may be possible to use an aqueous solution of Hcy removing the need for the large 
amounts of plasma that would be required in screening. An aqueous solution of L-Hcy 
with a target value of approximately 30µmol/L was spiked with 3DA up to 200µmol/L. 
If it is not possible to use aqueous Hcy, it may at least be possible to produce a batch of 
plasma spiked with 3DA to use in comparison studies, which could be aliquotted and 
stored frozen. Aliquots of the 3DA-spiked plasma with an Hcy concentration of 
35.3µmol/L used in section 3.2.2.3 had been stored at –80ºC for 4 days, these were 
assayed using the Axis-Shield Hcy method along side the aqueous Hcy solution and a 
freshly spiked plasma sample. 
Due to an observation of high readings in end wells, all samples and calibrators were 
run in triplicate to allow any suspected falsely high readings to be omitted. 
3.2.2.5 Further evaluation of the Double Strip MicroReader-1 
Although initial evaluation of the MicroReader-1 had not highlighted a problem with 
readings taken from end wells, the evaluation had been performed using microtitre 
plates from ThermoLife Sciences and absorbance readings were measured on an acid 
yellow 65 solution. 
It was plausible that the high readings were connected with using the microtitre 
plates supplied in the kit or were perhaps a feature of the coloured end product of the 
assay. In order to test these theories the resultant solution at the end of the assay was 
collected from several wells and pooled together. 200µL aliquots were dispensed into 
three strips of ThermoLife Sciences microtitre wells, and three strips of washed wells 
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taken from an Axis-Shield assay kit. Absorbance readings were taken at 450nm using 
the MicroReader-1. 
To further elucidate sources of variability in the assay, CV estimates of absorbance 
readings were assessed across strips of 8 wells for plasma samples containing 0 and 
100µmol/L 3DA replicated throughout the whole assay, compared with the same 
plasma samples in which a single aliquot was taken through the “sample pre-treatment 
procedure” and only dispensed into 8 aliquots for the “microtitre plate procedure”. 
The “sample pre-treatment procedure” involves reduction of disulphide bonds to 
convert all forms of Hcy to the monomer, followed by reaction with SAHH to convert 
Hcy to S-AdHcy. The final step in this procedure involves removal of excess adenosine, 
which can interfere with the antibody reaction, using adenosine deaminase. The 
“microtitre plate procedure”, involves a competitive immunoassay between S-AdHcy 
which coats the microtitre plates and S-AdHcy produced in the “sample pre-treatment 
procedure”. After washing away antibody bound to this later source S-AdHcy, a second 
antibody / horse radish peroxidase conjugate binds to any of the first antibody bound to 
the plate. Any colour produced using horse radish peroxidase is then inversely 
proportional to the concentration of Hcy in the original sample (provided there are no 
interfering substances present). 
3.2.3 Results 
3.2.3.1 Initial testing 
The calibration curve generated on initial testing of an Axis® Homocysteine Enzyme 
Immunoassay Kit is shown in Figure 6. 
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QC results were slightly low on Level 1 compared to ranges established for the DS30 
Hcy Assay kit; duplicate results were 11.0µmol/L and 11.2µmol/L (Target Range 11.5 
to 14.5 µmol/L). Level 2 QC results, 21.1µmol/L and 20.8µmol/L were within the target 
range (19.0 to 27.0 µmol/L). 
The measured Hcy results in two plasma samples with mean Hcy concentrations of 
4.6µmol/L and 17.8µmol/L, when spiked with water, are shown in Figure 7 plotted 
against the final concentration of 3DA present. A progressive interference from 3DA 
was observed in both plasma samples, however this was more apparent in the sample 
with the higher initial Hcy concentration. In this sample the IC50 was estimated at 
around 400µmol/L 3DA. 
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Figure 6 Calibration curve from initial testing of Axis Hcy Enzyme 
Immunoassay Kit. 
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Figure 7 Hcy concentrations measured on the Axis Hcy Enzyme 
Immunoassay Kit, in two plasma samples spiked with 3DA. 
 
3.2.3.2 Evaluation of the dual strip MicroReader-1 
The results of imprecision assessment on blank wells and at two absorbance readings 
within the manufacturers quoted dynamic range of 0.000 to 2.000 are shown in Table 9. 
A CV estimate is obviously not an appropriate measure on a zero reading, as division by 
a mean reading of 0.000 would result in an infinite CV (CV = 100*(SD/Mean)). The 
instrument was blanked before taking 20 absorbance readings from empty wells; the SD 
from these readings was 0.001 (mean = 0.001), which is within the manufacturers 
quoted performance of <0.005. At mean absorbance readings of 0.459 and 0.711, the 
CV estimated from 20 readings of acid yellow 65 solutions were 0.4% and 0.3% 
respectively. Again these readings are within the quoted performance specifications of 
<1.5%. For comparison, when using the MRX Absorbance Reader, Dynex 
Technologies quote a dynamic range of –0.100 to +4.000, with imprecision estimates 
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based on 20 readings of: 0.2% CV or 0.005 whichever is the greater for readings 
between 0.000 and 2.000, 0.6% CV for readings between 2.001 and 3.000, and 1.0% 
CV for readings between 3.001 and 3.500. 
 
 
Table 9 Imprecision assessment of the MicroReader-1 spectrophotometer. 
Acid Yellow 65 Reading No. Readings 
taken on empty wells. Solution 1 Solution 2 
1 0.001 0.453 0.705 
2 0.002 0.457 0.707 
3 0.001 0.458 0.710 
4 0.000 0.459 0.710 
5 0.001 0.458 0.710 
6 0.002 0.459 0.710 
7 0.001 0.459 0.711 
8 0.000 0.460 0.711 
9 0.000 0.460 0.711 
10 0.001 0.461 0.711 
11 0.000 0.461 0.710 
12 0.001 0.459 0.712 
13 0.000 0.460 0.712 
14 0.001 0.460 0.713 
15 0.001 0.459 0.712 
16 0.002 0.460 0.712 
17 0.000 0.460 0.712 
18 0.001 0.459 0.712 
19 0.000 0.459 0.712 
20 0.000 0.459 0.712 
Mean 0.001 0.459 0.711 
SD 0.001 0.002 0.002 
CV N/A 0.4% 0.3% 
n 20 20 20 
 
 
Figure 8 shows that the absorbance readings on the MicroReader-1 are linear across 
the working range (y=0.1457x – 0.0235, R2 = 0.9999). 
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3.2.3.3 Choice of plasma Hcy concentration & 3DA inhibition from 0 to 200µmol/L 
Calibration produced a curve similar to that shown in Figure 6; however the 
absorbance readings were in the range 0.290 to 1.457. As these results are within the 
dynamic range of the MicroReader-1 the method can be followed as per the kit 
instructions without the need to reduce one of the incubation steps. 
During this run there was a tendency for the first well in each strip of the microtitre 
plate to show higher absorbance readings than its duplicate sample. This could be due to 
a number of practical causes. As it was not observed during evaluation of the 
MicroReader-1 it may be due to a fault in the assay kit plates, as highlighted by the 
large error in the estimate of the mean at 50µmol/l 3DA in plasma 1 seen in Figure 9. 
Further investigation was required. 
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Figure 8 Assessment of linearity of the MicroReader-1 using 
acid yellow 65. 
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The measured Hcy results from the two plasma samples are shown in Figure 9 
plotted against the final concentration of 3DA. From these readings, compared to those 
seen in Figure 7, it becomes apparent that interference due to 3DA is insignificant 
between 0 and 50µmol/L. The results also show that for screening of potential inhibitors 
of SAHH it may be best to use a plasma sample with an initial Hcy concentration in the 
region of 30µmol/L and that due to variability between runs and poor precision, 
comparative assays should be performed to narrow down the selection of candidate 
compounds. 
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Figure 9 Hcy concentrations measured on the Axis Hcy Enzyme 
Immunoassay Kit, in two samples spiked with between 0 and 100µmol/L 
3DA. Error bars show ±2SEM. 
 
3.2.3.4 Further development of a potential in vitro screening method 
Unfortunately the calibration and results during this run were poor (not shown) CVs 
were over 12% on some triplicate readings. Omitting high readings from end wells 
brought the CVs down to around 6%, but all Hcy results, including the plasma assayed 
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in section 3.2.2.3, were higher than expected and approached the limits of the dynamic 
range. The progressive interference from 3DA observed in previous runs was not so 
apparent in this run. 
Results were no worse for frozen plasma or aqueous Hcy solution and these samples 
would warrant further investigation. 
3.2.3.5 Further evaluation of the Double Strip MicroReader-1 
The results of absorbance readings taken on pooled reaction product in microtitre 
wells from ThermoLife Sciences and washed wells from the Axis-Shield Hcy assay kit 
are shown in Table 10. Imprecision estimates are worse than those measured with acid 
yellow 65 solution (see Table 9). Using the ThermoLife Sciences wells the CV estimate 
at a mean absorbance of 0.714 was 1.8% exceeding the manufacturers specifications 
(<1.5%), compared with a CV of 0.3% at a mean absorbance of 0.711 when using acid 
yellow. In the Axis-Shield wells the same solution gave a lower mean absorbance of 
0.600, with a CV on 24 readings of 4.6%. One result stood out as high, but even 
removing this, the CV was still 2.5%. In any case the high results observed during assay 
runs in the end wells were not observed with pooled reaction product. 
Table 11 shows the absorbance readings measured on replicate samples in the 
microtitre plate procedure alone, compared with replicates taken through the whole 
assay procedure. In the microtitre plate procedure alone there was no difference in the 
imprecision estimated in the presence and absence of 3DA (CV values of 8.0% in each 
case), indicating that 3DA does not cause variability in the antibody reactions. 
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Table 10 Absorbance readings measured on the MicroReader-1 using pooled 
reaction product from the Axis-Shield Hcy assay. 
Absorbance 450nm Strip Well 
ThermoLife Sciences Axis-Shield 
1 A 0.742 0.618 
 B 0.751 0.710 
 C 0.716 0.607 
 D 0.726 0.603 
 E 0.722 0.608 
 F 0.721 0.614 
 G 0.709 0.610 
  H 0.715 0.620 
2 A 0.710 0.576 
 B 0.710 0.598 
 C 0.710 0.571 
 D 0.709 0.577 
 E 0.704 0.577 
 F 0.698 0.582 
 G 0.715 0.613 
  H 0.718 0.595 
3 A 0.703 0.598 
 B 0.703 0.593 
 C 0.703 0.583 
 D 0.716 0.591 
 E 0.704 0.580 
 F 0.709 0.583 
 G 0.719 0.590 
  H 0.693 0.596 
Mean 0.714 0.600 
SD 0.013 0.028 
CV 1.8% 4.6% 
n 24 24 
 
When adding in the pre-treatment steps, imprecision is increased as might be 
expected. In the absence of 3DA, additional pre-treatment steps only increased the 
imprecision by 3.1% (11.1% CV compared to 8.0% in the microtitre plate procedure 
alone), implying that the greatest source of variability was in the antibody reactions. 
However, when the plasma contained 100µmol/L 3DA, the additional pre-treatment 
steps caused the imprecision to increase by 8.3%, indicating a high degree of variability 
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attributable to sample to sample differences in the amount of inhibition caused by 3DA 
on the action of SAHH. 
 
Table 11 Absorbance readings for replicates in the "microtitre plate procedure" compared with the 
whole assay in the presence and absence of 100µmol/L 3DA. 
Absorbance 450nm 
Replicates in microtitre plate 
 procedure alone 
Replicates across  
the whole assay Well 
No 3DA 100µmol/L 3DA No 3DA 100µmol/L 3DA 
A 0.835 0.860 0.833 0.838 
B 0.747 0.826 0.704 0.887 
C 0.743 0.783 0.710 0.909 
D 0.673 0.712 0.644 0.677 
E 0.674 0.734 0.628 0.627 
F 0.664 0.733 0.634 0.630 
G 0.697 0.699 0.602 0.645 
H 0.696 0.703 0.634 0.679 
Mean 0.716 0.756 0.674 0.737 
SD 0.057 0.060 0.075 0.120 
CV 8.0% 8.0% 11.1% 16.3% 
n 8 8 8 8 
 
Figure 10 shows the reading plotted in the order that they were read, again a trend 
towards higher readings at one end of the plate was observed which does not appear to 
be related to the order in which samples are pipetted. Since the trend is not apparent 
with pooled reaction products measured in either ThermoLife Science or washed Axis-
Shield microtitre plate strips, it does not appear to be related to use of the MicroReader-
1 and could be a result of the coating process during kit manufacture. If this is the case 
then the trend may disappear when a new batch of kits is used. 
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Figure 10 Trends in absorbance readings on replicates measured in the Axis-Shield Hcy 
assay kit. 
 
3.2.4 Discussion 
Previously authors have reported that 3DA causes interference in the Abbott IMx 
immunoassay for Hcy124;125, Han et al. showed that interference was due to inhibition of 
SAHH, however to date there have been no published reports of 3DA causing 
interference in the Axis-Shield Hcy Enzyme Immunoassay. The results show that at 
100µmol/L 3DA and above significant and progressive interference is observed in line 
with the reports on the Abbott method. Although only a quick estimate of IC50 was 
conducted at 400µmol/L this is somewhat lower then that of 1500µmol/L reported by 
Dawling on the Abbott IMx124, however it should be noted that these values may be 
dependent on the assay conditions including the concentrations of enzyme and 
substrates. 
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Although QC results on a sample in the reference range were reported as lower than 
the target values, the ranges were established using the Drew DS30 Hcy HPLC method 
and new ranges should be established for each new method used. 
As time progressed the precision of results worsened. Evaluation of the new 
equipment purchased for work off site indicated that only a small degree of worsened 
imprecision could be assigned to use of the MicroReader-1. It was noted that the 
reagents in the kits have short shelf lives and there are several warnings in the kit insert 
regarding careful maintenance of the enzyme containing reagents and the microtitre 
strips. Increasing imprecision over time may, therefore, be due to degradation of the 
assay kits. If the screening method were to be employed careful planning would be 
needed to ensure that fresh kits were used to their full potential to avoid kits being 
exposed to fluctuating temperatures and humidity conditions. 
Due to time and financial constraints full development of the in vitro screening 
method was not possible within this thesis. The aim of the screening method is to enable 
selection of one or two compounds selected from a short list generated by molecular 
modelling techniques that may be capable of stabilizing whole blood samples for Hcy 
measurement at ambient temperatures. Initial testing indicated that use of a 30µmol/L 
Hcy sample spiked with 400µmol/L of inhibitor measured using the Axis-Shield Hcy 
Enzyme Immunoassay, would provide a suitable screen providing the results were 
compared to samples spiked with water or 400µmol/L 3DA run in the same assay. 
Similar results may be possible through spiking an aqueous solution of L-Hcy and this 
is worthy of further investigation. Nevertheless use of plasma samples in this method 
offers advantages versus trying to assess potential inhibitors in whole blood samples as 
fresh whole blood would be required, whereas it is possible to purchase larger volumes 
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of plasma from single donors from companies that supply pharmaceutical 
manufacturers. Plasma samples offer greater stability compared to having to assess Hcy 
production from viable red blood cells as the plasma can be stored frozen for long 
periods of time. 
One word of caution is that kit calibration is performed on aqueous samples of S-
AdHcy, which assumes that the SAHH conversion step works to completion. This is 
why quality control samples should be run in order to test that the whole assay is 
working correctly in the absence of inhibitor, or a comparative sample spiked with 3DA 
should be used to prevent false positive results in this screening method. 
A further caution, although interference is seen in the Abbott method and believed to 
due to SAHH interference it is possible that 3DA may also interfere with the antibody 
reaction due to its structural similarity with S-AdHcy. In fact in the Axis-Shield method 
adenosine deaminase is used to remove excess adenosine “to avoid interference by Ado 
[adenosine] in the succeeding [immunoassay] step”29. Han et al., however assessed 
3DA interference on SAHH in the conversion of S-AdHcy to Hcy in the absence of an 
immunoassay step123. Their results clearly indicated that 3DA interferes with the 
enzyme-catalysed reaction. 
In conclusion, if fresh kits are used the Axis-Shield Hcy Enzyme Immunoassay kits 
used in conjunction with samples containing 30µmol/L Hcy, spiked with 400µmol/L of 
potential SAHH inhibitor would provide a suitable screening method for candidate 
stabilisers of whole blood Hcy samples. 
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3.3 In silico screening method 
3.3.1 Theory 
Although 3DA inhibits SAHH, it is limited in its use for stabilising whole blood 
samples for Hcy measurement. Section 3.2 describes how a short list of candidate 
compounds may be experimentally screened but the problem that remains is how to 
create that short list. Once a compound has been identified as a ligand or inhibitor for a 
particular enzyme, with a little knowledge of the mechanism of the reaction and details 
of the active site it is relatively easy to explain why that compound is active, but with 
the vast multitude of potential molecules available how does one go about selecting 
which molecules should be investigated? It is this very frustration that led to the 
development of computational tools explicitly designed to have as their output a list of 
molecules, which may be active against a receptor, based on three-dimensional 
structural information. These tools are primarily used in drug design, but the theory can 
be adapted for other problems such as the task in hand. 
A number of terms have been used to describe this practice, including molecular 
modelling, computer aided drug design, virtual screening, computational chemistry and 
in silico screening, but they all basically cover the same ground. Of course the complex 
dynamics describing the macromolecules concerned requires large resources in 
computing power. Until very recently molecular modelling had to be conducted on 
dedicated computers, which were traditionally designed as graphics workstations with 
very fast processors, and it is only during the course of this study that personal 
computers have come onto the market with enough processing power to handle such 
computing programs. Where Unix was required as an operating system, there are now 
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Windows based programs available which opens up this previously restricted field to a 
much wider group of research scientists. 
Any molecular modelling study must start with the model itself. The Research 
Collaboratory for Structural Bioinformatics operate an international repository for the 
processing and distribution of experimentally determined three-dimensional 
macromolecular structure data; this service is referred to as the Protein Data Bank 
(formally operating as the Brookhaven Database) and is available at 
http://www.pdb.org. Data is submitted from experimental results such as X-ray 
crystallography, NMR or from fellow molecular modellers. Once the data has been 
published the Data Bank will release the structure, which then becomes freely available. 
From their website information on a number of proteins with experimentally determined 
structures can then be downloaded in a format which contains details of the relative 
locations of all the atoms with that protein. These files can then be used to enter the 
given starting model into the molecular modelling software. In many instances though 
the structure may not yet have been determined, in these cases receptor models may be 
built based on inference using homologous structures. Of course virtual screening is 
most successful in an information rich environment126, involving not only knowledge of 
the structure of the target site but also based on knowledge of ligand-protein interactions 
that are essential for binding and activity. 
A molecular model consists of spherical atoms joined together with springs that 
represent the bonds. Employing mathematical functions to describe Newtonian 
mechanics within the system, the molecular force field i.e. the total energy of a 
macromolecule associated with shifting conformers or with binding between ligand and 
protein can be estimated. This total energy can be expressed as the sum of the potential 
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energy functions created by interactions between each of the individual atoms. 
Knowing, or theoretically estimating, the force constants associated with each of the 
energy terms, the total energy of a molecule can be estimated based on the sum of 
several thousand individual contributions involving van der Waals, electrostatic and 
hydrogen interactions, together with stretching, bending and angular interactions 
between molecules that are covalently bonded127. 
Energy minimisation programs using molecular mechanics involves modifying the 
parameters governing the geometry in small increments in a number of successive 
iterative computations127. Comparison with the total energy of the previous conformer 
and acceptance or rejection based on whether the total energy is reduced or increased 
allows the approximation of the most stable system or “ideal geometry”. Minimum 
energy structures are found by reducing distortions and unfavourable interactions such 
as van der Waals forces, whilst optimising favourable interactions such as hydrogen 
bonding. Looking for minima in this way though, there is no guarantee that the absolute 
lowest energy structure, the “global minimum” will be found, it is possible that a system 
can fall into a local minima with a strained conformation. The introduction of molecular 
dynamics allows small barriers to be breached dependent on the temperature associated 
with the simulation. Following internal motions by computational simulation it is also 
possible to sample the relevant behaviour of a given system128. It should be noted 
however that the global minimum of a protein in isolation does not necessarily represent 
the receptor bound conformation, in which case it is wise to perform minimisations with 
a substrate in place127. 
In drug design two approaches are commonly used127. In the first type of screening 
compounds are matched against a template compound and similarities in electrostatic 
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potential, molecular surface, or molecular shape are searched for. In the second 
approach a more physical method is adopted where candidate molecules are forced to 
interact with a common binding sites defined by hypothetical points of interaction, 
rather than forcing them to directly superimpose, in this case the degree of interaction 
between the model and each candidate is assessed. This latter approach is referred to as 
“docking”. The challenge then is in constructing the “query”, i.e. the defined criteria or 
points of interaction that must be satisfied by a candidate drug129. 
The lock-and-key model suggested by Emil Fischer in 1894 as the origin of 
biological specificity unfortunately continues to dominate the thinking of many drug 
designers129. This model implies that for a molecule to be active it has to have steric 
characteristics that perfectly match the shape of the receptor. Although shape and steric 
interferences play a large part it is probably more important to think of the functional 
groups involved in specific binding to key regions of the receptor. Following on from 
this idea, one can think of two-dimensional constraints as the functional group 
specificity, three-dimensional constraints as the steric or geometric interactions and a 
finally a group of constraints that should not be forgotten in drug design, and for which 
the term one-dimensional constraints has been adopted, are the practical constraints 
such as cost and ease of manufacture and perhaps even the amount of compound in 
stock if rapid screening is to be conducted129. 
In setting up a query, a few factors should be remembered. Hydrophobic interactions 
are usually the major driving force for binding, whilst hydrogen-bonding and 
electrostatic interactions primarily provide specificity127. Van der Waals forces may also 
play a major part, and an extra radius across the surface of the receptor site atoms 
should be taken into account. Following docking of a given molecule energy 
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minimisation should again be conducted which will give a good indication of the 
plausibility of the model and a rough estimate of the relative interaction enthalpy of the 
candidate drug. Poor models will usually fall apart during this process. VanDrie129 
states that the use of two functional groups and one distance constraint seems to be 
highly effective in identifying active compounds. With a little experience it becomes 
clear that certain interactions contribute much more than others to the binding affinity. 
Queries may also be based on, or at least use information gathered from the literature 
on key amino acids present in the active site that are important in binding. This is where 
point mutation studies are particularly helpful126. The orientation of groups such as lone 
pairs or side chains relative to the target compound may also provide useful 
information, and these can be fixed in setting up the criteria for a given query. Such 
knowledge is not essential and docking techniques may be employed with a loose 
query, but a more specific approach will help to narrow down the search and increase 
the accuracy of the results. 
Once a query is defined databases containing large numbers of candidate compounds 
are screened to see which compounds may match the criteria, those that do are termed 
“hits”. 
Early screening methods relied on docking single conformers of each ligand, but as it 
was realised that the molecules may be under tension in the bound state, multi-
conformational or flexible docking was introduced126. Ideally movement within the 
receptor should also be allowed, although for ease of rapid screening the receptor is 
frequently treated as a rigid structure. 
For a thorough test of a given molecular model and query, a number of known 
inhibitors and substrates should be tested to see if they will be returned as hits, whilst 
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compounds that are inactive should be rejected. If the query fails to identify known 
inhibitors and substrates, then the factors defining the query should be modified until 
these compounds are returned as hits. 
In a successful modelling study a small, manageable, list of candidate compounds 
will be produced. Synthesis of these compounds followed by in vitro screening can be 
used to refine the model127. 
It might be assumed that a maximally diverse database, or library of compounds 
would be ideal for the identification of novel active compounds. In reality this concept 
is just not practical, as screening would take far too long. Databases should be focussed 
on specific types of problem, contain compounds which are drug-like, i.e. small not too 
lipophilic, and can be synthesized at large yield with reagents that can be bought or 
made at a reasonable cost126. 
Once a database has been searched and a number of hits identified a scoring system 
is required based on the strength of the receptor-ligand interaction in order to prioritise 
synthetic and in vitro screening efforts. A number of scoring systems have been 
developed, but several have limited results. Accurate affinity calculations rely on fast 
quantum calculations, taking into account the full flexibility of the molecules, solvation 
and entropy. In principle free energy, as opposed to binding enthalpies are more 
accurate methods of scoring ligand-receptor interactions, but these methods are 
processor intensive126. General purpose scoring functions may be more useful in the 
early stages of screening; one such scheme was designed by Boehm and includes terms 
of surface area, hydrogen bonds and ionic interactions, as well as a penalty for the 
number of rotatable bonds126. Each pose – i.e. a snapshot of a flexible ligand interacting 
with a flexible receptor, returns a number indicating the likelihood that the pose 
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represents a favourable binding interaction a low (negative) energy indicates a stable 
system and thus a likely binding interaction. 
One cannot, however, rely on the results of in silico screening methods alone as a 
large number of false positives will be included in the candidate short-list, to exclude 
these in vitro methods are required. Furthermore, sometimes human experience and 
intuition is required as compounds yielding poor scores may turn out to be false 
negatives and be highly active. 
3.3.2 Structure of SAHH 
Cells from several species have been tested and found to contain SAHH, the few 
exceptions include Escherichia coli and certain related bacteria where two enzymes are 
required for the hydrolysis of S-AdHcy to Hcy and adenosine130. The gene for human 
SAHH is located on the long arm of chromosome 20 and comprises of 1299 
nucleotides, resulting in a protein of 432 amino-acids with a molecular weight of 
47660131. The sequence shares a 97% amino-acid identity with that of the rat enzyme 
(91.5% match in the coding sequence); there is even 75% identity with slime mould 
Dictyostelium131. A 51-kDa enzyme obtained from Rhodobacter captulus also shares 
64% homology with its human counterpart130. This high degree of homology between 
diverse species, representing years of evolutionary development, is truly remarkable and 
may represent one of the highest levels of conservation that has been observed between 
a human and a prokaryotic enzyme; highlighting the importance of SAHH in cellular 
metabolism. 
Nicotinamide adenine dinucleotide (NAD+) acts as cofactor for SAHH, and the 
domain that incorporates its binding region is particularly well conserved between 
species. Several NAD-dependant dehydrogenases have been shown to possess a similar 
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3D structure in their NAD+ binding domains. Since SAHH performs a similar function 
to NAD+ dehydrogenases in terms of redox interconversion of NAD+ to NADH, it was 
believed that SAHH would also show structural similarities in the active site to NAD-
dependant dehydrogenases. Therefore, prior to the elucidation of an X-ray 
crystallographic structure of SAHH, Yeh et al.132 proposed a molecular model for the 
active site of SAHH based on the X-ray crystal structure of dogfish lactate 
dehydrogenase and the primary sequence of rat liver SAHH. 
As X-ray crystallography became possible for SAHH, Turner et al.133, were able to 
perform a detailed analysis on the structure of human SAHH, shown in Figure 11, this 
was followed a year later by another group who extracted the enzyme from rat liver134. 
The structure of the tetrameric rat liver enzyme is shown in Figure 12. Both these 
structures are filed in the Protein Data Bank under the file names 1A7A and 1B3R. 
Much of the following discussion on the structure of the protein comes from these two 
papers, however, it should be noted that there are significant differences in the spatial 
arrangement of the catalytic and cofactor binding domains between the two structures. 
In the file for human SAHH (1A7A) the enzyme was studied in the presence of 
inhibitor, whereas the rat liver enzyme is presented in the substrate free form. The effect 
that the presence of substrate or inhibitor has on the structure of the protein will be 
discussed below. 
The enzyme comprises of four identical subunits, each approximately 48,000 in 
molecular weight. Within each subunit a single molecule of NAD+ cofactor remains 
tightly associated with the enzyme. Since this domain is extremely well conserved 
between species 130;131 it may indicate the importance of enzyme structure within this 
region on the metabolic functioning of the enzyme. 
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Figure 11 Bottom view of the dimeric 
structure of human placental SAHH (1A7A). 
Reproduced from: http://www.ebi.ac.uk 
 
 
 
Figure 12 Bottom view of the tetrameric 
structure of rat liver SAHH (1B3R), 
showing the channel that runs down the 
centre of the enzyme. 
Reproduced from: http://www.ebi.ac.uk 
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Each subunit of the protein contains two or three key domains. The catalytic and 
NAD+ binding domains are folded into a structure reminiscent of NAD-dependent 
dehydrogenases, whilst a third domain comprises of the C-terminal region. 
The catalytic domain of human SAHH comprises of residues 1-190 and 355-432, 
compared to residues 1-181 and 352-402 in the rat, which are folded into a pattern 
similar to many methyltransferases. The crevice that holds S-AdHcy has a hydrophobic 
pocket at one end in which the adenine moiety is held, whilst Hcy and ribose are 
exposed to the solvent. The folding pattern of the whole catalytic domain implies that S-
AdHcy can travel freely in and out of this enzyme and other methyltransferases 
allowing it to properly regulate methyltransferase activity133;134. The C terminal domain 
exists far from the body of the main enzyme and extends into the opposite subunit of a 
dimeric structure134. Two main functions are served by the remaining amino acids 
which make up the middle portion of the protein chain, firstly they are responsible for 
binding the cofactor, and secondly they form the structural core of the tetrameric 
structure through numerous interactions with the three other subunits. 
In NAD+-dependent dehydrogenases, a single protein chain usually holds each 
molecule of NAD+. SAHH differs in that the cofactor is held in a region, which exists 
between the two units of a dimer, requiring contributions from both subunits. Although 
each NAD+ molecule is predominately held by one of the subunits, two amino acids 
from the C-terminal domain of the other subunit are also involved binding NAD+ 
through hydrogen bonding interactions. The molecule is thus held with its nicotinamide 
moiety close to, and adenine moiety far from, the catalytic domain. In all other ways 
NAD+ binding by SAHH is largely typical of NAD+-dependent dehydrogenases. 
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As a dimer, SAHH is capable of binding all the substrates and cofactors required for 
the catalysed reaction, however the dimeric structure does not form a strong enough 
rigid core framework. Formation of a tetramer provides this strength in addition to 
allowing flexibility of the catalytic sites. The four units are brought together through 
interactions between two regions of α helices within each subunit. In addition, 
interactions occur between the catalytic domains that are located on the outside of the 
quaternary structure. 
The NAD+ and substrate binding sites are held in a cleft between the two main 
domains of each subunit. This cleft forms a channel from the protein core to the 
exterior, which allows entry of the substrates into the catalytic domains of the protein. 
The coming together of the dimer places two NAD+ molecules at each end of a channel 
that passes through the centre of the tetramer, a channel that is unique to SAHH, the 
function of which is as yet unclear. Hu et al.134 however, identified twenty-four well 
defined water molecules within the channel. 
In the absence of substrate the catalytic and co-enzyme binding domains are 
physically remote, such that enzyme appears to have an “open” conformation134;135. 
Two conformational changes occur upon ligand binding136, the first of these will occur 
in the absence of cofactor, and therefore appears to be important in the formation of the 
enzyme-ligand complex. On binding of S-AdHcy, a flexible hinge element between the 
catalytic and NAD+ binding domains presumably allows the protein to shift such that 
the ribose moiety of S-AdHcy is brought into close proximity with the region in which 
the nicotinamide moiety of NAD+ would be held. A second conformational change then 
occurs as NAD+ is reduced to NADH, which, upon oxidation, becomes trapped in a 
“closed” form of the enzyme. Until recently, it was unclear which of the two processes 
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caused the formation of the closed enzyme. However, Yin et al.135 have studied these 
conformational changes in detail and it appears that the initial substrate binding is 
largely responsible for the enzyme shifting into a closed conformation, such that the 
overall radius of the protein dramatically reduced. In contrast, subsequent reduction of 
the coenzyme produces only a small change in the protein structure. 
The NAD+-binding domains form the core of the tetrameric enzyme, held together by 
both polar and non-polar interactions. These co-enzyme binding domains have much 
lower temperature factors than the catalytic domains and therefore contribute largely in 
determining the structure of the protein134. As the co-enzyme binding domains are 
attached together at the centre of the protein, entry of the substrate, and subsequent 
closing of the of the clefts which exist between the catalytic and co-enzyme binding 
domains must cause the catalytic domains to move closer to the core of the tetrameric 
protein, this flexibility is facilitated by the channel that exists through the centre of the 
protein. 
3.3.3 Preparation of the SAHH computer model 
Although there is a high degree of homology between rat and human SAHH, the 
Protein Data Bank file 1A7A contains the structure of the human placental enzyme in 
the presence of an inhibitor and cofactor. As discussed earlier the binding of a substrate 
has a significant effect on the overall structure of the protein. Any docking procedures 
are therefore likely to be more successful using the active, closed conformation. 
One potential downside to using the structure from the 1A7A file is that it only 
shows the structure of two subunits from the tetrameric protein, referred to as the A 
chain and the B chain. Formation of a tetramer adds strength to the structure of the 
protein; however as the dimer is capable of binding all substrates and cofactors required 
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there should be very little difference in the structure of the active site where docking of 
potential inhibitors will be conducted. 
The Protein Data Bank file 1A7A was therefore downloaded and visualised using the 
molecular modelling software, Sybyl 6.7 (Tripos UK Ltd, Milton-Keynes, UK). 
A number of modifications to the downloaded file were required to prepare the 
structure prior to database screening using a docking program. Firstly some of the atom 
types and valances where incorrectly identified by Sybyl and these needed to be 
modified. More importantly, during the X-ray crystallography procedure, Turner et 
al.133 had expressed the protein in the presence of selenomethionine. The presence of 
these groups in place of Met may have a significant effect on any minimisation 
conducted, and as Met groups are present in the active site it was also important to 
modify these groups back to Met residues prior to any docking procedures. Fourteen 
Met groups were replaced in each chain, and the structure at each of these locations was 
taken from the original paper of Turner et al.133. 
Before any screening was conducted the modified enzyme structure needed to be 
optimised. Initial optimisation was conducted using simplex minimisation, which was 
followed by the Powell method. The initial total energy of the dimer was over 
14000000kcals/mol. Following minimisation, using a termination gradient of 
0.02kcals/mol, over 21000 iterations had been conducted which resulted in the total 
energy being reduced to –2259.3kcals/mol. The model was then ready for use in 
determining a query for the docking procedures. 
3.3.4 Active site and docking query 
If the active site within a protein has not been identified, then there are programs that 
can locate potential binding pockets, however, as the file for 1A7A contains a bound 
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inhibitor the active site is known allowing selection of the pocket where docking should 
take place. Key residues within the protein can be identified from their proximity to 
important groups within the ligand requiring knowledge of the reaction mechanism in 
order to set up the docking query. 
The following work was conducted using the protein model prepared in section 3.3.3. 
 When the whole protein is displayed there is too much information on screen to be able 
to locate the residues of interest. In order to focus on the active site, a “cavity” set of 
amino acids was created for display, which contained all residues within a 15Å sphere 
from the centre of the ligand contained within the A chain. The size of this cavity is user 
defined; when a 20Å area was initially tried this produced a set which contained 330 
monomers, which was considered too large a set for dynamic docking since the time 
required to dock each compound increased based on the number of energy interactions 
that need to be minimised. Reducing the set to a 15Å sphere around the bound inhibitor 
meant that the number of included residues was reduced to 208. 
A “shell” set was then defined containing all atoms lying within 5Å of the ligand. 
This set was used to display amino acid residues that may be involved in hydrogen 
bonding interactions with the substrate or inhibitor. 
Although the ligand is used to define each group of amino acids it was removed 
before each set was saved. The cofactor and any residues present from the B chain were 
retained. 
The reaction mechanism for the reversible hydrolysis of S-AdHcy, shown in Figure 
13, was reported by Palmer and Abeles137. In either direction, the first step is oxidation 
of the 3’-hydroxyl group of the adenosine ring by NAD+ to produce a 3’-keto 
derivative. This facilitates abstraction of the 4’-proton by an enzyme base and the 
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resulting carbanion eliminates the 5’-substituent (either Hcy or water) to give 3’-keto-
4’-5’-dehydroadenosine. Addition of water or Hcy in a Michael type addition reaction, 
followed by reduction of the 3’-keto group by NADH, results in formation of the final 
product. 
 
 
 
 
A number of authors have proposed key amino acid residues within SAHH which 
may be involved in substrate binding and the reaction mechanism itself, although the 
Figure 13 The reaction mechanism of SAHH proposed by Palmer and Abeles137. 
Reproduced by kind permission of Dr. G.P. Moss from: http://www.chem.qmul.ac.uk/iumb 
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protein is highly conserved, some care must be taken with regards to the sequence as the 
papers often refer to different species and the residue numbering may differ. 
Chemical modification of three accessible Cys residues in the human placental 
SAHH (Cys 113, Cys 195, and Cys 421) led to complete inactivation of the enzyme. 
However, site directed mutagenesis of each of these residues in turn showed that only 
one, Cys 195, is important in the reaction mechanism of SAHH138. Comparison of the 
substrate binding energies between the wild type and mutant enzymes, together with the 
fact that the mutant enzyme was able to catalyse the 3’-oxidative and 5’-hydrolytic 
reactions, yet severely impaired when it came to the 3’-reduction indicated that Cys 195 
is involved in the catalytic centre and may play an important role in maintaining the 3’-
reduction potential for the effective release of the reaction products and regeneration of 
the active form of the cofactor (NAD+). The importance of Cys 195 in the function of 
SAHH is supported by the fact that this particular residue is highly conserved 
throughout evolution130;131. 
When looking for a potential inhibitor, however, clearly the release of the reaction 
products is not important and the focus must be on residues involved in the recognition 
of substrates. If irreversible inhibitors are to be found it may be more important to 
identify residues that allow binding of substrates, which can undergo the early stages of 
the reaction mechanism, but fail to be released. 
Lysine (Lys) 426 may be involved in 5’-hydrolytic activity and may also required for 
subunit interaction139, and is therefore not a good candidate. Glutamate (Glu) 155, Lys 
185, or Threonine (Thr) 157, have been cited as possible proton acceptors in the 
formation of the 3’-keto group134;140-143, while Histidine (His) 54 may act as a general 
acid-base catalyst134;143. Aspartate (Asp) 130 has been cited as being potentially 
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involved in the extraction of the 4’-proton resulting in the formation of the 
carbanion140;142;143. 
By evaluating the binding specificity of substructures of the substrate, Hu et al.140 
looked at the amino acid residues important in recognising and holding the substrate 
while the reaction takes places. They reported that binding of the substrate with the 
closed form of SAHH was highly specific, with the main recognition factor being the 
adenine moiety of the substrate, whilst the major role of the ribose moiety is not in 
recognition but is its involvement in the oxidation- reduction reaction. In this model Thr 
57, Glu 59, Met 351, and His 353 are important in binding the adenine ring. These 
residues are identical to those found in contact with the adenine fragment in the crystal 
structure133. In the open form of the enzyme, docking was non-specific and only Thr 57 
and Glu 59 were maintained in the model140. Computational mutation of the residues 
identified in the closed model, followed by redocking of the inhibitor found in 1A7A, 
confirmed that Thr 57 and Glu 59 are particularly important in substrate recognition140. 
Through interaction with Thr 57 and Glu 59, the adenine moiety resides in the 
deepest pocket within the active site cleft; adenine may act as the anchor locking the 
two hinged domains of each subunit into the closed conformation144. The side chains of 
Thr 57 and Glu 59 are believed to make contact with N6 and N1 of the adenine ring 
respectively133;140;144. 
When Hu et al.140 attempted to dock the complete substrate S-AdHcy, they found 
they needed to apply weak constraints in order to restrain the adenine ring in the general 
area of the binding site. In this model the substrate binds in a strained conformation. 
This straining may be important for the catalytic function of SAHH, as it may lower the 
energy barrier for the elimination reaction to take place140. 
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With the above information in mind an initial docking query was defined. The cavity 
set containing all amino acids within a 15Å radius from the centre of the ligand was 
displayed in Sybyl. Using the three-dimensional database searching application UNITY 
(version 4.3), N1 and N6 of the adenine ring of the bound ligand were defined as 
hydrogen bond donor atoms, corresponding to acceptor sites in the hydroxyl groups of 
the side chains of Glu 59 and Thr 57 respectively. Atoms within the shell set, in close 
contact with the ligand were used to define a receptor site constraint, with a van der 
Waals scaling factor of 0.5. A hydrophobic feature based on the 6 membered ring of the 
adenine fragment was also added to the query. Once all the features and constraints 
were defined the structure of the ligand was removed from the query to allow docking 
of alternative structures. The whole query was then saved before any database searching 
was conducted to allow it to be used as a base should any refinements be required. 
3.3.5 Database screening 
Having defined the query, UNITY was used to conduct a flexible search of the 
available databases. During this process a two-dimensional screen, looking for 
structural chemical features, is followed by a three-dimensional dynamic search, which 
allows flexing of the stored chemical structures in order to find a conformation that may 
match the active site constraints. In this case flexing of the structures is particularly 
important as Hu et al.140 reported that the substrate binds in a strained conformation, 
which is unlikely to match a database structure that may have undergone energy 
minimisation prior to storing. 
At the time of this investigation only two databases of chemicals were available for 
searching: the Maybridge Database, from the Maybridge Chemical Company (Tintagel, 
UK) containing approximately 61000 compounds, and the National Cancer Institute 
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Database, constructed from their Developmental Therapeutic Program containing over 
235000 compounds. Using the query as defined in section 3.3.4, the two dimensional 
screen reduced the number of compounds suitable in each database to 37, and 3806 
respectively. However, when followed by a flexible search none of the structures 
matched the active site constraints. 
Due to this lack of hits, the initial query was rechecked, at this point it was 
discovered that no spatial tolerances had been given for the donor atoms and acceptor 
sites, as such the three-dimensional database search would have tried to match the exact 
positions given for the original ligand. 
A second query was defined with less features and constraints than the original. Glu 
59, and N6 of the adenine moiety were maintained, this time with spatial tolerances of 
1Å and 3Å respectively. The receptor site constraint was tightened to a 3Å sphere 
around the ligand, again with a van der Waals scaling factor of 0.5. When used to screen 
the Maybridge database, the search was abandoned when only 10% complete when it 
was discovered that approximately 10% of the structures were identified as hits. Where 
the original query had produced no hits, this second query was producing too many. 
Unfortunately it was not possible to conduct any further work on database screening, 
but, as adenine is so important in substrate recognition, the next option would have been 
to add back into the query a hydrophobic feature, which would search the database for 5 
or 6 membered ring substructures. 
Should an appropriate query have been defined which would return a manageable 
number of hits from chemical database searches, these hits would then have been further 
screened in a docking approach using the FlexX module of Sybyl. In this program, a 
binding site needs to be redefined into which a number of potential ligands, i.e. the hits 
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obtained from database searching, are docked. FlexX uses an enhanced version of the 
scoring function of Boehm126, to estimate the strength of binding energy and to rank the 
different docking conformations for each ligand. Scoring can also be used to identify 
the best candidates for further investigation, based on their interaction with the protein. 
Comparison with the scores obtained whilst docking 3DA might also provide an 
indication of the suitability of potential inhibitors. 
3.3.6 Discussion 
Although a computer model for in silico screening was created, database screening 
for potential ligands was unsuccessful. Time and finances were limited and since hits 
were possible with the databases it is believed that the query could have been modified 
to produce a manageable number of hits. The two databases available at the time may 
not have been the best choice from which to identify potential inhibitors for SAHH. 
3DA, has been used as an antiviral agent145;146 and databases containing drugs of this 
type may have been more suitable. 
In retrospect the suitability of the database query and model could have been tested 
using the ligand contained in the 1A7A crystal structure. If this did not produce a hit 
then it would have been clear that there was an error in the definition of the query. 
Docking the same compound using FlexX would provide a method of verifying the 
docking procedure when compared with the docked structure defined by Turner et al. 
133;144
. 
It is possible that potential inhibitors would be discarded due to high binding 
energies which may come from binding in a strained conformation as was observed 
with S-AdHcy140. In all these procedures there is a trade off between wanting to make 
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sure that suitable compounds aren’t missed, and the chances of increasing the number of 
false positives. 
In a similar manner to the validation of their docking model conducted by Hu et 
al.140, computational mutagenesis of potentially important amino acid residues within 
the active site could have been performed, and the resulting binding energies generated 
in FlexX whilst docking the given ligand, used as an indictor of their suitability for 
defining a database search query. Key residues are also likely to be highly conserved 
across a number of species. 
3.4 Conclusion 
Although unable to complete the objectives of this part of the thesis, an outline as to 
how one might be able to use a molecular model of the active site of SAHH to identify 
agents capable of stabilising whole blood samples for plasma Hcy measurement has 
been proposed. Through scoring methods one might be able to short list a group of 
candidate compounds for further investigation in the in vitro screening method 
described above. Comparison of the results of in vitro testing with the theoretical 
binding energies should give an indication of one or two compounds that are likely to 
produce better results in stabilising plasma Hcy in whole blood than 3DA. It must be 
remembered that the enzyme used in the in vitro method is of bovine origin, however 
due to the fact that SAHH is highly conserved across species, it is fair to assume that the 
results would be very similar if a human enzyme had been used. 
One or two compounds would then be used in pilot studies similar to those described 
in Chapter 2, before full-scale clinical trials are conducted on one key inhibitor. Within 
the pilot studies other factors must be considered for suitability in a commercial 
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product. Such factors include the safety of production staff exposed to the chemicals, 
the cost of manufacture, and the solubility of the compound if it is to be spray dried into 
the blood tubes prior to evacuation. Another factor to be considered, which would not 
be accounted for in the in vitro screening method is the ability of the compound to cross 
the plasma membrane and enter the red blood cell to come into contact with SAHH, 
which is obviously crucial if the inhibitor is to be active in whole blood samples. 
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Chapter 4 HOMOCYSTEINE, B12 AND DEMENTIA 
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This section of the thesis focuses on work conducted in conjunction with the 
COBALZ Research Team: a group originally founded to investigate the links between 
vitamin B12 (COBalamin) and ALZheimer’s Disease. The work looked at Hcy as a 
marker of vitamin deficiency and explored possible mechanisms linking thiol 
metabolism into the development of cognitive decline eventually leading to dementia. 
4.1 Alzheimer’s Disease – History, Diagnosis and Pathology 
In 1906 Alois Alzheimer presented the case of a woman, who at the age of 51, was 
admitted to a state asylum with progressive cognitive and language impairment, 
hallucinations, delusions and psychosocial incompetence. The mental regression 
advanced steadily until, after suffering with the illness for four and half years, she died. 
On post mortem the brain was evenly affected with fibrils in the cortical neurones, and 
deposits of peculiar substance in the cerebral cortex, which was later determined to be 
amyloid plaque, otherwise known as senile plaque. Alzheimer also found ateriosclerotic 
changes, however these came to be ignored over the course of time as it was felt that the 
reports focussed on the novel factors in this case147;148. Thus the finding of 
neurofibrillary tangles and amyloid plaques has become known as the hallmark pattern 
in the brains of patients with a disease named Alzheimer’s Disease (AD). 
The disease itself may be described as the end point of a steady decline in cognitive 
and psychosocial function149. The process begins with a gradual loss of recent 
memory150. Although memory loss is a common complaint in the aging population, in 
AD and other forms of dementia related to vascular disease, including dementia caused 
by stoke, the degree of cognitive decline is extreme and could never be classed as 
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“normal”151. Other symptoms include confusion, impaired judgment, personality 
changes, disorientation, and loss of language skills. 
Age is considered to be the single most important risk factor in the development of 
dementia152;153. As the number of people surviving into their elderly years is rising, 
there is a growing burden on society caused by increasing numbers of individuals 
suffering from senile dementia. At the turn of the millennium it was estimated that the 
fraction of people who were older than 85 years and suffering from AD was almost 
50%154. It is estimated that there are currently 18 million people worldwide with 
Alzheimer’s disease155. In the UK, combined data from the Office for National Statistics 
and the Alzheimer’s Society predicts that the number of people living into old age is 
increasing significantly such that by 2010 the UK will be caring for an estimated 
840,000 people with dementia156. In every nation where life expectancy has increased, 
so has the incidence of AD. Predictions suggest that unless checked the burden in North 
America will triple, to around 14 million over the next 50 years153;155;157. These patients 
will obviously need medical care and may require possible institutionalisation putting a 
huge strain on the health systems of the Western world. 
Dementia is defined as significant memory impairment, and loss of intellectual 
functions. There are several forms of dementia, with possibly up to 70 different 
disorders being causal157, however dementia of the Alzheimer’s type accounts for the 
majority of cases (70%), whilst the second most frequent cause is vascular dementia, 
sometimes referred to as multiinfarct dementia, since in these cases cerebral damage is 
caused by repeated stroke attacks. Vascular dementia accounts for approximately 15% 
of dementia cases152;154. 
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Early diagnosis of AD is hindered by the fact that family members frequently fail to 
recognise the mild dementia that occurs in the initial stages, often assuming that the 
changes are simply a symptom of the normal aging process. An additional hindrance is 
that one of the criteria used in clinical diagnosis is the measurement of a gradual 
cognitive decline over an extended period157. Unfortunately to date the “gold standard” 
for a definitive diagnosis of AD remains the neuropathological findings at autopsy158, 
but even here there remains differences in opinion as to how to interpret the findings 
when there is more than one disease present157. 
As described by Alzheimer148, at post mortem the brain is found to contain 
extracellular amyloid plaques, and neurofibrillary tangles. Cortical atrophy is significant 
with widespread loss of neurones and synapses158. 
As yet there are no definite tests or biological markers of AD158, thus, in the living, 
AD diagnosis is guided by clinical criteria; a diagnosis of probable AD is made in the 
absence of other disorders that might contribute to dementia, whereas a diagnosis of 
possible AD is made when there may be other contributing causes for the dementia. 
Intellectual decline is well recognised as a key feature in AD, whereas behavioural 
disturbances are often overlooked. Current clinical diagnosis of AD is based upon a 
patient history, mental status testing, physical and neurological examination, a panel of 
conventional laboratory tests and neuroimaging to rule out other causes of dementia. 
Where there is an unusual case, additional laboratory testing and detailed psychometric 
testing may be conducted to increase the confidence of the diagnosis157. A number of 
examinations can be used to assess whether an individual has a lowered cognitive 
ability, and to provide a measure of disease severity, these include the Mini-Mental 
State Examination (MMSE), The Alzheimer's Disease Assessment Scale (ADAS), and 
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the Cambridge Cognitive Examination (CAMCOG). Each measures a variety of 
cognitive functions, such as orientation, concentration, and memory. From these tests 
scoring schemes have been devised so that on initial examination a poor score may 
mean a diagnosis of dementia. On follow up, repeat testing allows a way of assessing 
the extent of disease progression based on the degree of declining scores over a given 
time period. An additional tool for monitoring disease progression is the extent of 
atrophy of the medial temporal lobe159. 
As new therapies, both of a pharmacological and non-pharmacological nature, 
become available for the treatment of AD, it is important to be able to diagnose the 
condition early and accurately in order to prevent further deterioration and ideally to 
bring about a reversal in the process. If the clinician has to wait until (s)he is able to 
detect a decline in cognition this is clearly not good enough as it may by then be too late 
to reverse the process and maintain normal cognitive function. A number of markers 
have been proposed including ApoE, presenilin (PS) and amyloid precursor protein 
(APP) genotyping157. The relevance of each of these markers will become clear in later 
discussions regarding the possible pathological mechanisms behind the disease. Recent 
progress in this field has focussed on analytes present in the cerebrospinal fluid (CSF). 
Tau, a microtubule associated protein is the primary constituent of the neurofibrillary 
tangles reported by Alzheimer in 1906148 whilst the insoluble amyloid-β42 (Aβ42) forms 
the plaque deposits. 
Vascular dementia may be diagnosed on basis of computerised tomography (CT) or 
magnetic resonance imaging (MRI) showing subcortical lacunes and/ or multiple 
involvement of the inner white matter, whilst cerebral CT or MRI in probable AD 
shows cortical atrophy and normal aspects of the white matter160. 
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Although the gross pathological features of AD and vascular dementia are quite 
different, AD is often associated with atherosclerosis and cerebral microvascular 
abnormalities, in fact AD commonly co-occurs with stroke, leading many to believe that 
there may be vascular involvement in the aetiology of both forms149;161, it is perhaps for 
this reason that attention has shifted to a possible link between Hcy and AD. 
4.2 Possible links between AD, Hcy and Vitamin B12 
A possible link between low levels of serum vitamin B12 and AD was first reported 
in the mid 1980s162, however it was not until some ten years later, following a 
resurgence in interest in Hcy, that links with this aminothiol were investigated. 
Conflicting results have been published when looking at the levels of B12 in patients 
with AD. In humans only two enzyme reactions are known to depend on vitamin 
B12163. The action of MS in the metabolism of Hcy had already been discussed in 
Chapter 1. The other pathway, involves the enzyme methylmalonyl-CoA mutase in the 
conversion of methylmalonic acid to succinyl-CoA, which in turn is involved in energy 
production and the synthesis of porphyrins. Conversion is rapid such that 
methylmalonic acid levels within the plasma are usually very low, however B12 
deficiency, in addition to causing Hcy accumulation can lead to increased levels of 
methylmalonic acid (MMA), and a subsequent porphyrin deficiency leading to 
haematological symptoms163. Therefore Hcy and MMA, may be sensitive markers of 
subclinical B12 deficiencies. Further reasoning behind investigations of Hcy levels in 
patients with AD comes from the suggestion that there may be vascular involvement in 
the development of AD, coupled with the association of Hcy and vascular disease (see 
Chapter 1). 
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One possible factor in interpreting the results of these studies is the effect of 
institutionalisation on nutritional status. Joosten et al.164 compared patients with AD and 
two elderly controls groups, one being nondemented hospitalised patients and the other 
control group being healthy elderly subjects living independently at home. They found 
that although Hcy levels were significantly higher in AD, there was no difference in the 
B12 and folate levels across the three groups. They did however, find that MMA was 
raised in AD patients compared to the healthy controls living at home, but not compared 
to the hospitalised controls. These results highlight the need for careful selection of 
control groups and suggest that a subtle nutritional B12 deficiency may have been partly 
to blame for increased Hcy levels in hospitalised AD cases. However the difference 
between Hcy levels in AD and hospitalised controls indicates that there may be 
additional factors involved. 
In the COBALZ study, designed to investigate the relationship between cobalamin 
(or vitamin B12) and AD, higher levels of plasma Hcy were reported in individuals with 
senile dementia of Alzheimer’s type compared to age matched controls165. Scores of 
cognitive function were also inversely related to Hcy concentration. In this group 
hyperhomocystinaemia was independent of nutritional status (assessed by measurement 
of retinol binding protein concentrations), despite previous reports showing poor 
nutrition and vitamin B12 deficiency to be associated with AD. 
In trying to establish whether there is a true link between AD and any biochemical 
marker one of the major problems is establishing a correct diagnosis of the patient. 
Clarke et al.159 took a group of patients with Alzheimer’s type dementia and again 
looked at B12, Hcy and folate levels compared to controls. The difference in this study 
was that in almost half of the patient group, histological confirmation of the diagnosis 
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had been performed. Both Hcy and folate were significantly reduced in patients, and 
this association became stronger in the confirmed cases. Although clinically diagnosed 
patients had lower B12 levels than controls the levels failed to reach statistical 
significance, however in patients with a confirmed diagnosis B12 levels were 
significantly reduced. Two other important results from this study were that Hcy did not 
show escalating levels with increasing duration of symptoms and that over a three year 
follow up those with highest levels of Hcy at entry showed the worst radiological 
evidence of disease progression. These results argue against an explanation of increased 
Hcy, and reduced folate and B12 levels being a consequence of the disease. In contrast, 
Malaguarnera et al.160 interpreted the findings of raised Hcy with a low folate in both 
vascular dementia and AD, with B12 levels only being reduced in the AD cases as 
suggesting that Hcy damage to neurones could lead to a secondary B12 deficiency. 
Although low levels of B12 vitamins and high levels of Hcy may be associated with 
AD, these findings are also common in healthy elderly individuals. In one study low 
B12, folate, and B6 levels, and elevated Hcy were found in 6%, 5%, 9% and 30% of 
healthy elderly subjects compared to corresponding figures of 5%, 19%, 51% and 51% 
of AD patients. Due to the high prevalence of dementia and poor vitamin status in the 
elderly it is not unreasonable to expect that a combination of disorders is common. 
Alternatively low levels of vitamins and high Hcy levels may be an early, preclinical, 
indictor of the potential to develop the disease. 
McCaddon et al.166 followed up the control subjects from the original COBALZ 
study165 and showed that Hcy levels were correlated with cognitive decline over a 5 year 
period. Cognitive decline occurs with age, but it appears that increased Hcy 
concentrations may be responsible for accelerating the rate of deterioration. 
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The Framingham study was initially designed to identify common factors or 
characteristics that contribute to cardiovascular disease, however after following the 
enrolled cohort for over 50 years several additional observations have been worthy of 
publication. In a recent paper, a sub-cohort of over a thousand elderly individuals were 
selected from those originally recruited; in this group the Hcy levels measured at 
baseline predicted the development of dementia and AD, over the following 8 years167. 
In the majority of subjects, they were also able to measure Hcy concentrations on 
samples taken 8 years prior to baseline. The fact that elevated Hcy levels were also 
found in these samples on the patients that later went on to develop dementia excluded 
the possibility that subclinical dementia may have been present in an apparently healthy 
population. Raised Hcy clearly preceded the development of disease. Although earlier 
studies have shown that elevated Hcy may accelerate cognitive decline166, this was the 
first prospective study to show a strong graded risk of the development of dementia 
associated with Hcy concentration. A 5µmol/L increase in Hcy level was associated 
with 40% increase in the risk of developing dementia. Hcy levels over 14µmol/L, or in 
the upper quartile of Hcy level based on 5-year age brackets, showed twice the 
likelihood of developing dementia. 
Further studies continue to add weight to a link between Hcy and AD168-171, and few 
would now dispute that a patient with AD is likely to have a raised Hcy. However the 
picture is not as clear when it comes to B12. Some studies report reduced levels of B12 
in AD159;160;162;172, whilst other studies failed to find any difference between AD cases 
and the control group164;165;168;169, however the majority of studies show a tendency 
towards reduced B12 levels in the patient group which fails to reach clinical or 
statistical significance. This may reflect the difficulties seen in diagnosis, the controls 
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groups chosen, or the methodology when measuring B12 levels. It may also be that a 
reduction in B12 levels is secondary to damage caused by increased Hcy, such that the 
difference between studies is caused by the patient groups showing differing lengths of 
duration of the illness. 
A paradoxical relationship was seen in the original COBALZ study were AD patients 
showed decreasing cognition scores with increasing B12165. Where Hcy was concerned 
the relationship was as expected with increasing levels associated with declining 
cognition. The absence of such findings in the control group implies metabolic 
significance. 
Total vitamin B12 is a measure of cobalamin bound to both haptocorrin and 
transcobalamin (TC). Whilst haptocorrin binds the majority of serum B12, only the later 
is involved in transporting the vitamin to metabolically active tissues, with some 5 to 
30% of the total B12 bound as holoTC171;173;174. Decreasing cognitive scores with 
increasing “total” serum B12 could therefore be explained by aberrant tissue delivery in 
AD165;175. If this were true, in AD patients one would expect to find decreased holoTC 
levels, with holo-haptocorrin levels increased, leaving total B12 unchanged or perhaps 
even elevated. Recent developments have enabled routine measurement of 
holoTC174;176;177. As predicted, where total B12 levels were not found to be significantly 
low in AD patients compared to control groups, holoTC levels were reduced171. 
Paper II reports investigation of Hcy concentrations in an elderly population 
including 51 patients with dementia and 60 controls. HoloTC concentrations were found 
to show a significant and independent relationship to Hcy whereas total serum B12 
levels failed to show any association, proving that TC saturation may be a more reliable 
indicator of cobalamin status. 
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In humans TC has four common phenotypes as determined by their isoelectric points. 
Namour et al.178 suggested that a polymorphism at codon 259, where a neutral proline 
reside is replaced by arginine, could account for this phenotypic variability. They also 
showed that the polymorphism was a determinant of apoTC, i.e. unsaturated, with 
homozygotes 259-P having the highest concentration. Therefore the polymorphism may 
affect B12 cellular availability and hence Hcy concentrations. Strangely though, 
heterozygotes (R/P) showed significantly higher Hcy concentrations than either 
homozygote. No association was shown between genotype and total B12 levels. 
In Paper III and Poster XII, codon 259 was confirmed as a major determinant of TC 
phenotype. An apparent trend existed for increasing Hcy in the presence of a 259-R 
allele, which would fit with the findings of Namour et al. where homozygotes 259-R 
had the lowest apo-TC concentrations, however this was not found to be statistically 
significant. In response Namour and Guéant179 provided data which suggested that an 
increase in Hcy in the elderly population may have masked the difference between the 
genotypes in our papers. They confirmed that heterozygotes showed increased Hcy 
levels compared to homozygotes in younger adults, but the difference was not 
significant in an older subgroup. They proposed that a dimeric TC receptor would have 
a lower affinity for a heterodimer of Pro/Arg isoforms. 
Unfortunately holo-TC was not measured in these studies due to the high variability 
seen between methods available at the time. 
If, in AD patients, holo-TC levels are lowered and holo-haptocorrin levels increased, 
what brings about the shift in distribution leading to a tissue deficiency in B12? 
Cobalamin “analogues” resemble cobalamin in structure but are functionally inactive. 
The concentration of these analogues correlated positively with serum Hcy and 
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negatively with CSF B12172. In this study patients with AD had lower levels of active 
B12 than controls, and a higher ratio of analogue to active forms. Interestingly 
holohaptocorrin and haptocorrin saturation levels were significantly reduced in AD 
patients compared with controls, with slightly lower holo-TC and TC saturation levels 
failing to reach significance. When broken down by age, concentration of analogues and 
transcobalamin levels, two distinct groups emerged, thus suggesting that two separate 
mechanisms might exist leading to B12 deficiency in AD, although both could involve a 
disruption of the balance between selective assimilation of B12 and elimination of 
analogues. The distinction between the groups appeared to be related to age. The 
majority of patients had a high ratio of analogue to active forms of B12, with a low TC 
saturation; a small minority, who tended to be younger, showed a low analogue to 
active ratio and a high TC saturation. These patients may have a genetic predisposition 
causing them to develop cerebral B12 deficiency. This may be a defect in TC resulting 
in impaired ability to release B12 to the tissues, or a dysfunctional receptor. Despite the 
confusing results in this study, in patients with AD, increasing age and analogue 
concentrations were found to be factor influencing a reduction in holoTC, 
TC/haptocorrin ratio and TC saturation implying a shift in binding between the carrier 
proteins and reduced delivery to the tissues. This shift in binding may be caused by the 
analogues displacing active cobalamin from TC to haptocorrin. A similar age related 
decrease in holo-TC levels was reported in a later study173. The source of cobalamin 
analogues is largely unknown but they may be either the by-products of oxidative stress 
associated with AD, or originate from the diet or the enterohepatic circulation which 
should serve to remove them from the body. 
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Most studies seem to agree that mean holo-TC levels are reduced in AD; however 
caution should be used in interpreting the results for any individual. Gender, diurnal 
variation, and fasting status may all influence the concentration measured173, 
additionally analytical variation should be considered. As such holo-TC reference 
intervals may be of limited use. A change within an individual is probably more 
significant than the absolute concentration. Monitoring would therefore be required in 
high-risk individuals in order to use holo-TC as an early marker of change in B12 
status. Results of one particular study however indicated that values would need to 
change by nearly 50% in order to be 95% certain that the change was significant173. 
The mechanism behind an increase in B12 analogues and a shift in binding from TC 
to haptocorrin is unclear. One possible explanation is that B12 analogues are generated 
through damage caused by oxidative stress. Oxidative stress has been proposed as a 
mechanism leading to both hyperhomocysteinaemia and vascular disease 180. Poster 
XIII reports that although Hcy is a determinant of the presence of vascular disease, both 
are independently associated with a diagnosis of AD. Although the results fail to show a 
definitive link, there are clearly a number of associations here and it is possible that 
hyperhomocysteinaemia might reflect a common pathogenic mechanism in the 
development of vascular disease and AD. The influence of redox status on key enzymes 
in Hcy metabolism along with the sensitivity of vascular endothelium and brain tissue to 
oxidative stress, could explain the observed relationships. 
McCaddon et al.181, proposed a model which would complement the theory that Hcy 
potentiates vascular and neurological oxidative injury in both vascular dementia and 
AD, but also explaining how oxidative stress might cause hyperhomocysteinaemia in 
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the first place. This model accounts how B12 deficiency might be involved in AD in the 
absence of macrocytic anaemia162;165. 
As reported earlier age is perhaps the biggest risk factor in the development of AD 
152;153; aging is also associated with increased production of oxygen-derived free 
radicals and decrease in related cellular defences. Yet in AD the evidence of oxidative 
damage is more severe than in the average elderly brain182. Whether the oxidative stress 
is the cause of the AD or a secondary event, it is still an important neurodegenerative 
element in pathogenesis of the disease, and there may be benefits from treatment with 
antioxidants158. Increased levels of redox-active iron, catalysing hydroxyl radical 
formation from hydrogen peroxide, together with increased production of superoxide 
anions, from activated microglial cells surrounding the amyloid plaques, and a direct 
implication of Aβ in the formation of free radicals have all been cited as causes of 
oxidative stress in AD182. Furthermore, aluminium, which accumulates in neurones 
containing neurofibrillary tangles, may have an effect on cellular redox potential by 
stimulating iron-induced lipid peroxidation182;183. 
Under normal conditions the body is protected from damage due to oxygen radicals 
by an array of antioxidant systems that show a large degree of redundancy, for example 
the simultaneous metabolism of hydrogen peroxide by both catalase and glutathione 
peroxidase. In pathological conditions the balance between antioxidant and oxidant is 
disturbed, which may lead to damage. In order to locate the site where oxidative species 
were generated Smith et al.182 looked at a marker of primary attack (8-
hydroxyguanosine) and found that this was located in the cytoplasm of vulnerable 
neurones, whereas those affected by neurofibrillary tangles had low levels of this 
marker, despite evidence of previous oxidative damage. Furthermore cases of AD with 
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the most extensive Aβ deposits also showed lower levels of this short-lived marker of 
oxidative attack. These results suggest that senile plaques and neurofibrillary tangles 
may be cellular compensations for oxidative stress and may have some protective anti-
oxidant function. These results are supported in studies of Down’s syndrome and AD 
where levels of 8-hydroxyguanosine are increased prior to Aβ deposition, with levels 
declining after the plaques have formed. 
On release from cells Hcy is rapidly oxidised to form disulphide bonds with either 
other free thiols or proteins in the surrounding tissues and plasma. This oxidation may 
also result in the generation of free radicals, which may in themselves contribute to 
tissue damage. If hyperhomocysteinaemia is both a cause and a consequence of 
oxidative stress, its generation may lead to a harmful feed-forward cascade. 
Cysteine formed in the transsulphuration pathway (see Figure 1) is the rate limiting 
precursor for the synthesis of glutathione, an important intracellular antioxidant. In the 
brain S-AdMet, formed in the alternative pathway for Hcy, is the sole methyl donor for 
numerous reactions involving nucleoproteins, proteins, membrane phospholipids, and 
neurotransmitters. The relative fate of Hcy is determined by a number of factors 
including the maintenance of adequate S-AdMet levels, and the cellular redox state. 
These factors are described in more detail in Chapter 1, but in essence, S-AdMet is a 
key regulatory element. When in abundance S-AdMet increases CBS activity and 
inhibits MTHFR, such that 5-MeTHF is not available for remethylation of Hcy through 
MS, and flux through the transsulphuration pathway is enhanced. When S-AdMet levels 
are depleted, Hcy is conserved within the Met cycle. 
As discussed in Chapter 1 (see Figure 2) the intermediate form of B12, cob(I)alamin, 
involved in the transfer of a methyl group from 5-MeTHF to Hcy, catalysed by MS is 
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labile to oxidation, rendering the enzyme inactive. CBS, on the other hand contains 
haem group in which the oxidised ferric moiety is more favourable to Hcy binding. 
Thus an oxidative environment stimulates the transsulphuration pathway in order to 
provide the antioxidant, glutathione. 
If oxidative stress is increased in both AD and the elderly in general, MS may be 
impaired by enhanced oxidation of cob(I)alamin, resulting in a functional B12 
deficiency. MS reactivation requires S-AdMet to donate a methyl group to 
cob(II)alamin to reform methylcobalamin. Thus MS inactivation results in reduced 
levels of S-AdMet through decreased production and increased utilization. Although 
oxidative stress would stimulate CBS activity the effect is compromised through loss of 
the positive allosteric effect of S-AdMet, in a futile attempt to conserve Hcy within the 
Met cycle to regenerate S-AdMet. 
Hcy would therefore accumulate, and be exported from the cells, thus potentiating 
the generation of further free radicals. 
This model, proposed by McCaddon et al.181, accounted for the earlier finding of 
increased levels of inactive B12 analogues in AD172. It also explains the absence of 
haematological abnormalities in these patients; the activity of methylmalonyl-CoA 
mutase requires B12 but does not involve the formation of the reactive intermediate 
cob(I)alamin generated by MS. Oxidative stress therefore selectively impairs MS and 
spares methylmalonyl-CoA mutase. 
Further implications of this hypothesis involve the neuronal metabolism of B12. 
Neurones can internalise several different forms of the vitamin including 
methylcobalamin and adenosylcobalamin. On entering the cell, each is converted to 
glutathionylcobalamin (GS-B12), which appears to be the preferred substrate for the 
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reductase enzymes that convert the vitamin into its metabolically active forms184. GS-
B12 requires glutathione for its synthesis, however neurones lack cystathionase. 
Neurones therefore rely on their neighbouring glial cells to produce Cys, the precursor 
of glutathione in the transsulphuration pathway. This may be an additional explanation 
for a functional B12 deficiency in the presence of normal serum B12 levels in AD, as a 
result of cerebral oxidative stress under which conditions glutathione levels would be 
depleted for AD, and furthermore may explain poor response to B12 treatment in 
intervention studies. 
Although McCaddon et al. described a plausible model relating Hcy and oxidative 
stress in an escalating feed-forward cascade181, there is very little published information 
about the related aminothiols in AD. In Paper IV, total plasma Hcy, Cys, and 
glutathione was determined in patients with probable Alzheimer’s disease and compared 
to age matched controls. The results confirmed earlier reports of reduced folate and 
increased Hcy levels in AD, with total B12, and red cell folate levels showing no 
difference, indicating that the results were not a result of a dietary vitamin deficiency. 
AD patients also showed increased levels of Cys, but, in contrast to the expected results 
glutathione was not significant. Yet, within the AD group plasma glutathione levels 
were a highly significant and independent predictor of cognitive scores. Lower 
glutathione levels were associated with greater cognitive impairment. 
Increased Cys levels occurring in hyperhomocysteinaemia implies that 
transsulphuration is intact but remethylation is in some way impaired. MS inactivation 
could explain reduced plasma folate levels, as folate is trapped in the 5Me-THF form 
which cannot undergo polyglutamation, a prerequisite for cellular retention. As a 
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consequence folate is excreted in the urine resulting in folate depletion from which the 
red cells are spared4;185. 
These results fit with the model suggested above and also with the results reported by 
Mosharov et al.186, who showed that flux of Hcy through the transsulphuration pathway 
is increased in response to oxidative stress in order to maintain synthesis of the 
antioxidant glutathione. The reason that levels of glutathione did not differ from 
controls is unclear, but the correlation with disease severity may indicate that in a 
prolonged struggle to overcome the effects of oxidative stress, glutathione is eventually 
overcome. 
Paper V reports further findings from the study described in paper IV. In McCaddon 
et al.’s model of a functional B12 deficiency in AD181, oxidative stress leads to 
impaired MS activity, but methylmalonyl-CoA mutase is spared as it does not involve 
the reactive B12 intermediate, cob(I)alamin. If this is the case then AD patients are 
unlikely to show the haematological symptoms associated with B12 deficiency187. 
Although raised MMA levels were found in one group of hospitalised AD patients 
compared to controls living at home, comparison with hospitalised controls explained 
the finding as a coincident mild dietary deficiency164. These results were reflected in the 
comparable prevalence of anaemia and macrocytosis in hospitalised individuals, which 
differed significantly when compared to the healthy elderly group. 
In the investigation of biochemical markers, serum B12, methylmalonic acid, serum 
folate, and plasma Hcy, the latter appears to be the most consistent marker of tissue 
deficiencies in nutrient cofactors and cognitive performance in the elderly151. 
Paper V confirms the theory that AD is not associated with an increased incidence of 
macrocytic anaemia. Furthermore, a failure to develop these symptoms with increased 
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duration of AD argues against a longitudinal model in which a functional deficiency, 
with increased levels of metabolites, precedes the structural and morphological changes 
such as macrocytosis and anaemia. In this model one might explain the neurological 
features of AD as the primary presentation in the early stages of a classical B12 
deficiency. 
These results support both previous theories of a functional B12 deficiency in AD. 
Cerebral oxidative stress may lead to an increased degree of B12 oxidation, additionally 
impaired delivery to the central nervous system (CNS), would explain impaired MS 
activity, with spared methylmalonyl-CoA mutase activity. In fact these two theories 
could be linked by oxidation of B12 resulting in increased levels of B12 analogues, and 
a shift in binding from TC to haptocorrin, leading to reduced tissue delivery. 
4.3  A model for the development of AD associated with increased Hcy 
So far this thesis has described how increased Hcy, functional B12 deficiencies, and 
oxidative stress may be linked with AD, but it remains to be explained how these 
biochemical markers are associated with the hallmark features of the disease, notably 
amyloid plaques and neurofibrillary tangles. Figure 14 summarises the observed 
metabolic changes in Hcy metabolism in AD and shows the effects on brain function, 
which will be explained within this section. 
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Figure 14 Pathway summarising the metabolic observations in AD and the consequences on brain 
function. 
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Before progressing down this path is it worth noting that most studies report levels of 
Hcy, B12 and carrier proteins in the plasma or serum and there is little point trying to 
explain how these findings relate to the pathological patterns observed in the AD brain 
if plasma levels do not correlate with levels in the CSF. Agnati et al.170 proved that such 
a correlation was valid. They injected Hcy into the veins of experimental animals which 
penetrated the blood-brain barrier within 15 minutes. 
Perhaps understandably, until recently any hypothesis on the pathophysiology of AD 
has focused on the hallmark featuresof the disease188, and theories have been generated 
from studies of a small minority of patients in which AD is inherited as an autosomal 
dominant trait. The majority of early-onset, familial AD is accounted for by mutations 
in 3 genes associated with the formation of Aβ: APP, PS1 and PS2, with PS1 mutations 
being most frequent157. Late onset AD is associated with the possession of the apoE 
allele ε4157. 
APP is a transmembrane glycoprotein expressed in a variety of cell types, however 
its function is still unclear. Synthesised in the endoplasmic reticulum, APP passes 
through the golgi apparatus and is inserted into the membranes of intracellular 
vesicles147. Differential cleavage of the protein by three forms of secretase enzymes can 
result in the generation of fragments of differing chain lengths depending on the 
particular enzymes involved. Amyloid-β(1-42), here, for simplicity referred to as Aβ, has 
limited solubility, and is potentially amyloidigenic depositing in senile plaques and in 
the walls of cerebral blood vessels. Secreted forms are generated when α-secretases act 
on the protein as they cleave in the middle of the Aβ region of the precursor protein. Β-
secretases, also release a secreted form of APP, but they leave behind a membrane 
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spanning protein that contains the intact Aβ fraction. Further processing by γ-sectretases 
releases intact Aβ with the potential to form amyloid plaques. 
Deposition of Aβ may be triggered by a number of genetic or environmental 
factors188. A mis-sense mutation in the APP gene seen in some families leads to altered 
metabolism and increased production of Aβ. In Down’s syndrome there are three copies 
of chromosome 21 where the APP gene is located and patients almost invariably 
develop the pathology of AD before they reach the age of 40 years. 
Whether Aβ forms deposits is dependent on its physical state. Freshly formed Aβ 
possesses a random coil or α-helical structure that elicits a neurotrophic action. 
Following prolonged incubation in vitro changes in the local pH bring about a shift in 
the conformation into β-pleated sheets, a process stimulated by nucleation, which may 
be caused by proteins such as apoE, and acetylcholinesterase. This shift into β-sheet 
conformation results in the formation of fibrils, which are neurotoxic188. 
Whilst possession of the apoE ε4 allele is associated with familial late onset AD, it 
also appears to be risk factor in sporadic cases. Several studies have shown an increased 
carriage of the allele in AD patients compared to controls169;171, and possession of the 
allele alone may account for approximately 14% of cases188. In fact it appears that the 
other apoE alleles, especially ε2 may protect against the development of AD. In vitro 
studies suggest that apoE2 binds to Aβ more strongly than apoE3, and that apoE3 binds 
much better than apoE4. ApoE2 therefore may protect against the formation of amyloid 
plaques by maintaining amyloid protein in a soluble state188. 
PS1 and PS2 are integral membrane proteins found mainly in the nucleus, Golgi 
apparatus and endoplasmic reticulum with very little if any present in the plasma 
membrane188. Mutations in the presenilin genes do not seem to affect either the 
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processing or intracellular location of these proteins, but they do seem to alter 
processing of APP resulting in increased formation of Aβ in the brains of patients with 
AD. These two proteins, known as presenilins, make up the catalytic subunit of γ-
secretase, therefore one might expect that mutations within the genes encoding them 
could lead to altered activity, and hence altered APP processing. Whilst, in normal 
brains, the predominant amyloid protein (~90%) is 40 amino acids in length and the 
isoform with limited solubility (1-42) constitutes about 10%150, in AD the relative 
proportions of each are shifted to approximately equal. Furthermore, it is not just the 
balance that is shifted but the total burden of amyloid in the brains of patients with AD 
is increased dramatically, with increases in both forms of peptide189;190. 
PS1 activity is also required for processing of Notch, a signalling receptor that is 
essential for specifying the fate of neurones during neurogenesis and differentiation. 
Furthermore, PS1 involvement has been implicated in the formation of network 
connections (synaptogenesis)191. This might explain why investigations into the 
potential use of secretase inhibitors in the treatment of AD resulted in neuronal death, 
but non-neuronal cells were spared189. 
Increased expression of PS2 in neuronal cells has also been shown to increase their 
susceptibility to induced cell death, whereas lack of PS2 expression is related to 
increased formation of neurofibrillary tangles188  
In the majority of cases AD is not inherited, however presenilins may still be 
important in the development of disease. As described earlier, hyperhomocysteinaemia 
caused by whatever means, is associated with impaired remethylation and 
consequentially reduced levels of S-AdMet. Increased S-AdHcy levels lead to inhibition 
of virtually all methyltransferase enzymes, with a global decrease in cellular 
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methylation. The regulation of gene expression is often controlled by methylation of 
their promoter regions. Hypomethylation may lead to over expression of genes when the 
cytosine in CpG moieties becomes unmethylated. Such control is important in 
regulating PS1 activity; S-AdMet administered to cell cultures lead to a down regulation 
of PS1, and hence a reduction in Aβ production192. Down regulation of PS1, in cultured 
cells treated with S-AdMet was confirmed in a later study, but it was also shown that 
depriving the culture medium of folate and B12, lead to a decrease in S-AdMet levels 
and induced expression of both PS1, and a β-secretase (BACE or β site APP-cleaving 
enzyme) which was reversed when S-AdMet was administered193. APP, PS2 and α-
secretase expression was unaffected. If α-secretases were regulated in the same manner 
as BACE and PS1, there would be an unchanged ratio in APP processing. 
Many of the above papers report the results of studies conducted on secretase 
expression and Aβ production in response to hypomethylation in vitro. For the effects 
described, and in fact for many of the other mechanisms relating to hypomethylation 
described here, to be involved in the brain pathology of AD one would expect to find 
increased S-AdHcy, reduced levels of S-AdMet and increased 5-MeTHF concentrations 
in samples taken from AD cases compared to healthy subjects. Mulder et al.194 studied 
CSF samples in probable AD and found that the levels of each of these metabolites were 
unchanged compared to controls. They proposed that PS1 activity was regulated by 
posttranscriptional or posttranslational changes rather than over expression of the gene 
due to undermethylation of its promotor. It is clear that further studies are required 
before either theory is ruled out, and these should include cases with confirmed AD, as 
correct diagnosis may be an explanation for the conflict between in vitro and in vivo 
results. 
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Whilst looking at Hcy and its effect on gene regulation, Kokame et al.195 identified a 
novel protein which was termed Herp. The term comes from Homocysteine-responsive 
eR-resident protein. The protein is located in the membrane of the endoplasmic 
reticulum, and Hcy activates its production through endoplasmic reticulum stress. The 
endoplasmic reticulum is responsible for protein synthesis, folding, assembly and 
trafficking. Changes with the cell environment which cause the accumulation of 
unfolded proteins trigger a stress response, which results in a signalling pathway out of 
the endoplasmic reticulum, leading to transcriptional and translational regulation in 
order to prevent the further accumulation of unfolded protein. Herp is one of the 
proteins that are upregulated under such conditions. Sai et al. 196 found that Herp 
interacts with PS1 and PS2, and that a high expression of Herp was associated with 
increased generation of amyloid protein. 
Thus the formation of amyloid plaques in AD may be explained in relation to 
impaired remethylation of Hcy. The other key feature in AD is the presence of 
neurofibrillary tangles consisting primarily of tau, a microtubule associated protein. In 
healthy axons tau promotes polymerisation and stabilisation of tubulin, into “train 
track” structures, which guide nutrients and other molecules from the cell body down 
the length of the axon (see Figure 15). The functional properties of tau are determined 
by the degree of phosphorylation. For example, tau phosphorylation at the distal end of 
the axon regulates interaction between the cytoskeleton and the plasma membrane. The 
integrity of microtubule structure is critical for proper neuronal function and synaptic 
transmission however in AD and other neurodegenerative diseases, tau becomes highly 
phosphorylated and may be less effective at binding and stabilising the microtubules, 
leading to aggregation into paired helical filaments which are redistributed into the 
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somato-dendritic compartment of the cell in the form of neurofibrillary tangles147;188. 
Thus the microtubule transport system is disrupted and leading to impaired function and 
degeneration of neuronal cells197. 
 
 
Figure 15 The structure of a typical neurone showing the long 
axon where microtubules are normally located. 
Reproduced from: http://en.wikipedia.org/wiki/Neurone 
 
Phosphorylation of tau is catalysed by two specific kinases, whereas 
dephosphorylation is mediated by the enzyme protein phosphatase 2A. Tau 
hyperphosphorylation, therefore, is the result of an imbalance between the activities of 
these enzymes. Recent evidence suggests that tau hyperphosphorylation is the result of 
decreased phosphatase activity rather than increased kinase activity197. Phosphatase 
expression seems to decrease with age, but has been found to be significantly reduced in 
the brains of AD patients relative to controls. 
Protein phosphatase 2A, is a multimeric protein complex. Methylation is important in 
the assembly of this complex as it increases the affinity between the various subunits, 
which are crucial for directing activity towards tau197. As described above, impaired 
remethylation of Hcy, and accumulation of S-AdHcy, leads to hypomethylation. In this 
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case the result would be decreased phosphatase activity, leading to 
hyperphosphorylation of tau, a breakdown in microtubule structure, the formation of 
neurofibrillary tangles and eventually neuorodegeneration and cell death. 
Although the presence of amyloid plaques and neurofibrillary tangles are central 
features in AD, there are many other biochemical effects leading to cognitive decline 
and neuronal degeneration. The effects of Hcy can be broadly divided into two groups: 
vascular and neurotoxic. Vascular effects are increased proliferation of the smooth 
muscle cells, increased platelet aggregation and increased number of stokes and white 
matter lesions, much of which can be explained by oxidative stress leading to 
inflammation. Besides the neurotoxic effects of Hcy on the deposition of Aβ and the 
formation of neurofibrillary tangles, Hcy may also be involved in neurotoxic events 
through disruption of neurotransmitter synthesis and function, hyperactivation of N-
Methyl-D-Aspartate (NMDA) receptors, and apoptosis153. 
Before much experimental work had been done in this field. McCaddon and Kelly 
published their “cobalaminergic” hypothesis183, describing a mechanism whereby B12 
deficiency may result in the neurotransmitter and indeed the structural changes of AD. 
This hypothesis is divided into explanations of a monoaminergic deficiency and a 
cholinergic deficiency. 
Monoaminergic deficiency is explained essentially through an understanding of the 
“methyl-folate” trap, which is described in more detail in Chapter 1. If remethylation of 
Hcy to Met is impaired, or S-AdMet levels are depleted in anyway, folate is diverted 
from purine synthesis, involved in cell growth and division, and diverted into the 
production of S-AdMet in order to maintain methylation reactions, which are more 
important for cellular survival. Where B12 is deficient or inactive, such a survival 
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technique is futile, impaired MS activity results in folate becoming trapped in the 5-
MeTHF form. As a result, formyl polyglutamte forms of folate are depleted and these 
are essential in the synthesis of nucleotides. GTP, in turn is an essential precursor of 
tetrahydrobiopterin, which is a regulatory factor in the synthesis of the monoamine 
neurotransmitters dopamine, noradrenaline and serotonin. Additionally disruption to the 
Met cycle can affect the function of these neurotransmitters, as methylation is important 
in their deactivation147. 
Depletion of nucleotides, resulting from the folate trap, also affects the cells’ ability 
to repair DNA damage. Under oxidative conditions damaged DNA will accumulate 
within the cells and when this happens, factors that would normally shift a dividing 
cell’s activities from mitosis to repair can also trigger apotosis149. 
Cholinergic neurones play a key role in memory and learning, thus degeneration of 
this system contributes to cognitive deficits in AD147. Choline is required for the 
synthesis of the neurotransmitter acetylcholine. Choline is obtained from three main 
sources: intrasynaptic degradation of acetylcholine, extracellular choline and 
intraneuronal choline via sequential methylation of phosphatidyethanolamine located in 
neuronal membranes. Cholinergic deficiency may arise through a lack of B12 due to 
reduction of both extracellular supplies and intraneuronal synthesis. When MS activity 
is impaired some tissues exhibit an alternative pathway utilising betaine as methyl 
donor in place of 5-MeTHF, in order to regenerate Met, and maintain a supply of S-
AdMet. Even though the brain does not possess this alternative mechanism for Hcy 
remethylation151, extraneuronal supplies of choline will be depleted as other tissues in 
the body use choline to synthesise betaine in order to overcome the MS block. 
Intraneuronal choline synthesis may be compromised in that supplies of 
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phosphatidylcholine, formed by sequential methylation of phosphatidyethanolamine, 
will be reduced through lack of S-AdMet and inhibition of methylation reactions due to 
increased levels of S-AdHcy147;183. 
Cellular destruction may then be explained by neurones resorting to membrane 
phospholipids as a supply of choline. Membrane disruption could result in increased 
permeability, with loss of proteins and enzymes, or an increased influx of secondary 
messengers. Both theories may account for the selective destruction of central 
cholinergic neurones183. Membrane fluidity may also be influenced by methylation of 
phospholipids important in the function of various membrane receptors, influencing 
signal transmission across the cell membrane147. An asymmetry exists in the distribution 
of phospholipids within the membrane, with phosphatidylethanolamine largely facing 
the cytoplasm and phosphatidycholine located on the outer cell surface, facing the 
extracellular space. As phosphatidyethanolamine is sequentially methylated to become 
phosphatidylcholine it is translocated to the cell’s exterior surface in a “phospholipid 
flip-flop”. This rapid rearrangement increases membrane fluidity, which can lead to 
calcium influx and the release of extracellular secondary messengers, in this way a 
variety of neurotransmitters work by stimulating methylation when they bind to the cell 
surface. 
Hcy, or a derivative, may play a role in the direct stimulation of neuronal receptors. 
Glutamate is the major neurotransmitter in the CNS involved in some degree in all CNS 
functions from perception to cognition147. Postsynaptic membranes contain NMDA 
glutamate receptors that have unique modulatory features mediating synaptic plasticity, 
necessary for learning and long-term memory potentiation147;163. Glycine acts as co-
agonist for the receptor, and although its binding does not trigger the receptor, it is 
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required before glutamate can act on the receptor. Hcy can act as both a partial agonist 
at the glutamate binding site, and a partial antagonist at the glycine co-agonist site170. 
Under normal conditions, Hcy levels are not significant enough for it to have a 
noticeable effect on the receptor, and it may actually be neuroprotective through its 
antagonistic action. In pathological conditions, however, the excitotoxic (agonist) 
affects result from over stimulation of the receptor leading to excessive intracellular 
calcium, free radical generation, collapse of the mitochondrial membrane potential, 
release of cellular proteases and eventually neuronal cell death. In fact homocysteic 
acid, an oxidised metabolite of Hcy is more likely to be the cause of the disruption to 
the neuronal network as it is 250 times more effective than Hcy itself147;163. 
Hcy oxidation, and the generation of reactive oxygen species may also have an 
indirect effect on NMDA receptors through modulators of neuronal activity. Oxidative 
stress has also been implicated as a factor in the severely reduced levels of hydrogen 
sulphide seen in the brains of AD patients198. In the brain, hydrogen sulphide is 
produced by CBS, and acts as neuromodulator selectively enhancing NMDA receptor 
mediated responses. Dwyer et al.198 proposed that reduced CBS activity resulted from 
Hcy oxidation, an increase in redox-active iron in AD neurones, mobilisation of ferritin 
stores of iron and decreased levels of haem, vital for CBS activity, through increased 
activity of the haem degrading enzyme haem oxygenase 1. Activity of haem oxygenase 
1 is stimulated by oxidative stress, and may lead to a localised haem deficiency in the 
brain of AD patients, resulting in the loss of CBS redox responsiveness. This provides 
another explanation of how hyperhomocysteinaemia can be both the cause of 
consequence of oxidative stress. 
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Supporting evidence that Hcy or a derivative may play a role in excitotoxicty through 
NMDA receptors comes from the finding that, in healthy individuals, high Hcy levels 
predicted poor scores of constructional praxis (i.e. the ability to copy shapes). The 
association was stronger than for other tests of cognition including learning and 
memory. NMDA receptor mediated long-term potentiation is believed to be important 
in visuospatial processing166. For Hcy to exert a maximal effect on spatial copying 
skills, it seems that neurones may be more sensitive to NMDA receptor mediated 
damage than to the generalised vascular or oxidative damage that Hcy may cause. 
There is evidence supporting several mechanisms whereby hyperhomocysteinaemia 
is involved in the development of dementia. It is still not clear whether raised Hcy is the 
primary cause of these events or a marker of altered metabolism. In fact it seems likely 
that disruption of the Met cycle may be caused by any one of a number of factors, each 
of which potentiates the others in a cascading series of events leading to global cellular 
hypomethylation and eventually to neuronal death. 
Of course not all these mechanisms may play a part in each individual with AD, and 
B12 deficiency in whatever form may not be the primary cause of AD in all cases. It is 
likely that subgroups of patients exist with differing causes leading to a common 
pathological condition. Nevertheless an understanding of some of the potential 
mechanisms involved, and the possible consequences of interference, will assist in the 
development of suitable treatments with an eventual aim of disease prevention. 
4.4 Treatment Strategies 
As described above the differential diagnosis of dementia is a difficult task, however 
a number of causes are fully reversible. In addition some pharmacological treatments 
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may be beneficial in one type of dementia, whereas their possible side effects mean that 
they should not be used indiscriminately. It is important that a correct diagnosis is made 
as early as possible. Yet the long time frames involved in the development of AD means 
that many of the treatments aimed at alleviating the symptoms and pathological findings 
connected with the disease may simply be doing just that and not targeting the real 
cause. By the time the symptoms and pathology appear it may be too late to prevent, or 
reverse the disease and the best that may be possible is to delay progression, as much of 
the damage may be irreversible. 
Treatment may be targeted at preventing the development of Aβ, or neurofibrillary 
tangles, but whether either of these is a primary cause of the disease or merely a 
consequence is still uncertain. Other treatment strategies may involve repair of DNA 
damage, or targeting the prevention of a hypomethylation state, or oxidative state. 
An understanding of the mechanisms involved in the formation of Aβ plaques lead 
some to suggest that inhibitors of secretase enzymes might have potential in the 
treatment of AD. However in vitro studies showed that inhibition of β- or γ-secretase 
activity induced neuronal cell death, whilst sparing non-neuronal cells189. Incubation 
with the soluble form of amyloid (1-40) prevented the toxicity, suggesting a protective, 
physiological role for this peptide. Furthermore, loss of PS1 activity may result in 
severe defects in the formation of neuronal networks191. In fact, the formation of 
amyloid plaques results from an imbalance between the activities of the different forms 
of secretase enzyme and a more suitable form of treatment might be to re-establish a 
correct balance. Specific inhibitors designed to reduce the production of Aβ by 30-40% 
may be beneficial in the treatment of the early phases of the disease, where cognitive 
impairment is apparent150. Mild intervention by administration of S-AdMet has been 
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shown to reduce Aβ production through down regulation of PS1 and BACE rather than 
complete loss of gene expression192;193. 
Some non-steroidal anti-inflammatory drugs (such as ibuprofen) have been 
associated with protection from AD, and it was thought that the effect was due to a 
reduction in neurotoxic inflammatory responses through inhibition of cyclooxygenase-
1, however experiments in animal models imply that they may modulate the processing 
of γ-secretases, without lowering overall amyloid production or affecting neuronal 
differentiation150. 
Far fewer inhibitors of β-secretases, than for γ-secretases have been found to date but 
the fact that the crystal structure of a β-secretase with an inhibitor in place has been 
resolved suggests that effective inhibitors will soon be designed through the use of 
molecular modelling techniques. Such inhibitors may be more beneficial therapeutically 
as knock out mice for the β-secretase gene no not show an adverse phenotype150. 
An alternative approach to lowering the burden of Aβ protein in AD is to vaccinate 
patients against the protein, however early trials showed that a small number of patients 
(6%) developed an inflammatory response in the CNS, causing the trials to be 
abandoned. Nevertheless at subsequent follow-up, those who had developed antibodies 
towards Aβ seemed to show a slowing down of their cognitive and behavioural decline, 
such that human trials of passively administered antibodies are to be conducted150. 
Pharmaceutical treatment of the dementia in AD is currently restricted to 2 types of 
drug. Cholinergic deficiency  may be addressed through the use of acetylcholinesterase 
inhibitors, and more recently a NMDA receptor antagonist, memantine has been 
approved to tackle excitotoxicity147;183. However these agents only seem able to 
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temporarily relieve some of the symptoms and do not address the underlying pathology 
of the disease, or substantially slow its progress150. 
As oxidative stress appears to be a major player in the development of AD, whether 
causative or part of an escalating feed-forward effect, it seems sensible that treatments 
be aimed at reducing potential production of free radicals. A healthy balanced diet, with 
plenty of antioxidants should reduce the risk of developing AD, along with several other 
diseases associated with aging, but any lifestyle change may need to be introduced 
several years before as it is unclear just how long a latency period may be involved. The 
long time spans involved in this chronic disease also make it difficult to conduct 
thorough prospective studies. 
Antioxidants available in food and supplements include vitamin E (tocopherol), 
vitamin C (ascorbate) and carotenes. In vitro studies show suppressed levels of 
inflammation and oxidative stress, affects on catecholamine synthesis, and a reduction 
in lipid peroxidation respectively158. Antioxidants may also prevent the development of 
vascular events associated with dementia; in fact several treatments and dietary 
interventions aimed at lowering cardiovascular risk may help to prevent AD through 
vascular mechanisms. 
Another way of tackling oxidation is the administration of chelating agents in order 
to remove trace metals such as zinc, copper, and aluminium which may all play a role in 
the generation of free radicals150;182. 
Reduction in oxidative stress and the restoration of neurotransmitter and gene 
function may be possible through dietary or pharmaceutical intervention however it 
unlikely that the structural abnormalities associated with AD can be reversed. 
Therefore, primary prevention, rather than cure seems to be key to alleviating the 
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burden on society caused by the increasing numbers of patients suffering from AD. 
Screening of the elderly particularly those at risk of developing dietary deficiencies of 
B12 and folate should enable identification of those where intervention might be 
beneficial before any signs of cognitive decline are noted. Such screening requires that 
suitable plasma markers are measured and evidence supports the use of Hcy and holo-
TC. 
If vitamin deficiency and / or a raised Hcy level are found, due to the complex 
pathology involved, and the possibility that different mechanisms are involved in 
different subsets of individuals, it seems sensible to supplement with all the nutrients 
required for Hcy and Met metabolism, including folate, B12 and B6. Supplementation 
of B vitamins may lower Hcy78, but whether this is effective in the treatment of AD 
remains to be proved. Some studies have shown improvements in cases of cognitive 
impairment, but reversal of dementia is rare163. Although trials have shown conflicting 
reports of the benefits of each of these treatments, case control studies may be trying to 
treat too late in the disease progression. Well designed primary intervention trials may 
provide more convincing evidence that these treatment plans will assist in lowering the 
incidence of AD and cognitive decline, but the chronic nature of the diseases means that 
the trials require long periods of follow up. Three large trials into the benefits of B12, 
folate and B6 in slowing down or preventing the development of dementia are currently 
underway and the first, VITAL (VITamins to Slow ALzheimer’s Disease) is due to 
report in 2006199. Dietary supplementation is inexpensive and relatively safe as long as 
folate is provided with B12, therefore it seems sensible to encourage all those at risk of 
developing vitamin deficiency, whether functional or dietary, to take all the nutrients 
required for effective metabolism of Hcy and Met, including B12, folate and B6. 
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One of the factors complicating trials of vitamin B12 is the different forms of 
cobalamin that exist. The two metabolically active forms methyl-cobalamin and 5-
deoxyadenosylcobalamin, are cofactors in the reactions catalysed, respectively by MS 
and methylmalonyl-CoA mutase173. Oral B12 preparations are obtainable but are rarely 
used, perhaps due to concerns regarding the unpredictability of absorption, therefore 
intramuscular administration is currently used in most countries200. Two forms of 
intramuscular preparation are available: cyanocobalamin and hydroxocobalamin. The 
latter is more widely used as it is retained in the body longer and can be administered at 
intervals of up to three months200. Yet hydroxocobalamin may be easily reduced to the 
supernucleophilic cob(I)alamin, which is highly reactive towards xenobiotic epoxides 
formed by mammalian metabolism of dienes such as the industrial chemicals 
chloroprene and 1,3-butadiene. Glutathione, however, inhibits reduction of 
hyroxocob(III)alamin by forming GS-B12 which potentially affords greater protection 
against B12 depletion201. In fact, as described above, on entering the cell all currently 
available pharmaceutical forms of B12 require conversion to GS-B12, which is used 
much more efficiently in the synthesis of the metabolically active cofactors184. The apo-
enzyme of MS binds cob(II)alamin, S-AdMet then supplies a methyl group to give the 
active form, thus reduced GS-B12, binds quicker than methyl-cob(III)alamin. 
Under conditions of oxidative stress, where glutathione and S-AdMet are depleted, 
administered forms of vitamin B12 may not be utilised by neurones. In such cases 
antioxidant therapy, GS-B12, or B12 given with a glutathione precursor may be 
preferential forms of treatment. 
N-acetylcysteine is a precursor of glutathione and also a potent antioxidant in its own 
right. In a recent publication McCaddon and Davies presented case studies in which 
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they had evaluated the co-administration of N-acetylcysteine with B vitamin 
supplements in three cognitively impaired hyperhomocysteinaemic patients202. In each 
case initial treatment with B12 (injections of hydroxocobalamin) and oral folic acid 
successfully lowered the patients Hcy levels but cognitive function failed to improve. 
As the patients were also found to have low glutathione levels, N-acetylcysteine was 
added to their treatment regimes. In all three cases mood, well being and general 
alertness were noticeably improved. Two of the patients also showed improvements to 
cognitive scores within one month; in the third case N-acetylcysteine was commenced 
late in the course of the disease when the patient already had a very poor score on 
MMSE (5/30), although he failed to show an improvement in that score, he had started 
to recognise and communicate with his wife for the first time in many years. 
In light of these results COBALZ Ltd., has been issued with a US licence to have 
suitable preparations produced in the US where trials should soon be underway to 
determine whether the antioxidant (N-acetylcysteine) together with high-dose B 
vitamins is superior to standard B-vitamin supplements in slowing the rate of cognitive 
decline and the accumulation of structural abnormalities in the brains of patients with 
AD203. COBALZ Ltd. is actively seeking partners to conduct similar studies in other 
countries. Should the results of these trials, and other studies looking at novel therapies 
prove successful, we may soon have ways to treat AD patients rather than simply 
alleviate the symptoms of the disorder. Such treatment combined with measures to 
screen those at risk of developing vitamin deficiencies and the initiation of prophylactic 
treatment, may soon enable a drastic reduction to the severe burden caused by dementia 
on the health systems of the Western world. 
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